Mastering Systematic Reviews in Toxicology: A Step-by-Step Guide for Researchers and Drug Developers

Abstract

This comprehensive guide provides researchers, scientists, and drug development professionals with a practical framework for conducting rigorous and reliable systematic reviews in toxicology. It moves beyond clinical review models to address the unique challenges of toxicological evidence, such as integrating multiple evidence streams (in vivo, in vitro, in silico) and extrapolating from animal studies to human health. The article covers the foundational principles of evidence-based toxicology, details a methodological workflow from protocol development to data synthesis, offers solutions for common pitfalls in search strategy and bias assessment, and explores advanced validation techniques and future methodological directions. By synthesizing current guidance from authoritative sources like the NTP/OHAT handbook and recent methodological research, this article equips professionals to produce transparent, reproducible reviews that can robustly inform regulatory decisions and safety assessments.

The Why and What: Building the Foundation for Evidence-Based Toxicology Reviews

In toxicology, the traditional approach to synthesizing evidence has historically been the narrative review, where an expert summarizes a field based on a selective, often non-transparent, examination of the literature [1]. While such reviews can provide valuable perspectives, they are intrinsically susceptible to bias, lack reproducibility, and may lead to conflicting conclusions about the same chemical, as seen in historical assessments of substances like Bisphenol A [1]. This undermines consistent, evidence-based decision-making in public health and regulation.

A systematic review is defined as a scholarly synthesis that uses explicit, pre-defined, and reproducible methods to identify, select, appraise, and summarize all available evidence on a clearly formulated question [2] [3]. This methodology, pioneered in clinical medicine, is now recognized as a cornerstone of Evidence-Based Toxicology (EBT), aiming to improve the transparency, objectivity, and reliability of toxicological assessments [1].

The core distinction lies in the methodology. Narrative reviews often employ an implicit process, while systematic reviews are characterized by a rigorous, protocol-driven workflow that minimizes bias and enables independent verification [1] [4]. The following table summarizes the fundamental differences:

Table 1: Comparison of Narrative and Systematic Reviews in Toxicology [1]

Feature	Narrative Review	Systematic Review
Research Question	Broad, often informal or implicit.	Specified, precise, and explicit.
Literature Search	Sources and strategy usually not specified; potentially selective.	Comprehensive, multi-database search with explicit, documented strategy.
Study Selection	Criteria usually not specified; subjective.	Explicit, pre-defined inclusion/exclusion criteria applied consistently.
Quality Assessment	Often absent or informal.	Critical appraisal using explicit, standardized tools (e.g., risk of bias).
Synthesis	Qualitative summary.	Structured synthesis (qualitative and, where possible, quantitative meta-analysis).
Time & Resources	Generally lower (months).	Substantially higher (often >1 year).
Expertise Required	Subject matter expertise.	Subject expertise + systematic review methodology, search, and analysis.
Output	Expert opinion summary.	Transparent, auditable evidence synthesis suitable for informing decisions.

Systematic reviews in toxicology face unique complexities not always present in clinical medicine, including multiple evidence streams (e.g., in vitro, animal, human observational), diverse species and strains, complex exposure scenarios, and the frequent need for hazard identification versus therapeutic benefit assessment [1]. Adapting the systematic review framework to address these challenges is the central thesis of modern evidence-based toxicology.

Core Methodology: A Stepwise Protocol for Toxicological Systematic Reviews

Conducting a rigorous systematic review in toxicology follows a structured, multi-stage process. Adherence to this protocol is essential to ensure the review’s validity and reliability.

1. Formulating the Research Question & Protocol Development The process begins with a precisely framed research question. The PICO framework (Population, Intervention/Exposure, Comparison, Outcome) is a standard tool for structuring questions in evidence-based research [5] [3]. In toxicology, this adapts to: Population/Species (e.g., human, rodent, in vitro system), Exposure (chemical, dose, duration, route), Comparator (control or alternative exposure), and Outcome (specific adverse effect or biomarker) [1]. Before beginning the search, a detailed protocol must be written and registered on a platform like PROSPERO. This pre-defines the methods, including eligibility criteria and analysis plans, to reduce bias and prevent arbitrary decision-making during the review [5] [1].

2. Systematic Search & Study Selection A comprehensive, unbiased search is critical. It involves searching multiple electronic databases (e.g., PubMed/MEDLINE, Embase, TOXLINE, Scopus) with a tailored, sensitive search strategy [5] [3]. The strategy should include controlled vocabulary (e.g., MeSH terms) and keywords, and may be supplemented by scanning reference lists and grey literature [3]. Search results are imported into review management software. At least two reviewers then independently screen titles/abstracts and subsequently full-text articles against the pre-defined inclusion/exclusion criteria. Disagreements are resolved through discussion or a third reviewer [5] [4]. This process is documented in a PRISMA flow diagram.

3. Data Extraction & Critical Appraisal (Risk of Bias Assessment) Data from included studies are extracted into standardized forms by two independent reviewers. Extracted information typically includes study design, sample characteristics, exposure details, outcome measures, results, and funding sources [5]. Concurrently, the methodological quality and risk of bias of each study is critically appraised. For animal toxicology studies, tools like the SYRCLE’s risk of bias tool or the NTP/OHAT risk of bias rating are employed [1]. This step evaluates internal validity by assessing elements like randomization, blinding, allocation concealment, and handling of incomplete data [5]. The overall quality of evidence across studies for a specific outcome may be graded using systems like GRADE [5].

4. Evidence Synthesis & Interpretation The final stage involves synthesizing the extracted data. A qualitative synthesis summarizes the findings, often tabulating results and describing patterns across studies. Where studies are sufficiently homogeneous in design, exposure, and outcome, a quantitative synthesis (meta-analysis) can be performed. This uses statistical methods to calculate a pooled effect estimate (e.g., standardized mean difference, relative risk) [5] [3]. Heterogeneity among studies is statistically assessed (e.g., using I²). The synthesis must transparently relate the strength and limitations of the evidence—considering risk of bias, inconsistency, and indirectness—to the final conclusions [1].

Table 2: Key Steps and Methodological Considerations in a Toxicology Systematic Review

Review Stage	Core Action	Toxicology-Specific Considerations & Tools
Planning	Define PICO question; Write/register protocol.	Adapt PICO for exposure; Use PROSPERO for registration.
Searching	Execute comprehensive, multi-database search.	Include toxicology-specific databases (e.g., TOXLINE); Account for complex chemical nomenclature.
Screening	Apply inclusion/exclusion criteria via dual independent review.	Manage large volumes of in vitro and in vivo studies; Use software for efficiency.
Appraisal	Assess risk of bias/study quality.	Use specialized tools (e.g., SYRCLE's RoB for animal studies; OHAT tool).
Extraction	Systematically extract relevant data.	Design forms for diverse endpoints (histopathology, clinical chemistry, omics data).
Synthesis	Qualitatively and/or quantitatively synthesize evidence.	Address high heterogeneity across species, strains, and designs; Consider dose-response.

Visualization of Systematic Review Workflows

Systematic Review Workflow in Toxicology

Adapting the PICO Framework for Toxicology Questions

The Scientist's Toolkit: Essential Software for Systematic Reviews

Modern systematic reviews are supported by specialized software that manages the workflow, from reference screening to data synthesis. The choice of tool depends on project scale, budget, and specific needs [6] [7].

Table 3: Key Software Tools for Managing Systematic Reviews [8] [6] [7]

Tool Name	Primary Function & Key Features	Cost Model	Best For
CADIMA	A free, web-based platform supporting the entire review process: protocol writing, literature screening, data extraction, and reporting.	Free	Academic researchers and projects with limited funding.
Covidence	Streamlines title/abstract screening, full-text review, risk-of-bias assessment (Cochrane RoB), and data extraction. Features machine learning to prioritize records.	Subscription (Institutional licenses common)	Medical and health science reviews; teams valuing an intuitive, guided workflow.
Rayyan	AI-powered tool focused on efficient and collaborative blind screening of abstracts and titles. Uses machine learning to suggest inclusion/exclusions.	Freemium (Free with paid upgrades)	Rapid screening phases; collaborative teams needing a low-cost entry point.
DistillerSR	An enterprise-level platform with high configurability, advanced workflow automation, and robust audit trails. Strong API for integration.	Subscription (Higher cost)	Large-scale projects (e.g., regulatory agencies, large research consortia) requiring compliance and customization.
EPPI-Reviewer	A comprehensive tool for complex data synthesis, supporting meta-analysis, textual data coding, and diverse review types (mixed methods, qualitative).	Subscription	Reviews requiring deep qualitative or complex quantitative synthesis beyond basic meta-analysis.
SUMARI (JBI)	Supports the entire lifecycle for 10+ review types (effectiveness, qualitative, economic, scoping). Integrated with JBI methodology.	Subscription	Researchers aligned with Joanna Briggs Institute (JBI) methodology for evidence synthesis.
RevMan 5	The standard software for preparing and maintaining Cochrane Reviews. Includes tools for meta-analysis and generation of 'Summary of Findings' tables.	Free for non-commercial use	Teams conducting Cochrane-style reviews or requiring rigorous meta-analysis.

For toxicology-specific assessments, the Health Assessment Workspace Collaborative (HAWC) is a notable open-source platform designed to support the entire workflow of chemical health assessments, including systematic review, data extraction, dose-response analysis, and evidence visualization [8] [9].

The discipline of toxicology is undergoing a foundational shift from a reliance on traditional, often siloed data assessment toward a rigorous, transparent, and reproducible Evidence-Based Toxicology (EBT) paradigm. This transition is critical for addressing modern challenges, including the evaluation of novel chemical substances, integrating New Approach Methodologies (NAMs), and maintaining public trust in regulatory decisions [10]. At the core of EBT lies the systematic review, a methodological process designed to minimize bias and subjectivity by comprehensively identifying, appraising, and synthesizing all relevant evidence on a specific question [11].

Systematic reviews provide the essential scientific foundation for credible hazard identification, dose-response assessment, and ultimately, risk-informed regulation. Their formal adoption by agencies like the U.S. National Toxicology Program (NTP) underscores their role as a gold standard for evidence integration [12]. This guide details the procedural framework for conducting a systematic review within toxicology, providing researchers and regulatory professionals with the methodological toolkit necessary to generate defensible, high-quality evidence assessments.

Methodological Framework: The Systematic Review Workflow

The conduct of a systematic review is a multi-stage, iterative process. Adherence to a predefined, peer-reviewed protocol is essential to ensure objectivity and reproducibility. The following workflow outlines the critical phases, emphasizing steps specific to toxicological evidence.

Table 1: Key Phases of a Systematic Review in Toxicology

Phase	Core Activities	Key Outputs & Tools
1. Problem Formulation & Protocol	Define the scope using PECO; develop and register the review protocol.	PECO statement; pre-registered protocol [13].
2. Systematic Search	Execute comprehensive, multi-database searches; manage records.	Search strategy document; de-duplicated library (EndNote, Covidence) [11].
3. Study Screening & Selection	Apply PECO criteria via title/abstract and full-text screening in duplicate.	Flow diagram of included/excluded studies; inter-reviewer agreement metrics.
4. Data Extraction & Quality Assessment	Extract predefined data using standardized forms; assess risk of bias/study reliability.	"Characteristics of Included Studies" table; risk-of-bias ratings [14].
5. Evidence Synthesis & Integration	Synthesize data qualitatively or via meta-analysis; grade confidence in the body of evidence.	Narrative synthesis; forest plots; evidence profile tables (e.g., OHAT approach) [12].
6. Reporting & Application	Draft final report following PRISMA guidelines; articulate conclusions for hazard assessment or regulation.	Published systematic review; summary for regulatory docket (e.g., EPA SNUR analysis) [15].

Phase 1: Problem Formulation and Protocol Development The initial and most critical step is crafting a precise and actionable research question, typically structured using the PECO framework (Population, Exposure, Comparator, Outcome) [13]. In toxicology:

• Population: The organism (e.g., human, rodent, zebrafish embryo).
• Exposure: The chemical agent, its dose, route, and duration.
• Comparator: The control group (e.g., vehicle control, low-dose cohort).
• Outcome: The measured health effect (e.g., hepatocellular adenoma, serum ALT elevation).

A narrowly scoped PECO question enhances specificity but may limit generalizability, while a broad question increases resource demands [11]. Recent discussions highlight the value of an iterative approach to problem formulation, where preliminary screening results can inform refinements to PECO criteria to streamline the assessment without compromising its objectives [13]. The finalized question forms the basis of a detailed protocol, which should be registered in a public platform to enhance transparency and reduce bias.

Phase 2: Comprehensive Literature Search and Management A systematic search aims to capture all potentially relevant evidence, mitigating publication bias. This requires searching multiple bibliographic databases (e.g., PubMed/MEDLINE, Embase, TOXLINE, Scopus) with tailored syntax [11]. Searches must be supplemented by reviewing reference lists of included studies and key reviews, and by searching for gray literature (e.g., regulatory reports, thesis repositories). Retrieved records are imported into reference management software, and duplicates are removed using tools like EndNote, Covidence, or Rayyan [11].

Phase 3: Study Screening and Selection Studies are screened in two sequential stages (title/abstract, then full-text) against the pre-defined PECO eligibility criteria. This process should be conducted independently by at least two reviewers, with conflicts resolved through discussion or a third adjudicator [14]. The screening process, including reasons for exclusion at the full-text stage, should be documented in a flow diagram.

Phase 4: Data Extraction and Risk of Bias Assessment Data from included studies are extracted using standardized, pilot-tested forms [14]. Extraction should also be performed in duplicate to ensure accuracy. Key data points include study design, exposure parameters, participant/subject characteristics, outcome data, and funding sources.

Concurrently, the methodological risk of bias (internal validity) or reliability of each study is evaluated using established tools. For animal studies, tools like the OHAT Risk of Bias Rating or SYRCLE's tool are common. For human epidemiological studies, the Newcastle-Ottawa Scale may be used [11]. This assessment is crucial for interpreting findings and weighting studies during synthesis.

Phase 5: Evidence Synthesis and Integration Extracted data are synthesized to answer the PECO question. For quantitative data on a common outcome, a meta-analysis can be performed using statistical software (e.g., R, RevMan) to calculate a pooled effect estimate [11]. Heterogeneity between studies must be assessed (e.g., via I² statistic). Where statistical pooling is inappropriate, a structured narrative synthesis is conducted.

The final step is grading the confidence in the body of evidence. Frameworks like OHAT or GRADE evaluate factors such as risk of bias, consistency, directness, and precision across studies to categorize confidence as high, moderate, low, or very low [12]. This graded confidence directly informs the strength of the hazard conclusion.

Phase 6: Reporting and Regulatory Application The review should be reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The final output provides a transparent, auditable evidence base. This evidence directly supports regulatory actions, such as the U.S. EPA's development of Significant New Use Rules (SNURs), where the systematic review substantiates the identification of potential unreasonable risk and the need for exposure controls [15]. It also informs the integration of NAMs into next-generation risk assessments by establishing a robust baseline of traditional evidence for comparison [10].

Experimental Protocols & The Scientist's Toolkit

A pivotal application of systematic reviews in toxicology is to determine whether existing data are sufficient for safety assessment or if new, targeted research is required. The following protocol exemplifies a hypothesis-driven in vivo study designed to fill a specific evidence gap identified through a systematic review.

Targeted Experimental Protocol: 28-Day Repeated Dose Oral Toxicity Study

• Objective: To characterize the dose-response relationship for hepatic and renal effects of Chemical X, identified as a data gap for subchronic endpoints.
• Test System: Young adult Sprague-Dawley rats (e.g., n=10/sex/group).
• Test Article & Dose Selection: Chemical X, administered via oral gavage in a suitable vehicle. Doses are selected based on a systematic review of acute data (e.g., No Observed Adverse Effect Level [NOAEL] from a 14-day study) and may include that NOAEL, a mid-dose, and a higher effect-level dose.
• Core Measurements:
  • Clinical Observations: Twice daily for morbidity/mortality; detailed weekly physical examinations.
  • Body Weight & Food Consumption: Measured and recorded at least twice weekly.
  • Clinical Pathology: At termination, collect blood for hematology and clinical chemistry (e.g., ALT, AST, BUN, Creatinine). Collect urine for urinalysis.
  • Necropsy & Histopathology: Full gross necropsy. Preserve liver, kidneys, and other target organs (as indicated by the literature) for microscopic examination by a board-certified veterinary pathologist.
• Statistical Analysis: Data analyzed using appropriate parametric or non-parametric methods. Dose-response trends evaluated, and a benchmark dose (BMD) may be modeled for critical endpoints.
• Reporting: Results reported per OECD Test Guideline 407 principles, ensuring compatibility for inclusion in future systematic reviews and regulatory dossiers.

Table 2: Research Reagent Solutions for Core Toxicological Assays

Research Reagent / Material	Primary Function in Toxicology Studies
Formalin (10% Neutral Buffered)	Standard fixative for preserving tissue architecture for histopathological evaluation.
ALT (Alanine Aminotransferase) & AST (Aspartate Aminotransferase) Assay Kits	Colorimetric or kinetic measurement of these enzymes in serum as sensitive biomarkers of hepatocellular injury.
Creatinine Assay Kit & BUN (Blood Urea Nitrogen) Assay Kit	Key diagnostic reagents for assessing renal function by measuring filtration and waste product concentration.
Hematology Analyzer Controls & Calibrators	Essential for ensuring accuracy and precision in complete blood count (CBC) analysis, assessing effects on hematopoiesis and immune cells.
RNA Stabilization Reagent (e.g., RNAlater)	Preserves RNA integrity in tissues for subsequent transcriptomic analysis, a key component in NAMs and mechanistic toxicology.
CYP450 Enzyme Activity Assay Substrates	Fluorescent or luminescent probes used to measure the activity of specific cytochrome P450 isoforms, indicating potential for metabolic induction or inhibition.
LC-MS/MS Grade Solvents and Standards	Critical for the accurate quantification of chemical concentrations in dosing formulations, serum, and tissues via liquid chromatography-tandem mass spectrometry.

Visualizing Workflows and Relationships

Systematic Review Methodology in EBT

PECO Framework for Problem Formulation

The systematic review is not merely a literature summary but a rigorous, transparent scientific investigation in its own right. Its disciplined application is imperative for advancing EBT, resolving "dueling assessments" through methodological clarity, and building a robust, credible foundation for chemical safety decisions [13]. As toxicology evolves with NAMs and complex data streams, the principles of systematic review—structured problem formulation, comprehensive evidence collection, critical appraisal, and transparent synthesis—will remain the indispensable bedrock for trustworthy science that effectively informs public health protection.

Systematic reviews in toxicology and environmental health represent a distinct methodological paradigm from clinical medical reviews, primarily due to their fundamental purpose: hazard identification and risk assessment. While clinical reviews typically evaluate the efficacy and safety of interventions within controlled settings, toxicological systematic reviews assess whether an environmental agent, chemical, or mixture causes an adverse effect under specific exposure conditions [16]. This core objective necessitates the integration of multiple evidence streams—including human epidemiological studies, controlled animal toxicology experiments, and mechanistic in vitro data—to reach a causal conclusion about hazard [17]. The process demands tailored frameworks, such as the OHAT (Office of Health Assessment and Translation) approach or the COSTER (Conduct of Systematic Reviews in Toxicology and Environmental Health Research) recommendations, which extend traditional systematic review methodology to handle this breadth and complexity [12] [18]. This guide delineates the key methodological distinctions, with a focus on evidence integration and hazard conclusion formulation, providing researchers with a technical roadmap for conducting rigorous toxicological systematic reviews.

Foundational Methodological Distinctions

The conduct of a systematic review in toxicology diverges from its clinical counterpart at every stage, from problem formulation to conclusion. These differences stem from the nature of the research questions, the available evidence, and the intended use of the output for public health protection and regulatory decision-making.

Table 1: Core Differences Between Clinical and Toxicology Systematic Reviews

Aspect	Clinical Systematic Review (e.g., Therapeutic Intervention)	Toxicology Systematic Review (e.g., Hazard Identification)
Primary Objective	Determine efficacy and safety of an intervention (therapy, prevention).	Determine whether an agent causes an adverse health effect (hazard identification) [16].
Key Question Framework	PICO (Population, Intervention, Comparator, Outcome).	PECOTS (Population, Exposure, Comparator, Outcome, Timing, Setting) [16].
Primary Evidence Streams	Human studies only (RCTs as gold standard, observational studies).	Integrated streams: Human (observational), Animal (experimental), Mechanistic (in vitro, in silico) [16] [17].
Common Study Designs	Randomized Controlled Trials (RCTs), cohort, case-control.	Cohort, case-control (human); controlled laboratory experiments (animal); biochemical, cell-based assays (mechanistic).
Exposure Assessment	Controlled, known dose/intervention.	Often estimated, historical, or measured with error; wide range of doses/relevant to environmental levels.
Outcome Assessment	Clinical endpoints, patient-reported outcomes.	Broad range of pathological, physiological, and molecular endpoints across species and systems.
Risk of Bias Tools	Cochrane RoB (for RCTs), ROBINS-I (for observational).	Domain-based tools specific to evidence stream (e.g., OHAT Risk of Bias Tool for human & animal studies) [16].
Evidence Synthesis Goal	Quantitative meta-analysis of effect measures (e.g., RR, OR).	Qualitative weight-of-evidence integration; quantitative synthesis may be performed within a stream if studies are sufficiently similar [17].
Final Output	Summary of clinical effect, often with a quantitative estimate.	Hazard identification conclusion (e.g., "known to be a hazard," "suspected hazard," "not classifiable") [12].

The Seven-Step Framework for Toxicology Systematic Reviews

The OHAT framework provides a standardized, seven-step procedure for conducting systematic reviews that integrate multiple evidence streams to reach hazard identification conclusions [16].

Step 1: Problem Formulation & Protocol Development This critical first stage involves defining the PECOTS criteria, which explicitly frames the review around Exposure rather than a clinical intervention [16]. A detailed, publicly registered protocol is developed a priori, specifying the methods for all subsequent steps, including how different evidence streams will be identified and integrated.

Step 2: Search & Study Selection A comprehensive search is executed across multidisciplinary databases (e.g., PubMed/MEDLINE, TOXNET, Embase, Scopus) to capture literature from medical, toxicological, and environmental sciences [16]. The study selection process, documented via a PRISMA flow diagram, applies eligibility criteria independently by two reviewers to minimize bias [19] [20].

Step 3: Data Extraction Structured forms are used to extract detailed data on study design, population/exposure characteristics, outcomes, and results. Data extraction is typically performed by one reviewer and verified by a second to ensure accuracy [21]. Data from different streams (human, animal, mechanistic) are often extracted into separate, tailored forms.

Step 4: Risk of Bias Assessment of Individual Studies The credibility of each study is evaluated using evidence-stream-specific tools. For human studies, tools assess domains like confounding and exposure characterization. For animal studies, domains include randomization, blinding, and attrition. Mechanistic studies are evaluated for reliability and relevance [16]. This step is distinct from clinical reviews, which may not assess laboratory-based evidence.

Step 5: Rate Confidence in the Body of Evidence The overall reliability of the evidence for a specific outcome within each stream (e.g., human evidence for liver toxicity, animal evidence for liver toxicity) is rated. Systems like GRADE (Grading of Recommendations Assessment, Development and Evaluation) or its adaptations are used, considering risk of bias, consistency, directness, precision, and other factors [16].

Step 6: Translate Confidence Ratings into Levels of Evidence The confidence ratings are converted into discrete levels of evidence for each stream (e.g., "high," "moderate," "low," or "evidence of no effect") [16]. This creates a standardized input for the final integration step.

Step 7: Integrate Evidence Streams to Develop Hazard Identification Conclusions This is the most distinctive step. Using a predefined method (e.g., the OHAT approach or a visual integration tool), the levels of evidence from all streams are weighed together [17]. The process is deliberative and consensus-based, considering the strengths and limitations of each stream: human data provide direct relevance but often have exposure uncertainty, animal data provide controlled exposure but require cross-species extrapolation, and mechanistic data support biological plausibility but may not predict apical outcomes. The final output is a hazard conclusion (e.g., "known/suspected/likely to be a hazard" or "not identified as a hazard") [12] [16].

OHAT Framework: Evidence Integration Workflow

Detailed Methodological Protocols for Key Experiments

Implementing the systematic review framework requires precise protocols for handling different evidence streams. The following table outlines the core methodological considerations for each.

Table 2: Methodological Protocols for Evidence Streams in Toxicology Reviews

Evidence Stream	Core Study Designs	Key Data Extraction Elements	Risk of Bias Assessment Domains	Special Considerations for Synthesis
Human (Epidemiological)	Cohort, Case-Control, Cross-Sectional	- Exposure assessment method & metric.- Outcome definition & ascertainment.- Confounder adjustment & statistical model.- Effect estimate (RR, OR, HR) with CI.	1. Participant selection.2. Exposure characterization.3. Outcome assessment.4. Confounding control.5. Incomplete data.6. Selective reporting [16].	- Meta-analysis often limited by heterogeneity in exposure/outcome measurement.- Emphasis on consistency, dose-response, and temporal relationship.
Animal (Toxicology)	Controlled Laboratory Experiments (in vivo)	- Species, strain, sex, age.- Exposure route, duration, frequency, dose levels.- Detailed outcome data (incidence, severity, time-to-onset).- Historical control data.	1. Sequence generation (randomization).2. Allocation concealment.3. Blinding.4. Incomplete outcome data.5. Selective outcome reporting [16].	- Quantitative synthesis possible for similar studies (e.g., benchmark dose modeling).- Critical evaluation of study relevance to human exposure scenarios (e.g., dose, route).
Mechanistic (Other Relevant Data)	in vitro assays, ex vivo studies, in silico models, read-across.	- Test system (cell line, primary cells, tissue).- Biological endpoint (cytotoxicity, genotoxicity, receptor binding).- Concentration/dose-response relationship.- Relevance to hypothesized Adverse Outcome Pathway (AOP).	1. Reliability (e.g., protocol adherence, replication).2. Relevance (biological/chemical similarity to human case).3. Consistency (within and across test systems) [16].	- Not used in isolation for hazard identification.- Serves to support biological plausibility, explain concordance/discordance between human and animal data, or fill data gaps.

Conducting a high-quality toxicology systematic review requires leveraging specialized tools and databases beyond those used in clinical medicine.

Table 3: Research Reagent Solutions for Toxicology Systematic Reviews

Tool/Resource Category	Specific Examples	Function & Utility
Specialized Literature Databases	TOXNET (via PubMed), Scopus, Embase, Web of Science, ISTA (Index to Scientific & Technical Abstracts).	Broad coverage of toxicological, pharmacological, and environmental science literature not fully indexed in MEDLINE [16].
Systematic Review Management Software	Covidence, Rayyan, DistillerSR.	Platforms for collaborative title/abstract screening, full-text review, data extraction, and generation of PRISMA flow diagrams [21] [20].
Risk of Bias / Study Quality Tools	OHAT Risk of Bias Tool, SYRCLE's RoB tool for animal studies, Klimisch Score for in vitro studies.	Standardized, evidence-stream-specific tools to evaluate internal validity of individual studies [16].
Data Extraction & Management	Custom forms in Excel or Google Sheets, systematic review software modules, electronic lab notebooks.	Structured templates to consistently capture critical data from heterogeneous study designs across multiple streams [21].
Evidence Integration & Visualization	The UK COC/COT Visualisation Tool [17], OHAT evidence profile tables, AOP (Adverse Outcome Pathway) knowledgebase.	Frameworks and graphical tools to transparently document the weight-of-evidence judgment and communicate how different streams contributed to the final hazard conclusion [17].
Chemical & Toxicological Data Repositories	EPA CompTox Chemicals Dashboard, NTP CEBS (Chemical Effects in Biological Systems), OECD eChemPortal.	Sources for chemical identifiers, properties, and curated toxicological data to inform problem formulation and data extraction.

Visualizing Evidence Integration: A Weight-of-Evidence Approach

A major challenge is transparently communicating the integration process. Frameworks like the one proposed by the UK Committees on Toxicity and Carcinogenicity advocate for visual synthesis tools [17]. The following diagram conceptualizes this deliberative, qualitative process, where the strength and consistency of evidence within each stream, along with considerations of biological plausibility and concordance across streams, inform a final expert judgment on the probability of causation.

Weight of Evidence Integration Process

Executive Summary Within toxicology research—a field that directly informs chemical safety, regulatory decisions, and public health—the robustness of evidence is paramount. Systematic reviews and meta-analyses represent the pinnacle of the evidence hierarchy, providing synthesized conclusions from all available studies [11]. The validity of these conclusions and their utility for risk assessment depend entirely on the rigorous application of three core principles: transparency, reproducibility, and minimizing bias. This guide provides a technical roadmap for embedding these principles into every phase of a systematic review in toxicology, from question formulation to data synthesis. Adherence to this framework ensures that reviews produce reliable, actionable evidence capable of withstanding scientific and regulatory scrutiny.

Foundational Framework: The Systematic Review Protocol

A pre-registered, detailed protocol is the bedrock of a transparent, reproducible, and unbiased systematic review. It commits the research team to a predetermined plan, safeguarding against selective reporting and data-driven analysis.

1.1 Formulating a Structured Research Question The process begins with a precisely defined research question, commonly structured using the PICO(TTS) framework, adapted for toxicology [11].

• Population (P): The biological system (e.g., "in vivo mammalian models," "primary human hepatocytes").
• Intervention/Exposure (I/E): The toxicant or chemical of interest, including dose, route, and duration.
• Comparator (C): The control group (e.g., vehicle control, low-dose exposure, an alternative chemical).
• Outcome (O): The measured toxicological endpoint (e.g., mortality, tumor incidence, serum ALT level, gene expression change).
• Time, Type of Study, Setting (TTS): Specifies the relevant exposure windows, preferred study designs (e.g., randomized controlled trials, cohort studies), and experimental settings [11].

Table 1: Application of PICO(TTS) to a Toxicology Research Question

PICO(TTS) Element	Generic Definition	Example: Hepatotoxicity of Compound X
Population (P)	The biological system under investigation.	Adult Sprague-Dawley rats
Intervention/Exposure (I/E)	The toxicant, its dose, route, and duration.	Oral gavage of Compound X, ≥ 28 days
Comparator (C)	The control condition for comparison.	Vehicle control (e.g., corn oil)
Outcome (O)	The measured toxicological endpoint(s).	Serum alanine aminotransferase (ALT) activity, histopathological liver score
Type of Study (T)	The preferred experimental design.	Randomized controlled trials, controlled cohort studies
Time & Setting (TS)	Relevant exposure time and lab environment.	Not specified for this question

1.2 Protocol Registration & Reporting The finalized protocol should be registered on a public platform such as PROSPERO or the Open Science Framework. Reporting must follow established guidelines like PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols), ensuring all methodological choices are documented before literature screening begins.

The Systematic Review Workflow: A Phase-by-Phase Application of Core Principles

The following workflow diagram outlines the major stages of a systematic review, highlighting the critical actions required to uphold transparency, reproducibility, and bias minimization at each step.

Diagram 1: Core Principles in the Systematic Review Workflow (Max Width: 760px)

2.1 Phase 1: Comprehensive Literature Search (Transparency, Reproducibility) The goal is to identify all relevant evidence, minimizing selection bias. A reproducible search strategy is mandatory [11].

• Databases: Search multiple relevant databases (e.g., PubMed/MEDLINE, Embase, Scopus, TOXLINE) [11].
• Search Strategy: Develop a structured syntax using controlled vocabulary (e.g., MeSH terms) and free-text keywords, tailored for each database. The full strategy must be included in the review's supplement.
• Gray Literature: Include unpublished studies, theses, and conference abstracts from sources like clinical trial registries (e.g., ClinicalTrials.gov) to combat publication bias [11].

2.2 Phase 2: Study Screening & Selection (Minimizing Bias) This phase filters search results to identify studies meeting the PICO(TTS) criteria.

• Blinded Screening: Use dedicated software (e.g., Rayyan, Covidence) to have at least two independent reviewers screen titles/abstracts and full texts based on pre-defined eligibility criteria [11]. Discrepancies are resolved by consensus or a third reviewer.
• Documentation: A PRISMA flow diagram must document the number of records at each stage, with explicit reasons for exclusions at the full-text level.

2.3 Phase 3: Data Extraction & Critical Appraisal (Minimizing Bias, Reproducibility)

• Standardized Extraction: Data is extracted by independent reviewers using piloted, electronic forms. Extracted information includes study design, population characteristics, exposure details, outcome data, and funding sources.
• Risk of Bias (RoB) Assessment: The methodological rigor of each included study is evaluated using tools appropriate to its design. For animal studies, the SYRCLE's RoB tool is standard. For human observational studies, the Newcastle-Ottawa Scale is often used [11]. This assessment directly informs the synthesis and grading of evidence.

Table 2: Common Risk of Bias Assessment Tools for Toxicology Research

Tool Name	Primary Study Type	Key Domains Assessed	Role in Minimizing Bias
SYRCLE's RoB Tool	Animal Intervention Studies	Selection, performance, detection, attrition, reporting bias.	Identifies methodological flaws in preclinical data that may lead to overestimated effects.
Newcastle-Ottawa Scale (NOS)	Observational (Cohort, Case-Control)	Selection of groups, comparability, outcome/exposure assessment.	Evaluates susceptibility to confounding and measurement error in human studies.
Cochrane RoB 2.0	Randomized Controlled Trials (Human)	Randomization, deviations, missing data, outcome measurement, selective reporting.	Assesses the internal validity of human clinical trials included in the review.

2.4 Phase 4: Data Synthesis & Analysis (All Principles) Synthesis integrates findings from the included studies and can be qualitative, quantitative (meta-analysis), or both [22].

• Qualitative Synthesis: A structured narrative summary that explores patterns, relationships, and heterogeneity across studies. It should link findings to the RoB assessment [22].
• Quantitative Synthesis (Meta-Analysis): A statistical method for combining numerical results from multiple studies to produce an overall effect estimate [11].
  • Feasibility: Requires sufficient studies with clinically and methodologically similar designs and outcomes [22].
  • Statistical Methods: Software like R (with metafor package) or RevMan is used to calculate pooled effect sizes, confidence intervals, and assess statistical heterogeneity (e.g., I² statistic) [11].
  • Investigating Heterogeneity & Bias: Sources of variation are explored via subgroup analysis (e.g., by species, dose). Publication bias is assessed visually (funnel plots) and statistically (e.g., Egger's regression) [11].

The following diagram illustrates the decision pathway and methods for data synthesis and bias analysis.

Diagram 2: Data Synthesis and Bias Analysis Pathway (Max Width: 760px)

Adhering to the core principles requires leveraging specific tools and reagents throughout the review process.

Table 3: Research Toolkit for Systematic Reviews in Toxicology

Tool Category	Specific Tool/Resource	Primary Function in Upholding Principles
Protocol & Registration	PROSPERO, Open Science Framework	Transparency, Reproducibility: Creates a public, time-stamped record of the review plan before commencement.
Literature Management	EndNote, Zotero, Mendeley	Reproducibility: Manages citations, removes duplicates, and maintains a searchable library of all identified records [11].
Screening & Selection	Rayyan, Covidence	Minimizing Bias, Reproducibility: Enables blinded, independent screening by multiple reviewers with conflict resolution features [11].
Risk of Bias Assessment	SYRCLE's RoB Tool, Newcastle-Ottawa Scale	Minimizing Bias: Provides a structured, standardized framework to critically appraise study validity, informing analysis and conclusions.
Data Extraction & Management	Custom electronic forms (e.g., Google Forms, REDCap), Covidence	Reproducibility, Minimizing Bias: Ensures consistent and accurate capture of data from studies by independent extractors.
Statistical Synthesis	R (metafor, meta packages), RevMan, Stata	Transparency, Reproducibility: Performs meta-analyses with code/scripts that can be shared, allowing full independent verification of results [11].
Reporting Guidelines	PRISMA, ARRIVE (for animal studies)	Transparency: Provides a checklist to ensure all critical methodological and result information is reported completely.

In toxicology, where research outcomes guide decisions with significant societal and health implications, systematic reviews must be bastions of scientific integrity. The principles of transparency, reproducibility, and bias minimization are not abstract ideals but practical necessities. By rigorously implementing the protocol-driven framework, methodological safeguards, and specialized tools outlined in this guide, toxicologists can produce synthesized evidence that is reliable, auditable, and fit for purpose. This elevates the standard of evidence in the field, ultimately strengthening the foundation for chemical risk assessment and public health protection.

The field of toxicology is increasingly adopting evidence-based approaches to improve the transparency, objectivity, and reproducibility of hazard and risk assessments [1]. This shift addresses the limitations of traditional narrative reviews, which often suffer from implicit selection processes, potential for bias, and lack of reproducibility [1]. Evidence synthesis methodologies provide structured frameworks to comprehensively and systematically identify, evaluate, and summarize scientific evidence. Within this ecosystem, Systematic Reviews (SRs), Scoping Reviews, and Evidence Maps serve distinct but complementary purposes. The choice of methodology is pivotal and must be driven by the specific research question, whether it demands a definitive answer on toxicity (suited for an SR), seeks to map the breadth of literature on a broad topic (suited for a Scoping Review), or aims to catalog and characterize existing evidence to identify gaps (suited for an Evidence Map). This guide details the technical specifications, protocols, and applications of each review type within the context of toxicology and environmental health research.

Comparative Analysis of Review Types

The following table summarizes the core characteristics, purposes, and methodological distinctions between Systematic Reviews, Scoping Reviews, and Evidence Maps, drawing from established guidance in clinical epidemiology and toxicology [23] [1] [24].

Table 1: Core Characteristics of Evidence Synthesis Methodologies

Feature	Systematic Review (SR)	Scoping Review	Evidence Map (Mapping Review)
Primary Goal	To answer a focused research question by synthesizing evidence, often to inform a specific decision or conclusion.	To map the extent, range, and nature of research activity on a broad topic; to clarify key concepts [24].	To systematically catalog and characterize existing evidence on a broad field to identify gaps and inform future research priorities [23] [24].
Typical Research Question Framework	PICO (Population, Intervention/Exposure, Comparator, Outcome) or adaptations for toxicology (e.g., Population, Exposure, Comparator, Outcome) [1].	PCC (Population, Concept, Context) [23] [24].	Often uses PICO or similar frameworks focused on effectiveness or presence of evidence [23] [24].
Scope of Question	Narrow and specific.	Broad and exploratory.	Broad and cataloging.
Study Selection & Inclusion Criteria	Strict, pre-defined criteria focused on relevance to the specific question.	Broad and inclusive to cover the conceptual scope; may include diverse study designs.	Broad but focused on coding for specific characteristics (e.g., intervention type, population, study design).
Critical Appraisal (Risk of Bias)	Mandatory. Formal quality assessment of included studies is a defining feature.	Optional. Not required, as the aim is mapping, not weighted synthesis.	Typically not conducted. Focus is on characterizing the evidence base, not appraising it.
Data Extraction	Comprehensive and detailed to enable synthesis and analysis.	Charts key information relevant to mapping the field.	Limited to coding of predefined study characteristics and interventions [23].
Synthesis	Qualitative and/or quantitative (meta-analysis). Aims to generate a summary of findings with an assessed strength of evidence.	Descriptive summary or thematic analysis. No synthesis in the SR sense; results in a narrative and tabular presentation.	Descriptive and visual. Results are presented in searchable databases, tables, and graphical maps (e.g., bubble plots).
Key Output	Answer to a specific question; often used for risk assessment or guideline development.	Map of the literature, identification of research gaps, clarification of concepts/definitions.	Visual map and inventory of evidence; clear identification of clusters and gaps to guide research funding or commissioning [23].
Time & Resource Intensity	High (often >1 year) [1].	Moderate to High.	Moderate.

Table 2: Application in Toxicology & Environmental Health Research

Review Type	Best Use Cases in Toxicology	Example Toxicology Research Question
Systematic Review	Hazard identification, dose-response assessment, evaluating efficacy of an antidote or therapeutic intervention, supporting regulatory decision-making.	"In adult mammalian animal models, does chronic oral exposure to chemical X compared to control increase the incidence of hepatocellular carcinoma?"
Scoping Review	Exploring how a toxicological concept (e.g., "endocrine disruption," "non-monotonic dose response") is defined and measured across disciplines; identifying all reported health outcomes associated with a broad class of chemicals.	"What is the scope and nature of research on the neurodevelopmental effects of per- and polyfluoroalkyl substances (PFAS) in epidemiological studies?"
Evidence Map	Identifying what primary and secondary research exists on a large family of chemicals (e.g., pesticides, flame retardants) to prioritize substances for future SRs or targeted testing.	"What is the volume and distribution of evidence from in vivo and in vitro studies on the genotoxicity of substituted phenols?"

Methodological Protocols

Systematic Review Protocol (Based on COSTER Recommendations)

The Conduct of Systematic Reviews in Toxicology and Environmental Health Research (COSTER) guidelines provide a consensus standard for SRs in this field [18]. The protocol must be registered (e.g., in PROSPERO) prior to commencement.

• Planning & Team Assembly: Form a multidisciplinary team including subject matter experts, information specialists, and review methodologies. Declare and manage conflicts of interest [18].
• Framing the Question: Define the review question using a structured framework (e.g., PECO: Population, Exposure, Comparator, Outcome). Precisely specify the toxicological agent, population(s) (species, strain, cell type), outcomes, and study designs of interest.
• Developing the Search Strategy: Work with an information specialist. Search multiple bibliographic databases (e.g., PubMed, Embase, TOXLINE, Web of Science), trial registers, and grey literature sources. Use a comprehensive list of search terms and chemical synonyms/CAS numbers. Document the full strategy.
• Study Selection: Screen titles/abstracts and full texts independently by two reviewers against pre-defined eligibility criteria, using software (e.g., Rayyan, Covidence). Resolve conflicts via consensus or third-party adjudication.
• Data Extraction: Use a piloted, standardized form. Extract study design, population characteristics, exposure details, outcome data, and key results. Perform extraction in duplicate.
• Risk of Bias / Quality Assessment: Assess internal validity of each study using a domain-based tool appropriate to the design (e.g., SYRCLE's RoB tool for animal studies, OHAT/NTP tool for human and animal studies) [1].
• Evidence Synthesis: Tabulate study characteristics and results. Conduct a qualitative synthesis. If studies are sufficiently homogeneous, perform a meta-analysis to calculate summary effect estimates. Address heterogeneity through subgroup or sensitivity analyses.
• Rating the Confidence in Evidence: Use a framework (e.g., GRADE for human studies, adapted GRADE for animal studies) to rate the overall body of evidence for each key outcome as high, moderate, low, or very low confidence.
• Reporting: Adhere to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. For environmental health SRs, the COSTER recommendations provide additional reporting guidance [18].
• Interpretation & Knowledge Translation: Discuss the strength and limitations of the evidence, implications for research and policy, and relevance to risk assessment.

Scoping Review Protocol (Based on Arksey & O'Malley Framework)

Scoping reviews follow an iterative, flexible framework [24].

• Identifying the Research Question: Establish a broad question based on the PCC (Population, Concept, Context) framework.
• Identifying Relevant Studies: Conduct comprehensive searches across multiple databases and grey literature. The search strategy may be refined iteratively as reviewers become more familiar with the literature.
• Study Selection: Apply inclusion/exclusion criteria to map the literature. Selection is typically performed in two stages (title/abstract, full-text), often with a second reviewer verifying a subset.
• Charting the Data: Develop a data-charting form to extract relevant information about the study design, methods, concepts, and key findings relevant to the mapping objective. The form may be updated during the process.
• Collating, Summarizing, and Reporting the Results: Analyze the extracted data quantitatively (e.g., counts of study designs, years, geographic locations) and qualitatively (thematic analysis). Present results in tables, charts, and a narrative summary.
• Consultation (Optional): Engage with stakeholders (e.g., researchers, policymakers) to inform the review process or validate findings.

Evidence Map Protocol

The protocol for an Evidence Map shares steps with Scoping and SR protocols but has a distinct analytical focus [23] [24].

• Question Formulation: Often uses a PICO-style question focused on the existence and characteristics of evidence (e.g., "What evidence exists on the health effects of chemical class Y?").
• Search & Selection: Conducts a systematic search with broad inclusion criteria to capture all relevant evidence on the topic. Study selection is documented via a PRISMA flow diagram.
• Data Extraction & Coding: Extracts a standardized set of descriptive data about each study (e.g., chemical, population, study type, outcome domain, funding source). This creates a coded database.
• Critical Appraisal: Usually omitted, as the goal is descriptive mapping.
• Synthesis & Visualization: Analyzes the coded database to quantify the volume and distribution of research. Results are presented as:
  • A searchable database or evidence inventory.
  • Structured tables summarizing evidence volume by key dimensions.
  • Visual maps (e.g., bubble plots) where axes represent two key dimensions (e.g., chemical vs. outcome), bubble size represents number of studies, and color may represent study type.

Figure 1: Decision Pathway for Selecting a Review Methodology [23] [24].

Table 3: Research Reagent Solutions for Evidence Synthesis in Toxicology

Item / Resource	Function / Purpose	Key Examples & Notes
Protocol Registries	To pre-register the review plan, reduce duplication of effort, and minimize reporting bias.	PROSPERO (International prospective register of systematic reviews).
Reporting Guidelines	To ensure transparent and complete reporting of the review process and findings.	PRISMA (Systematic Reviews & Meta-Analyses) [1], PRISMA-ScR (Scoping Reviews) [24], COSTER (Environmental Health SRs) [18].
Toxicology-Specific Guidance	To address methodological challenges unique to toxicology (e.g., multiple evidence streams, species extrapolation).	COSTER Recommendations [18], OHAT/NTP Handbook [1], EFSA Guidance [1].
Information Sources	To ensure a comprehensive search for toxicological evidence.	Bibliographic Databases: PubMed/MEDLINE, Embase, TOXLINE, Web of Science. Chemical Databases: PubChem, ChemIDplus. Grey Literature: gov't reports (EPA, EFSA), dissertations, conference abstracts [18].
Study Selection & Data Extraction Tools	To manage the screening process and extract data in a standardized, reproducible manner.	Rayyan, Covidence, DistillerSR, EPPI-Reviewer.
Risk of Bias Tools	To critically appraise the internal validity of included studies.	Animal Studies: SYRCLE's RoB tool, OHAT/NTP tool. Human Observational Studies: ROBINS-I, Newcastle-Ottawa Scale. In Vitro Studies: (Emerging tools, often adapted from other designs).
Evidence Grading Frameworks	To rate the confidence in the body of evidence for a given outcome.	GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) and its adaptations for pre-clinical research.
Data Synthesis & Visualization Software	To perform meta-analysis and create informative graphs.	Statistical: R (metafor, meta packages), Stata, RevMan. Visualization: R (ggplot2), Python (matplotlib, seaborn), standard graphing software.

Figure 2: Core Systematic Review Workflow in Toxicology [1] [18].

Selecting the appropriate review methodology is a critical first step in any evidence synthesis project in toxicology. Systematic Reviews are the gold standard for answering focused questions to support hazard characterization and decision-making but are resource-intensive. Scoping Reviews provide the necessary breadth to explore under-researched or complex topics and clarify definitions. Evidence Maps offer a strategic overview of a research landscape, efficiently pinpointing where sufficient evidence exists for a full SR and where critical knowledge gaps remain.

For toxicologists and environmental health scientists, the emergence of field-specific guidance like the COSTER recommendations provides a crucial toolkit for navigating the unique challenges of integrating heterogeneous evidence streams [18]. Ultimately, the choice hinges on a clear articulation of the review's purpose: to answer, to explore, or to map. By applying these methodologies rigorously, the toxicology community can produce more transparent, reliable, and actionable syntheses of evidence to inform both science and policy.

The How-To: A Stepwise Protocol for Executing Your Toxicology Systematic Review

The formulation of a precise and answerable research question is the foundational step of any systematic review in toxicology [1] [25]. This initial step defines the scope, determines the methodology for the subsequent search and synthesis, and directly impacts the review's validity and utility for decision-making [26]. Unlike traditional narrative reviews, which often address broad topics, a systematic review requires a tightly focused question that can be addressed through a transparent and reproducible process of evidence identification, evaluation, and synthesis [1].

The PECO framework (Population, Exposure, Comparator, Outcome) is the toxicological adaptation of the PICO (Population, Intervention, Comparator, Outcome) model used in clinical medicine [26]. Its primary function is to structure a review question with unambiguous components, which then translate directly into the review's inclusion/exclusion criteria and literature search strategy [27]. A well-constructed PECO question minimizes bias, enhances reproducibility, and ensures the review efficiently targets the most relevant evidence [28].

Table 1: Key Distinctions Between Narrative and Systematic Reviews in Toxicology

Feature	Narrative Review	Systematic Review
Research Question	Broad and often not explicitly specified [1]	Specific and structured using frameworks like PECO [1]
Literature Search	Not typically specified or systematic [1]	Comprehensive, from multiple databases, with explicit search strategy [1]
Study Selection	Implicit, based on expert knowledge [1]	Explicit, based on pre-defined inclusion/exclusion criteria [1]
Quality Assessment	Usually informal or absent [1]	Critical appraisal using explicit risk-of-bias tools [27]
Evidence Synthesis	Qualitative summary [1]	Structured qualitative and/or quantitative (meta-analysis) summary [1]
Time & Resources	Generally lower (months) [1]	Substantially higher (often >1 year) [1]
Output	Expert opinion, state-of-the-science overview [1]	Transparent, reproducible evidence base for decision-making [25]

Deconstructing the PECO/PICOS Framework for Toxicology

The PECO framework provides the necessary structure for toxicological questions, which differ from clinical questions by focusing on hazardous exposures rather than therapeutic interventions.

Population (P): This defines the subject of study, which in toxicology can include humans (specific populations, e.g., workers, children), experimental animal models (species, strain, sex, life stage), in vitro systems (cell lines, primary cultures), or environmental species [1]. Clarity here is crucial for defining the biological context and applicability of the evidence.

Exposure (E): This is the toxicological agent or condition of interest. It must be precisely defined, including the specific chemical or stressor, its form, route of exposure (oral, inhalation, dermal), duration (acute, chronic), and timing (e.g., developmental window) [28]. For complex mixtures, the definition becomes more challenging and must be carefully considered.

Comparator (C): This defines the reference against which exposure is evaluated. In animal or in vitro studies, this is typically a control group (e.g., vehicle-treated, sham-exposed). In human epidemiology, it may be a population with lower exposure levels or background exposure [29]. The choice of comparator influences the interpretation of the effect.

Outcome (O): This specifies the adverse health effect or endpoint under investigation. Outcomes in toxicology span multiple levels of biological organization, from molecular initiating events (e.g., receptor binding) and key cellular events (e.g., oxidative stress, proliferation) to organ-level effects (e.g., steatosis, fibrosis) and apical disease outcomes (e.g., cancer, reproductive dysfunction) [26] [28]. Defining relevant outcomes is key to linking mechanistic data to adverse effects.

Study Design (S - optional): Sometimes included as "S" in PICOS, this component can restrict evidence to specific methodological approaches (e.g., randomized controlled trials, cohort studies, controlled laboratory studies). In toxicology, specifying evidence streams (epidemiological, in vivo, in vitro) at the question stage can help manage the complexity of integrating diverse data types [28].

Constructing a High-Quality PECO Question: A Stepwise Guide

Constructing an effective PECO question is an iterative process that requires balancing specificity with feasibility.

Step 1: Define the Core Problem Begin with a broad problem statement (e.g., "Concerns about the potential hepatotoxicity of Chemical X"). Engage stakeholders, including subject matter experts, to understand the decision-making context and key uncertainties [27].

Step 2: Specify Each PECO Element with Precision

• Population: Avoid overly broad definitions. Instead of "mammals," specify "adult female Sprague-Dawley rats" or "human occupational cohorts."
• Exposure: Provide chemical identifiers (CAS RN), define relevant real-world exposure scenarios (e.g., "oral exposure, ≥ 90 days"), and consider metabolites if relevant.
• Comparator: State the exact reference (e.g., "vehicle control (corn oil)," "population with exposure below the 10th percentile").
• Outcome: Use standardized terminology where possible. Define the outcome operationally (e.g., "hepatocellular hypertrophy diagnosed by histopathology," "serum alanine aminotransferase activity increased ≥ 2-fold over control").

Step 3: Evaluate and Refine the Question Test the question for feasibility (is there likely to be sufficient evidence?), clarity (would different reviewers interpret it the same way?), and relevance (does it address the core problem?) [25]. A question that is too narrow may yield no evidence; one that is too broad becomes unmanageable.

Step 4: Align with the Adverse Outcome Pathway (AOP) Framework (Where Applicable) For mechanism-focused reviews, the PECO question can be structured around elements of an Adverse Outcome Pathway. This is particularly powerful for integrating New Approach Methodologies (NAMs). The Molecular Initiating Event (MIE) or a Key Event (KE) can serve as the Outcome in a PECO question aimed at collecting evidence for a specific segment of the AOP [26].

From Question to Protocol: Operationalizing PECO

The finalized PECO question is the cornerstone of the systematic review protocol, a publicly registered document that pre-specifies the review's methods to minimize bias [29].

Protocol Development: The protocol explicitly translates each PECO element into operational criteria.

• Population becomes the eligibility criteria for test systems.
• Exposure defines the search terms and chemical identifiers.
• Comparator sets the threshold for study inclusion.
• Outcome lists the exact endpoints and measurement methods that will be extracted from studies [27].

Search Strategy: A biomedical librarian or information specialist should be involved. The search strategy uses controlled vocabulary (e.g., MeSH terms) and free-text words derived from the PECO elements, combined with Boolean operators. It should be designed for sensitivity (to capture all relevant evidence) across multiple databases (e.g., PubMed, Web of Science, Embase, ToxLine) [29].

Screening and Data Extraction: The PECO framework is used to create standardized forms for title/abstract screening and full-text review. At least two independent reviewers screen studies, with conflicts resolved by consensus or a third reviewer [29]. Data extraction templates are structured to capture detailed information pertinent to each PECO element from every included study.

Table 2: Key Components of a Systematic Review Protocol Derived from PECO

Protocol Section	Description	Direct Link to PECO
Review Question	Statement of the primary question.	The fully articulated PECO question.
Eligibility Criteria	Detailed rules for including/excluding studies.	Operational definitions of P, E, C, and O.
Information Sources	List of databases and other resources to be searched.	Strategy to capture all evidence for the defined PECO.
Search Strategy	Complete, reproducible search query.	Translates PECO concepts into search syntax.
Study Selection	Process for screening references.	Application of eligibility criteria based on PECO.
Data Extraction	Items to be collected from each study.	Detailed characterization of P, E, C, O, and study design.

Case Study: PECO in Action

The SYRINA framework for Endocrine Disrupting Chemicals (EDCs) provides a clear case study [28]. To evaluate whether a chemical is an EDC per the WHO/ICPS definition, three evidence needs must be met. A series of linked systematic reviews, each with its own PECO question, can be conducted:

• Question for Adverse Effect: "In female rats (P), does in utero exposure to Chemical Z (E), compared to vehicle control (C), increase the incidence of reproductive tract malformations (O)?"
• Question for Endocrine Activity: "In estrogen receptor alpha transactivation assays (P), does Chemical Z (E), compared to solvent control (C), demonstrate agonist activity (O)?"
• Question for Plausible Link: This involves an integrated assessment of evidence from the first two reviews, examining biological plausibility and coherence [28].

Table 3: Research Reagent Solutions for Systematic Review Implementation

Tool / Resource	Category	Function in PECO-Based Review
PROSPERO Registry	Protocol Repository	Public registration of review protocol to enhance transparency and reduce bias.
Cochrane Risk-of-Bias (RoB) Tools	Quality Assessment	Structured tools to evaluate internal validity of randomized trials (RoB 2.0) and observational studies (ROBINS-I).
OHAT / Navigation Guide RoB Tool	Quality Assessment	Tool adapted for environmental health studies, assessing selection, performance, detection, attrition, and reporting bias [27].
EndNote, Covidence, Rayyan	Reference Management & Screening	Software platforms to manage search results, enable blinded screening by multiple reviewers, and track decisions.
GRADE (Grading of Recommendations, Assessment, Development, and Evaluations)	Evidence Grading	Framework for rating the overall certainty (high, moderate, low, very low) of a body of evidence across studies.
AOP-Wiki (aopwiki.org)	Knowledge Organization	Repository of Adverse Outcome Pathways; useful for defining mechanistic outcomes and contextualizing evidence [26].

Formulating a focused question using the PECO framework is a non-negotiable first step in conducting a rigorous, reproducible, and unbiased systematic review in toxicology. It transforms a general concern into a structured, investigable query that guides every subsequent methodological choice [1]. As evidence-based toxicology matures, mastery of PECO question formulation remains a fundamental skill for researchers and professionals aiming to produce syntheses that reliably inform scientific understanding, risk assessment, and public health policy [25].

The Critical Role of a Protocol in Toxicology Systematic Reviews

In evidence-based toxicology, the systematic review is the cornerstone for synthesizing data to inform risk assessments and regulatory decisions [1]. A meticulously developed protocol is the essential foundation of any rigorous systematic review. It serves as a pre-defined roadmap, minimizing arbitrariness in decision-making and safeguarding against selective reporting bias, which is crucial when evaluating potentially hazardous substances [30]. Unlike traditional narrative reviews, which may lack transparency, a protocol ensures the review process is explicit, reproducible, and methodologically sound [1].

The development and registration of a protocol are particularly vital in toxicology due to the field's unique complexities. Reviews must often integrate evidence from multiple streams, including human observational studies, in vivo animal models, in vitro assays, and in silico models [1]. Furthermore, challenges such as assessing multiple species, strains, and diverse adverse outcome endpoints necessitate a priori planning to ensure consistency and objectivity [1]. A publicly registered protocol also prevents unnecessary duplication of effort and allows the scientific community to scrutinize the planned methods, thereby enhancing the credibility of the eventual review [31] [30].

PRISMA-P: The Reporting Guideline for Protocols

The Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) is an evidence-based guideline developed to ensure the complete and transparent reporting of systematic review protocols [32] [30]. Published in 2015, its primary objective is to improve the quality of systematic review protocols by providing a minimum set of items that should be addressed in the protocol document [30].

It is critical to distinguish PRISMA-P from protocol registries. PRISMA-P is a reporting guideline—it dictates what information should be included in a protocol document to make it complete [30]. In contrast, a registry like PROSPERO is a public database where key information about the planned review is recorded for the world to see [30]. The two tools are complementary: authors should use the PRISMA-P checklist to develop a robust, detailed protocol and then register the key details from that protocol in a registry [31] [30].

Table 1: The PRISMA-P 2015 Checklist (17-Item Summary)

Section	Item #	Item Description
Administrative	1	Identification: Protocol title, registration, authors, contributions, contact, amendments.
	2	Contributions: Names, affiliations, contributions of protocol contributors.
	3	Amendments: Procedure for documenting and reporting protocol changes.
Introduction	4	Rationale: Description of the health problem and rationale for the review.
	5	Objectives: Explicit statement of the primary and secondary review questions.
Methods	6	Eligibility Criteria: PICO/PECO elements (Population, Intervention/Exposure, Comparator, Outcome).
	7	Information Sources: Planned databases, trial registers, websites, journals, contact with experts.
	8	Search Strategy: Draft search strategy for at least one primary database (e.g., MEDLINE).
	9	Study Records: Data management, selection process, data collection process.
	10	Data Items: List and define all variables for extraction (outcomes, exposures, effect modifiers).
	11	Outcomes & Prioritization: Define and prioritize all primary and secondary outcomes.
	12	Risk of Bias Assessment: Tools and process for assessing methodological quality of individual studies.
	13	Data Synthesis: Criteria for quantitative synthesis (meta-analysis); statistical methods; heterogeneity investigation.
	14	Meta-bias(es): Plans for assessing publication/reporting bias across studies (e.g., funnel plots).
	15	Confidence in Evidence: Planned approach for assessing the overall strength/certainty of the body of evidence (e.g., GRADE).

Developing a Toxicology Systematic Review Protocol: A Stepwise Methodology

Defining the Review Question and Eligibility Criteria (PECO)

The foundation of a toxicology systematic review is a precisely framed research question, commonly structured using the PECO framework (Population, Exposure, Comparator, Outcome) [1]. This framework is adapted from clinical medicine's PICO, replacing "Intervention" with "Exposure" to reflect toxicological inquiry.

• Population: Define the biological system (e.g., human, specific animal species/strain, cell line). For human studies, specify relevant demographics [1].
• Exposure: Specify the chemical agent(s), including details on form, dose, duration, and route of administration (e.g., oral gavage, inhalation) [1].
• Comparator: Define the appropriate control (e.g., vehicle control, placebo, low-dose or background exposure group).
• Outcome: Clearly state the adverse health outcomes or toxicological endpoints of interest (e.g., mortality, tumor incidence, reproductive toxicity, biomarker change). Predefine primary and secondary outcomes [30].

Designing a Comprehensive Search Strategy

A systematic search must be designed to maximize sensitivity (finding all relevant studies) while maintaining manageable precision [30]. The strategy should be peer-reviewed, often by a research librarian [31].

• Database Selection: Search multiple bibliographic databases beyond PubMed/MEDLINE. Toxicology-specific databases are essential. Table 2: Key Information Sources for Toxicology Systematic Reviews

  Database/Resource	Scope and Relevance
  PubMed/MEDLINE	Core biomedical literature.
  Embase	Strong coverage of pharmacology and toxicology, including conference abstracts.
  TOXLINE	Specialized in toxicology, environmental health, and chemical safety.
  Scifinderⁿ / CAS	Covers chemical literature, including patents and obscure journals.
  Web of Science Core Collection	Multidisciplinary science citation index.
  EPA WebFIRE / IRIS	Source for regulatory reports and risk assessments.
  Government & Agency Websites (EFSA, NTP, IARC)	Grey literature, technical reports, and monographs.

• Search String Development: Use controlled vocabulary (e.g., MeSH terms for PubMed) combined with free-text keywords for the PECO elements. Include synonyms, related terms, and chemical registry numbers (e.g., CAS RN) [33].

Planning Study Selection, Data Extraction, and Risk of Bias Assessment

The protocol must detail a reproducible, unbiased process for handling studies [30].

• Study Selection Process: Describe a two-stage screening (title/abstract, then full-text) conducted independently by at least two reviewers. Define and pilot the eligibility criteria using the PECO framework. Use tools like Rayyan or Covidence for management [33].
• Data Extraction: Specify the variables to be extracted into a standardized form. These include study identifiers, PECO details, experimental design, funding source, and quantitative results (e.g., mean, SD, N for each group) [30].
• Risk of Bias (RoB) Assessment: Selecting an appropriate tool is critical. The protocol must state the chosen tool and justify its use. For animal studies, tools like SYRCLE's RoB tool or the NTP/OHAT Risk of Bias Rating Tool are relevant [1] [34]. For in vitro studies, adapted tools or criteria-based checklists are used [34]. The process should also be performed in duplicate.

Planning Data Synthesis and Evidence Integration

The protocol must pre-specify the approach for synthesizing findings from the included studies [30].

• Qualitative Synthesis: Plan a structured summary of study characteristics and findings, often presented in tables.
• Quantitative Synthesis (Meta-analysis): State the preconditions for performing a meta-analysis (e.g., sufficient homogeneity in PECO, available statistical data). Specify the statistical models (e.g., random-effects vs. fixed-effect), effect measures (e.g., odds ratio, mean difference), and methods for assessing heterogeneity (I² statistic) [30].
• Assessing Confidence in the Evidence: Describe the planned method for grading the overall strength or certainty of the evidence for each key outcome. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework, adapted for toxicology, is widely recommended for this purpose [1] [33]. This involves rating confidence (High, Moderate, Low, Very Low) based on RoB, consistency, directness, precision, and other factors.

Protocol Registration and Publication

Registering the protocol is a mandatory step that locks in the research plan, protects against duplication, and promotes transparency [31] [35].

• PROSPERO: The International Prospective Register of Systematic Reviews is the primary, free, publicly accessible registry for health-related systematic reviews [31] [33]. It requires submission of key protocol elements and assigns a unique registration number. Note that PROSPERO currently does not accept scoping reviews [35].
• Open Science Framework (OSF) Registries: A flexible, open-source platform suitable for registering any review type, including scoping reviews and systematic reviews that may not fit PROSPERO's criteria [31] [33].
• Publishing the Protocol: Consider submitting the full protocol to a peer-reviewed journal (e.g., BMJ Open, Systematic Reviews) for formal dissemination and feedback [31].

Toxicology-Specific Adaptations and Considerations

Applying the PRISMA-P framework to toxicology requires specific adaptations to address the field's methodological challenges [1].

• Integrating Multiple Evidence Streams: A key challenge is integrating data from divergent study types (e.g., human epidemiology, animal toxicology, in vitro mechanistics). The protocol should outline a pre-planned framework for evidence integration, such as aligning results across streams based on biological plausibility or using weight-of-evidence approaches [1].
• Including Non-Standard Study Types: For certain questions, such as rare adverse events or acute poisonings, case reports and case series may provide critical evidence. The protocol can define rigorous criteria for their inclusion, such as adherence to the CARE guidelines for reporting and the use of specific critical appraisal tools [33].
• Assessing Toxicological Study Quality: Beyond generic risk of bias, toxicology-specific methodological quality concerns must be addressed. The protocol should specify checks for test substance characterization, dose verification, blinding in pathology assessment, and appropriateness of animal models, drawing on guidance like that from the National Toxicology Program [34].

The Systematic Review Toolkit for Toxicologists

Table 3: Essential Research Reagent Solutions for Toxicology Systematic Reviews

Tool / Resource	Category	Primary Function in Protocol Development
PRISMA-P Checklist [32] [30]	Reporting Guideline	Provides the mandatory 17-item structure for the protocol document to ensure completeness.
PROSPERO Registry [31] [33]	Protocol Registry	Publicly registers the review plan to prevent duplication, reduce bias, and ensure transparency.
PECO Framework [1]	Question Formulation	Structures the toxicology review question (Population, Exposure, Comparator, Outcome).
SYRCLE's RoB Tool [34]	Quality Assessment	Assesses risk of bias specifically in animal intervention studies.
OHAT/NTP RoB Tool [1] [34]	Quality Assessment	Tool for assessing risk of bias in human and animal studies of environmental exposures.
GRADE Framework [1] [33]	Evidence Grading	Systematically rates the overall certainty (High to Very Low) of the body of evidence for each outcome.
Navigation Guide Methodology [1] [33]	Review Methodology	Provides a structured, stepwise process for evidence-based reviews in environmental health.
Rayyan / Covidence	Review Management	Web-based tools for managing collaborative screening, selection, and data extraction phases.
EndNote / Zotero	Reference Management	Manages citations and PDFs, crucial for handling large search results.
TOXLINE / HSDB	Specialized Database	Key toxicology-specific bibliographic and factual databases for comprehensive searching.

In the rigorous framework of evidence-based toxicology, the systematic review is established as the core tool for transparently and reproducibly synthesizing available evidence on a precisely defined research question [1]. Unlike traditional narrative reviews, which may employ implicit and non-transparent processes, a systematic review employs explicit, methodologically sound procedures to minimize bias and error in the selection and summary of studies [1]. The search strategy is the foundational component of this process. Its comprehensiveness directly dictates the quality and validity of the entire review, as it determines the body of evidence upon which all subsequent analysis and conclusions are based.

Designing a search strategy for toxicology presents unique challenges not always encountered in clinical medical reviews. Toxicology questions often involve integrating evidence from multiple streams, including human observational studies, animal toxicology, in vitro assays, and in silico models [1]. Furthermore, reviews may concern a wide array of outcomes and endpoints, exposures to complex chemical mixtures, and the need for cross-species extrapolation in the frequent absence of direct human data [1]. A poorly constructed search that fails to capture relevant evidence from these diverse sources can lead to incomplete or biased conclusions, undermining the review's utility for risk assessment and regulatory decision-making [1]. This guide provides a detailed technical protocol for constructing a comprehensive, multi-database search strategy tailored to the specific demands of toxicology research.

Foundational Principles and Protocol Development

Defining the Research Question: The PECO Framework

A precise and answerable research question is the indispensable first step. In toxicology, the PECO framework (Population, Exposure, Comparator, Outcome) is the standard for structuring and focusing the question [36].

• Population: The organisms or systems under study (e.g., human populations, specific animal species and strains, primary hepatocytes).
• Exposure: The chemical, substance, or mixture of interest, including specific details on route, duration, and dose where relevant.
• Comparator: The control or reference condition (e.g., placebo, unexposed group, a different dose level).
• Outcome: The toxicological endpoints or effects measured (e.g., mortality, clinical observation, histopathology, specific biomarker changes).

A well-defined PECO statement directly informs the development of inclusion/exclusion criteria and the selection of search terms. For example, a PECO statement for a review on perfluoropropanoic acid (PFPrA) would specify the chemical, relevant models (human, animal), and health outcomes of interest [36].

The Imperative for Searching Multiple Databases

Relying on a single database is a critical methodological flaw. Empirical research demonstrates that different bibliographic databases yield significantly different sets of relevant articles, even for the same search concept [37]. This variability arises from:

• Differential Journal Coverage: Databases index different sets of journals. A study on psychiatry journals found approximately one-third were indexed in only one major database [37].
• Controlled Vocabulary Disparities: Databases use unique indexing terms (e.g., MeSH in PubMed vs. the Thesaurus of Psychological Index Terms in PsycINFO) [37]. Synonyms for the same concept (e.g., "Attention Deficit Hyperactivity Disorder" vs. "Hyperkinetic Disorder") may not be mapped uniformly [37].
• Search Engine Functionality: Capabilities like filtering by study type can vary between platforms [37].

Consequently, guidance for systematic reviews mandates searching multiple databases to ensure a comprehensive capture of the literature and to minimize source selection bias [38]. For toxicology, this means moving beyond core biomedical databases to include specialized toxicological and chemical resources.

Table 1: Core and Specialized Databases for Toxicology Systematic Reviews

Database Name	Primary Focus/Publisher	Key Features & Relevance to Toxicology	Access Notes
PubMed/Medline	Biomedical and life sciences (NLM)	Comprehensive coverage of human health, pharmacology, and some toxicology; uses MeSH terms.	Free access.
Embase	Biomedical and pharmacology (Elsevier)	Strong international coverage of pharmacology, toxicology, and drug research; uses Emtree thesaurus.	Subscription required.
Web of Science Core Collection	Multidisciplinary science (Clarivate)	Provides powerful citation searching; covers a broad range of high-impact journals across sciences.	Subscription required.
Scopus	Multidisciplinary science (Elsevier)	Large abstract and citation database; includes robust tools for analysis and tracking citations.	Subscription required.
ToxLine (via various platforms)	Toxicology literature (Historically NLM)	Specialized resource for toxicological literature. Content may now be integrated into other NLM products.	Varies by platform.
EPA's HERO Database	Environmental health risk assessment (U.S. EPA)	Archives references used in EPA scientific assessments; includes many gray literature sources [36].	Free access.
ScienceDirect	Multidisciplinary full-text (Elsevier)	Provides direct access to a vast collection of journal articles and book chapters in toxicology.	Subscription required for full text.

Registering the Protocol

Prior to executing searches, the full methodology should be documented in a publicly accessible review protocol. This pre-commitment minimizes bias, enhances transparency, and reduces duplication of effort. Platforms like PROSPERO are widely used for registering systematic review protocols.

Developing and Executing the Search Strategy: A Technical Protocol

Search Term Development

The process involves building a complex Boolean search string tailored for each database's syntax.

• Identify Core Concepts: Extract key elements from the PECO statement.
• Brainstorm Synonyms and Variants: For each concept, list all plausible terms.
  • Chemical/Exposure Terms: Include systematic names, common names, acronyms, abbreviations, trade names, and CAS Registry Numbers [36]. Resources like the EPA CompTox Chemicals Dashboard are invaluable for identifying synonyms [36].
  • Outcome Terms: Include general (e.g., "toxicity," "adverse effect") and specific terms (e.g., "hepatotoxicity," "neurodevelopment").
  • Methodological Terms: For some reviews, terms related to study design (e.g., "cohort," "bioassay") may be necessary.
• Utilize Controlled Vocabulary: Identify and incorporate relevant indexing terms (MeSH, Emtree) for each database.
• Construct Boolean Strings: Combine terms using Boolean operators (AND, OR, NOT).
  • Group synonyms for a single concept with OR.
  • Link different PECO concepts with AND.
  • Use NOT cautiously to exclude clearly irrelevant categories (e.g., NOT "review" if only seeking primary studies).
• Apply Field Tags and Proximity Operators: Use database-specific tags (e.g., [tiab] in PubMed, :ti,ab,kw in Ovid) to restrict searches to title, abstract, and keyword fields. Proximity operators (e.g., NEAR/n) can find closely related terms.

Protocol Example: Developing a Search String for an Animal Toxicity Study

• PECO Concept (Exposure - Chemical X): "Chemical X" OR "CX" OR "12345-67-8"[RN] OR (("synonym A"[tiab] OR "synonym B"[tiab]) AND "manufacturer Z"[affil])
• PECO Concept (Outcome - Liver Effects): "liver" OR "hepatic" OR "hepatotoxicity" OR "ALT" OR "alanine transaminase" OR "steatosis" OR "Liver"[Mesh]
• PECO Concept (Population - Rodent): "mouse" OR "mice" OR "murine" OR "rat" OR "rats" OR "rodent" OR "Mice"[Mesh] OR "Rats"[Mesh]
• Final Boolean String (PubMed): ("Chemical X"[tiab] OR "CX"[tiab] OR "12345-67-8"[RN]) AND ("liver"[tiab] OR "hepatic"[tiab] OR "hepatotoxicity"[tiab] OR "ALT"[tiab] OR "alanine transaminase"[tiab] OR "steatosis"[tiab] OR "Liver"[Mesh]) AND ("mouse"[tiab] OR "mice"[tiab] OR "murine"[tiab] OR "rat"[tiab] OR "rats"[tiab] OR "rodent"[tiab] OR "Mice"[Mesh] OR "Rats"[Mesh])

Gray literature (unpublished or non-commercially published material) is crucial in toxicology to mitigate publication bias and access regulatory studies. Database searches must be supplemented with targeted searches of:

• Chemical-Specific Databases: ECHA registration dossiers provide detailed study summaries submitted under REACH regulations [36].
• Toxicity Value Databases: EPA's ToxValDB aggregates point-of-departure data from sources like REACH dossiers and IRIS assessments [36].
• Existing Evidence Maps: Resources like the PFAS-Tox Database can provide a curated starting point for relevant references [36].
• Clinical Trial and Study Registries: e.g., clinicaltrials.gov.
• Citation Searching: Reviewing reference lists of included studies and key reviews ("backward citation chasing") and using citation indices to find papers that cite key studies ("forward citation chasing") [38].

Managing Search Results and Deduplication

Executing multi-database searches yields thousands of citations that must be managed systematically.

• Export Results: Export full citation data from each database into a reference manager (e.g., EndNote, Zotero, Mendeley) or a systematic review platform (e.g., Covidence, DistillerSR, Rayyan).
• Deduplication: Use automated tools to remove duplicate records. Advanced tools, such as the machine learning-based DeDuper tool described in EPA methods, use a two-phase approach of automated logic and predictive algorithms to identify duplicates that are then verified manually [36].
• Record Keeping: Maintain a complete, unedited log of all search strings, dates of execution, and the number of records retrieved from each source. This is essential for reproducibility and for inclusion in the PRISMA flow diagram.

Diagram 1: Multi-Database Search Execution Workflow

Modern Innovations and Semi-Automation

The increasing volume of scientific literature makes manual screening a significant bottleneck [39]. Text mining and active learning technologies offer promising solutions for improving efficiency while aiming to maintain comprehensiveness.

• Prioritization Screening: Machine learning models can rank citations from most to least likely to be relevant based on training from initial reviewer decisions. This allows reviewers to identify the majority of included studies faster, enabling parallel workflow [39].
• Automated Exclusion: More advanced systems can learn to automatically exclude citations with a high predicted probability of being irrelevant. Evaluations suggest such semi-automation can save 30–70% of screening workload, though potentially with a small loss of relevant studies (e.g., 95% recall) [39].
• Evidence Stream Filtering: Software like SWIFT-Review can use preset search strategies ("evidence streams") to automatically tag and filter references by type (e.g., human, animal, in vitro), streamlining the initial sorting of large result sets [36].

These tools require careful implementation and validation but are increasingly considered safe for use in live reviews, particularly for prioritization tasks [39].

Beyond methodological tools, conducting toxicology research relies on specialized reagents and materials. The following table details key items used in experimental toxicology, which may be the subject of or essential for interpreting studies identified in a systematic review.

Table 2: Key Research Reagent Solutions in Experimental Toxicology

Reagent/Material	Primary Function	Common Application in Toxicology	Example(s)
Cytochrome P450 (CYP) Isozyme Inhibitors & Inducers	Modulate the activity of specific drug-metabolizing enzymes.	Used in in vitro (e.g., liver microsomes) and in vivo studies to identify metabolic pathways, assess drug-drug interaction potential, and study bioactivation of toxins.	Ketoconazole (CYP3A4 inhibitor), Phenobarbital (broad CYP inducer).
Reactive Oxygen Species (ROS) Detection Probes	Chemically react with ROS to produce a measurable signal (fluorescence, luminescence).	Used in cell-based and biochemical assays to quantify oxidative stress, a key mechanism of chemical-induced toxicity (e.g., hepatotoxicity, neurotoxicity).	DCFH-DA (general ROS), MitoSOX (mitochondrial superoxide).
Cytokine/Chemokine ELISA Kits	Quantify specific protein biomarkers of inflammation via enzyme-linked immunosorbent assay.	Measure inflammatory responses in serum, plasma, or tissue homogenates following exposure to immunotoxic or pro-inflammatory chemicals.	Kits for TNF-α, IL-6, IL-1β.
Apoptosis Detection Assays	Identify and quantify programmed cell death.	Determine if observed cytotoxicity is mediated via apoptotic pathways; used in high-throughput screening for compound safety.	Annexin V/PI staining by flow cytometry, Caspase-3 activity assays.
Ames Test Strain Kits	Engineered Salmonella typhimurium strains used to detect mutagenic potential.	Standard in vitro assay for genotoxicity screening of chemicals and environmental mixtures as part of regulatory safety assessment.	Commercial kits containing strains TA98, TA100, etc., with and without metabolic activation (S9 fraction).
Mass Spectrometry Internal Standards	Stable isotope-labeled analogs of target analytes.	Essential for accurate quantification of chemicals, drugs, or metabolites in complex biological matrices (e.g., serum, urine, tissue) using LC-MS/MS, supporting toxicokinetic and biomonitoring studies.	¹³C- or ²H-labeled versions of the analyte of interest.
Primary Cell Cultures & Media Systems	Provide a more physiologically relevant in vitro model than immortalized cell lines.	Used to study tissue-specific toxicity (e.g., primary hepatocytes for liver toxicity, primary neurons for neurotoxicity) while maintaining differentiated phenotypes.	Cryopreserved primary human hepatocytes with specialized culture media.

Within the structured methodology of a systematic review (SR), the application of pre-defined inclusion and exclusion criteria represents a critical gatekeeping step. This step transforms a broad collection of potentially relevant literature into a finalized set of studies that will underpin the entire evidence synthesis. In toxicology and environmental health research, this process is paramount for ensuring objective and reproducible hazard identification and risk assessment [1].

Traditional narrative reviews in toxicology often employ implicit, undisclosed selection processes, which can introduce significant bias and limit reproducibility [1]. In contrast, a systematic review requires that eligibility criteria be established a priori in a published protocol. The subsequent screening of retrieved records against these criteria must be a transparent, rigorous, and well-documented process [40]. Dedicated systematic review software is now considered essential for managing this complex task efficiently, minimizing human error, and providing an audit trail that fulfills the demands of regulatory-grade science, such as that conducted by the National Toxicology Program or the Texas Commission on Environmental Quality (TCEQ) [41] [42].

This guide details the technical execution of this step, framing it within the broader SR workflow for toxicology, which is commonly broken into stages such as problem formulation, literature search, study selection, data extraction, and evidence synthesis [1] [41].

Developing the Eligibility Criteria

The foundation for effective screening is a set of unambiguous, protocol-defined criteria. In toxicology, these criteria are derived directly from the research question, typically formulated using a specialized framework.

• The PECO Framework: While clinical reviews often use PICO (Population, Intervention, Comparator, Outcome), toxicological questions are best framed using PECO (Population, Exposure, Comparator, Outcome) [42]. This adaptation is crucial for accurately defining the parameters of environmental and chemical hazard assessments.

  • Population: The organism(s) of interest (e.g., human cohorts, specific animal models like Sprague-Dawley rats, in vitro systems).
  • Exposure: The chemical, mixture, or environmental agent under investigation, including details on route, duration, and dose where relevant.
  • Comparator: The control group (e.g., placebo, sham-exposed, background exposure, or a lower dose group for dose-response assessment).
  • Outcome: The specific toxicological endpoint(s) (e.g., mortality, clinical observation, histopathology, genomic alteration, tumor incidence).

• Key Components of Eligibility Criteria: A comprehensive set of criteria expands upon PECO to include methodological and practical considerations essential for a robust toxicology review [43].

  • Study Design: Specify acceptable designs (e.g., randomized controlled trials, cohort studies, case-control studies for human data; guideline-compliant in vivo studies, in vitro assays). The TCEQ guidance emphasizes defining designs suitable for toxicity factor development [41].
  • Publication Status & Timeframe: Decide on the inclusion of grey literature (theses, conference abstracts, government reports) to mitigate publication bias [11], and define a date range for the search.
  • Language Restrictions: While sometimes necessary, limiting to English-language studies can introduce bias and should be justified [40].
  • Minimum Data Requirements: Define the essential data that must be reported for a study to be included (e.g., sample size, mean effect and measure of dispersion, dose information).

Table 1: Common Inclusion/Exclusion Criteria for a Toxicology Systematic Review

Criterion Category	Inclusion Examples	Exclusion Examples
Population (P)	Adult mammalian animal models; Human occupational cohorts; Relevant human cell lines.	Non-mammalian species (unless specified); Studies on microbial populations.
Exposure (E)	Oral gavage exposure to Chemical X; Inhalation studies with defined concentrations.	Topical exposure only; Studies on chemical analogs without data on Chemical X.
Comparator (C)	Concurrent vehicle control group; Unexposed control group from same population.	Historical controls only; Comparison to a different toxicant without a true control.
Outcome (O)	Liver weight change; Serum alanine aminotransferase (ALT) levels; Incidence of hepatocellular adenoma.	Behavioral outcomes only; Outcomes measured with unvalidated methods.
Study Design	OECD Guideline 407 (Repeated Dose 28-Day) studies; Prospective cohort studies.	Case reports without controls; Narrative reviews; In silico modeling studies only.
Data Reporting	Reports mean/median, variability (SD, SE), and group size (n).	Only reports significance levels (p-values) without raw or summary data.

The Role of Dedicated Screening Software

Manual screening of thousands of records using spreadsheets is error-prone and inefficient. Dedicated SR software platforms automate and streamline the process, ensuring consistency and providing essential project management tools [11] [14].

• Core Functions of Screening Software:
  • De-duplication: Automatically identifies and removes duplicate records retrieved from multiple databases.
  • Blinded Screening: Presents titles and abstracts to reviewers independently, preventing one reviewer’s decision from influencing another.
  • Conflict Resolution: Highlights discrepancies between reviewers' decisions for a specific record, facilitating efficient consensus meetings.
  • Document Management: Links PDFs of full-text articles directly to the record for easy access during the second screening phase.
  • Audit Trail: Permanently logs every action (inclusions, exclusions, reasons), which is critical for regulatory transparency and reproducibility [42].

Table 2: Comparison of Systematic Review Software Tools for Screening

Software Tool	Primary Function	Key Features for Screening	Considerations
Covidence	End-to-end SR management	Built-in de-duplication, title/abstract & full-text screening forms, conflict resolution, PRISMA flow diagram generator.	Subscription-based; highly user-friendly and collaborative.
Rayyan	Screening and collaboration	AI-assisted keyword highlighting to speed up screening, mobile-friendly interface, free for public and nonprofit projects.	Free tier has limitations; strong focus on the screening phase.
EPPI-Reviewer	Comprehensive data management	Highly customizable workflows, supports complex coding schemas, integrates text mining.	Steeper learning curve; more expensive; powerful for large, complex reviews.
DistillerSR	Regulatory-compliant SR	Strong audit trail, 21 CFR Part 11 compliance for regulated research, advanced reporting.	Enterprise-focused; highest cost; designed for audits.
Excel/Sheets	Spreadsheet software	Complete flexibility, no direct cost.	No native support for blinding, conflict resolution, or audit trails; high risk of error in large reviews [14].

The Stepwise Screening Methodology

The screening process is universally conducted in two sequential phases: title/abstract screening and full-text screening [11] [43]. The COSTER recommendations emphasize the importance of pre-piloting the process to ensure consistent application of criteria [18].

Phase 1: Title/Abstract Screening

• Objective: To quickly eliminate clearly irrelevant records.
• Process: Two independent reviewers assess each record against the eligibility criteria. Software like Rayyan or Covidence is typically used [11]. Decisions are "Include," "Exclude," or "Maybe." Records marked "Include" or "Maybe" by either reviewer proceed.
• Piloting: The review team should screen a common batch of 50-100 records, compare decisions, and refine the criteria or their interpretation until a high level of agreement (e.g., >90%) is achieved.

Phase 2: Full-Text Screening

• Objective: To make final inclusion decisions based on a thorough examination of the complete article.
• Process: Two independent reviewers obtain and assess the full-text PDF of each record that passed Phase 1. The specific reason for exclusion (e.g., "wrong exposure," "inadequate control," "insufficient data") must be recorded for every excluded study. This is a requirement for PRISMA flow diagrams [40].
• Consensus & Adjudication: All conflicts are resolved through discussion. If consensus cannot be reached, a third senior reviewer (adjudicator) makes the final decision.

Documentation: The outcome of this process is meticulously documented in a PRISMA flow diagram, which visually charts the flow of records from identification to final inclusion [40] [43].

Systematic Review Screening and Selection Workflow

Best Practices and Special Considerations in Toxicology

• Dual-Reviewer Independence: Every record should be screened by at least two independent reviewers to minimize bias and error. Single-reviewer screening is only acceptable for clearly irrelevant records in the first phase if justified and documented in the protocol [14] [18].
• Handling Multiple Evidence Streams: Toxicology reviews often integrate human, animal, and in vitro data [1]. Criteria may need separate, tailored branches for each stream (e.g., specific quality checks for animal housing or in vitro metabolically competent systems).
• Managing Grey Literature: Including regulatory reports or unpublished data requires careful planning. Screening criteria should define what constitutes an acceptable grey literature document, and the same rigorous screening process must be applied [11] [18].
• Software-Assisted Prioritization: Some tools use machine learning to rank records by predicted relevance based on early reviewer decisions, potentially improving efficiency in very large reviews.

Dual-Independent Reviewer Process with Adjudication

Table 3: Research Reagent Solutions for Systematic Review Screening

Tool / Resource	Category	Function in Screening
Covidence	Software Platform	Manages the entire screening workflow: de-duplication, independent review, conflict resolution, and document linkage [11] [14].
Rayyan	Software Platform	Facilitates collaborative blinded screening with AI-assisted keyword highlighting to accelerate the title/abstract review [11].
PRISMA Flow Diagram Generator	Reporting Tool	Creates standardized flow diagrams to document the study selection process, required for transparent reporting [40] [43].
PECO Framework	Methodological Framework	Provides the structural basis for developing relevant, focused inclusion/exclusion criteria in toxicology and environmental health reviews [42].
Cochrane Handbook	Guidance Document	The gold-standard reference for systematic review methodology, including detailed guidance on designing and conducting study selection [1] [40].
COSTER Recommendations	Guidance Document	Provides domain-specific recommendations for conducting rigorous systematic reviews in toxicology and environmental health, including best practices for screening [18].

Critical appraisal, also referred to as risk of bias assessment, is a fundamental and mandatory step in the systematic review process in toxicology [44]. It involves the systematic evaluation of the methodological quality of included studies to judge their trustworthiness, value, and relevance [44]. The core purpose is to assess the internal validity of a study—the degree to which its design, conduct, and analysis have minimized systematic errors (bias) that could distort the true effect of an exposure or intervention [45].

Within the framework of a broader thesis on conducting systematic reviews in toxicology, this step is pivotal for transforming a mere collection of studies into a reliable evidence synthesis. Systematic reviews in toxicology aim to provide transparent, reproducible, and objective summaries of evidence to inform regulatory and public health decisions [1]. Unlike traditional narrative reviews, which may lack explicit methodology and are susceptible to selective citation, systematic reviews employ a structured process to minimize bias at every stage [1]. Critical appraisal directly addresses the "risk of bias" in the included studies, which is distinct from other quality concerns like imprecision (random error) or general reporting quality [45]. By identifying studies with high risk of bias, reviewers can gauge the strength of the evidence, explore sources of heterogeneity, and determine the confidence that can be placed in the review's conclusions [45]. Failing to rigorously assess risk of bias undermines the entire systematic review, as flawed primary studies can lead to incorrect synthesis and misguided decisions [1].

Core Concepts: Understanding Bias and Its Types in Toxicology

Bias is defined as a systematic distortion in research findings that leads to conclusions deviating from the true effect [45]. It arises from flaws in study design, conduct, analysis, or reporting. It is crucial to distinguish between bias itself (often theoretically measurable but not directly detectable in a single study) and risk of bias, which is an assessment of the likelihood that bias exists based on observable methodological features [45].

Toxicological studies, encompassing in vivo, in vitro, and in silico approaches, are susceptible to specific biases. The major types of bias are categorized into domains, as outlined in specialized tools and summarized below.

Table 1: Key Types of Bias in Toxicological Studies and Their Implications

Bias Type	Definition	Common Manifestation in Toxicology	Potential Impact on Results
Selection Bias	Systematic differences between comparison groups at baseline.	Inadequate randomization of animals to treatment/control groups; non-random allocation of cell cultures to assay plates [45].	Groups are not comparable; observed effects may be due to pre-existing differences rather than the exposure.
Performance Bias	Systematic differences in care or exposure provided to groups, apart from the intervention.	Lack of blinding of caregivers/researchers to treatment groups during in vivo study conduct [45].	Differential handling, monitoring, or environmental exposure can influence outcomes.
Detection Bias	Systematic differences in how outcomes are assessed.	Lack of blinding of pathologists or technicians during histological analysis or clinical scoring [45].	Subjective or semi-quantitative endpoints may be influenced by knowledge of treatment.
Attrition Bias	Systematic differences in withdrawals or exclusions from the study.	Unequal loss of animals from different groups due to mortality or sacrifice, with incomplete reporting of reasons [45].	The analyzed data set may not be representative of the initial cohort, skewing results.
Reporting Bias	Systematic differences between reported and unreported findings.	Selective reporting of only statistically significant or favorable outcomes; failure to report all pre-specified endpoints [45].	Overestimates or underestimates the true effect size; hides non-significant or adverse results.

Methodological Frameworks and Tools for Assessment

Selecting an appropriate, validated tool is critical for a consistent and transparent appraisal [44]. The tool must match the design of the studies being assessed. Using multiple tools is necessary if a review includes different study types (e.g., animal studies and human observational studies) [44].

Table 2: Selected Risk of Bias Assessment Tools for Toxicological Evidence

Tool Name	Primary Study Design	Key Bias Domains Assessed	Notable Features
SYRCLE's RoB Tool [44]	Animal intervention studies	Selection, performance, detection, attrition, reporting, and other biases.	Adapted from the Cochrane RoB tool for clinical trials to address animal-specific concerns (e.g., baseline characteristics, random housing).
OHAT Risk of Bias Rating Tool [1] [45]	Human and animal studies (broad).	Similar to SYRCLE/Cochrane domains, structured for environmental health questions.	Developed by the U.S. NTP; includes guidance for evaluating human observational and animal toxicology studies within the same framework.
ROBINS-I [44]	Non-randomized studies of interventions (human).	Bias due to confounding, participant selection, intervention classification, deviations, missing data, outcome measurement, selective reporting.	Tool for "Risk Of Bias In Non-randomized Studies - of Interventions." Useful for human occupational/cohort exposure studies.
Cochrane RoB 2 [44]	Randomized controlled trials (human).	Randomization process, deviations, missing data, outcome measurement, selection of reported result.	The current standard for human RCTs; informs the structure of other tools.
ToxRTool	In vitro and in vivo mechanistic studies.	Reliability (test substance, controls), relevance (dosing, endpoints), other (adherence to guidelines).	Provides a scoring system to categorize studies as "reliable without restrictions," "reliable with restrictions," or "not reliable."

The assessment process should be conducted independently by at least two reviewers, with a pre-defined method for resolving disagreements (e.g., consensus or third-party adjudication) [44]. The review protocol must specify the chosen tool(s), how judgments will be reached, and how assessments will be used in the synthesis (e.g., sensitivity analyses) [44].

Experimental Protocol for Risk of Bias Assessment Using SYRCLE's Tool

The following protocol details the step-by-step methodology for assessing risk of bias in an in vivo animal study included in a systematic review.

1. Preparation & Pilot Phase:

• Tool Selection: Confirm SYRCLE's Risk of Bias Tool is appropriate for all animal intervention studies.
• Reviewer Training: Reviewers independently study the SYRCLE handbook and guidance documents.
• Piloting: Both reviewers independently assess the same 2-3 studies not included in the final review. Compare judgments for each domain and discuss discrepancies to calibrate understanding and application of criteria.

2. Independent Assessment Phase:

• For each included study, each reviewer independently extracts methodological data relevant to the tool's signaling questions.
• Based on this data, reviewers make a judgment for each bias domain (e.g., Selection Bias, Performance Bias) as "Low," "High," or "Unclear" risk of bias.
• All judgments must be supported by direct quotes or descriptions from the study publication.

3. Consensus & Finalization Phase:

• Reviewers compare their independent judgments for each domain of each study.
• Where disagreements occur, reviewers discuss the specific evidence until consensus is reached.
• If consensus cannot be reached, a third reviewer (or the review lead) makes the final determination.
• Final judgments are recorded in a standardized data extraction form or spreadsheet.

4. Synthesis & Reporting Phase:

• Results are summarized in a risk of bias table (study-by-domain matrix) and a traffic light plot (summary figure) to visualize the distribution of biases across all studies [44].
• The overall pattern of bias is considered when interpreting the results of the evidence synthesis.

Diagram: Risk of Bias Assessment Workflow. This flowchart outlines the standardized, multi-phase protocol for conducting critical appraisal, emphasizing independent review and consensus.

Data Extraction and Presentation of Appraisal Results

Quantitative data from the critical appraisal must be presented clearly and comprehensively. The results have two primary components: 1) the detailed assessment for each study, and 2) a summary across all studies.

Study-by-Study Presentation: A table should present each included study as a row, with columns for each domain of the risk of bias tool and the final judgment. This provides full transparency [44].

Summary Presentation: A visual summary, such as a stacked bar chart or "traffic light" plot (generated by tools like ROBVIS), is considered best practice [44]. It displays the proportion of studies rated as low, high, or unclear risk for each bias domain, allowing for an immediate visual grasp of the major methodological weaknesses in the evidence base.

Table 3: Template for Presenting Quantitative Critical Appraisal Data

Study ID (First Author, Year)	Selection Bias	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other Biases	Overall Judgment
Smith et al. 2020	Low	High	Unclear	Low	Low	Low	Some Concerns
Jones et al. 2018	Unclear	Unclear	High	High	Low	Low	High Risk
Chen et al. 2021	Low	Low	Low	Low	Low	Low	Low Risk
...	...	...	...	...	...	...	...
Summary across n studies	e.g., 75% Low, 15% High, 10% Unclear	e.g., 50% Low, 30% High, 20% Unclear	...	...	...	...	—

Data should be organized to show frequency distributions. For the summary, categorical data (Low/High/Unclear) can be presented as absolute counts and relative frequencies (percentages) for each domain [46]. This quantitative summary is crucial for the next step: incorporating risk of bias judgments into the evidence synthesis, such as through subgroup or sensitivity analyses [44].

Table 4: Research Reagent Solutions for Risk of Bias Assessment

Item / Resource	Function / Purpose	Application Notes
Structured Risk of Bias Tools (e.g., SYRCLE, OHAT, ROBINS-I)	Provide a validated checklist of methodological criteria to systematically evaluate internal validity.	The core "reagent" for the assessment. Must be selected a priori and applied consistently [44] [45].
Guidance Documents & Handbooks	Offer detailed instructions, examples, and rationale for signaling questions and judgments within a tool.	Essential for proper calibration and reducing subjectivity among reviewers (e.g., SYRCLE guidance, Cochrane Handbook) [44].
Dual Independent Reviewer System	Acts as a methodological control to minimize random error and personal bias in the appraisal process.	A non-negotiable protocol requirement. Inter-rater reliability should be calculated and reported [44].
Data Extraction & Management Software	Platforms (e.g., Covidence, Rayyan, DistillerSR) facilitate blinding of reviewers, manage conflicts, and compile data.	Streamlines the logistical process, especially for large reviews, and maintains an audit trail.
Visualization Packages (e.g., ROBVIS in R)	Generate standardized summary plots (traffic light, summary bar charts) from appraisal data.	Ensures clear, consistent visual reporting of results as recommended by PRISMA and other guidelines [44].
AI-Assisted Screening & Bias Detection Tools	Emerging tools use machine learning to help flag potential methodological limitations or reporting omissions during screening and extraction.	Can improve efficiency but must not replace human judgment. Output requires careful verification and validation [45].

The critical appraisal step culminates in a clear profile of the methodological strengths and limitations of the evidence base. This profile is not an endpoint but a critical input for the final stages of the systematic review. The overall risk of bias across studies directly informs the certainty of the evidence (e.g., as assessed via GRADE for toxicology) and the review's conclusions [44].

Reviewers must explicitly describe how risk of bias assessments were incorporated into the synthesis [44]. This may involve:

• Sensitivity Analysis: Re-running the primary synthesis (e.g., meta-analysis) excluding studies rated as having a high overall risk of bias to see if conclusions change.
• Subgroup Analysis: Stratifying results by risk of bias judgment (e.g., low vs. high/unclear risk) to explore its influence on effect estimates.
• Interpretive Weighting: Providing greater emphasis to findings from studies with lower risk of bias during the narrative discussion and formulation of conclusions.

By rigorously executing Step 5, researchers ensure the systematic review's conclusions are grounded in the most trustworthy evidence available, thereby fulfilling the core objective of evidence-based toxicology: to inform decision-making with transparency, objectivity, and scientific rigor [1] [45].

In the context of a systematic review for toxicology research, data extraction and management is not a mere administrative step but a foundational scientific process that determines the validity of the entire evidence synthesis. Systematic reviews, adopted from clinical research, provide a transparent, methodologically rigorous, and reproducible means of summarizing available evidence on a precise research question [1]. Unlike traditional narrative reviews, which may rely on implicit, expert-driven selection of data, systematic reviews employ an explicit, pre-defined protocol to minimize bias and error [1].

The field of toxicology presents unique standardization challenges. Evidence streams are highly diverse, encompassing human observational studies, controlled animal experiments (in vivo), mechanistic in vitro studies, and in silico models [1]. Each stream has its own data structures, terminologies, and reporting norms. A dose in an animal study may be reported in mg/kg/day, while an occupational exposure in an epidemiological study is in ppm-years. Standardization is the process of transforming these disparate data into a common format and representation, enabling valid comparison, integration, and analysis [47] [48]. Failure to rigorously standardize evidence at the extraction stage introduces noise and bias, jeopardizing the review's conclusions and its utility for regulatory decision-making and risk assessment [1].

Foundational Principles of Data Standardization

Data standardization is the comprehensive process of transforming data into common formats, structures, and semantic representations to ensure consistency and compatibility across different systems and analytical workloads [49]. In toxicology, this process is guided by several core principles:

• Schema Design Standards: Defining consistent structures for extracted data (e.g., table formats, variable names) ensures all team members and subsequent analytical tools interpret data uniformly [49].
• Data Types and Constraints: Enforcing rules for data types (numeric, text, categorical) and valid ranges (e.g., positive values for dose) protects data integrity from corruption or duplication [49].
• Semantic Consistency: This is the most critical principle for toxicology. It involves mapping varied terminologies (e.g., different names for the same chemical, or different codes for the same pathological finding) to a standardized vocabulary. This ensures that "hepatocellular adenoma" in one study is correctly recognized as equivalent to "liver adenoma" in another [49] [48].

The process balances normalization (organizing data into non-redundant, structured tables) with practical needs for analysis, sometimes requiring selective "denormalization" for specific queries [49]. The ultimate benefits are interoperability between different evidence streams, enhanced analytical capabilities, and robust regulatory compliance [49].

A Framework for Standardizing Diverse Toxicological Data

Implementing standardization in a systematic review follows a logical sequence from assessment to execution. The following workflow details this process.

Standardization Workflow for Toxicology Data Extraction

Step 1: Comprehensive Data Discovery and Source Analysis

Before extraction begins, the team must profile the formats, units, and terminologies used across all included studies [49]. This involves creating a data inventory to identify inconsistencies—for example, a chemical may be listed by its common name, IUPAC name, or CAS number across different papers. A quality assessment documents gaps like missing standard deviations or unclear exposure metrics [49].

Step 2: Standards Definition and Governance

Here, the team establishes the concrete rules for the review. This includes:

• Formatting Rules: Mandating SI units for dose, a single date format (YYYY-MM-DD), and standard representations for categorical data [49].
• Data Dictionary: Creating the definitive extraction spreadsheet or database schema, with clear definitions for each variable (e.g., "LOAEL: Lowest dose producing a statistically significant adverse effect compared to control").
• Semantic Standards: Selecting the controlled vocabularies and ontologies (e.g., Medical Subject Headings (MeSH), Chemical Entities of Biological Interest (ChEBI)) that will be used to map free-text terms [49] [48].

Step 3: Execution of Extraction and Transformation

Data extractors populate the predefined data dictionary. Transformation rules are applied concurrently or immediately after extraction [47]. Key operations include:

• Stripping extraneous characters (e.g., removing asterisks from footnotes in numerical data) [47].
• Rearranging or reordering data into a canonical form (e.g., reformatting "Last, First" to "First Last") [47].
• Value conversion and mapping: This is central to toxicology. It involves converting all doses to a common unit (e.g., mg/kg/day) and mapping all reported outcomes to standardized terms from the chosen ontology [47] [48].

Step 4: Validation and Harmonization

The final step ensures reliability. Automated or manual checks verify that transformed data adheres to rules (e.g., all dates are valid, all numeric doses are positive) [49]. A harmonization review, often by a second reviewer, checks for consistency in qualitative judgments (e.g., Was a specific histopathological finding correctly categorized as "adverse"?). Discrepancies are resolved through consensus.

Standardizing Qualitative vs. Quantitative Toxicological Data

Toxicological evidence comprises both quantitative (numerical) and qualitative (descriptive) data, each requiring distinct standardization approaches [50].

Quantitative Data is numerical and measurable (e.g., body weight change, enzyme activity level, tumor count) [50]. Standardization focuses on numerical consistency.

• Collection Method: Extracted directly from tables, text, or figures in studies [50].
• Standardization Actions: Unit conversion, calculation of derived metrics (e.g., percent control, change from baseline), and imputation of summary statistics (e.g., estimating SD from SEM) following pre-specified statistical rules [47].
• Analysis & Presentation: Analyzed via statistical methods (meta-analysis) and presented in forest plots, tables of means, and dose-response curves [50].

Qualitative Data is descriptive and interpretative, explaining the "why" and "how" (e.g., histopathology descriptions, author conclusions about mechanism, reported symptom narratives) [50].

• Collection Method: Extracted from results, discussion, and conclusion text, often requiring judgment [50].
• Standardization Actions: Coding and thematic analysis. Text snippets are categorized into a pre-defined framework (e.g., "evidence of oxidative stress," "hormonal disruption," "cytotoxicity") using standardized vocabularies [1] [50].
• Analysis & Presentation: Analyzed for themes and patterns, presented in structured summaries, evidence matrices, and conceptual diagrams [50].

Table 1: Standardization Approaches for Qualitative and Quantitative Toxicological Data

Aspect	Quantitative Data	Qualitative Data
Nature & Purpose [50]	Measures "how much" or "how many"; used for hypothesis testing and magnitude estimation.	Explains "why" or "how"; used for exploring mechanisms, contexts, and patterns.
Toxicology Examples	Dose, response magnitude, EC50, biomarker concentration, survival time.	Histopathology descriptions, mechanistic conclusions, symptom reports, study author interpretations.
Key Standardization Challenge	Harmonizing diverse units, scales, and statistical reporting methods.	Consistently categorizing free-text descriptions and subjective assessments.
Core Standardization Action	Value conversion and calculation to common metrics and units.	Coding and thematic mapping to controlled vocabularies and ontologies.
Tool Support	Statistical software (R, Python), spreadsheets with formulas.	Qualitative analysis software (NVivo), text annotation tools, LLM-assisted coding [51].

Detailed Experimental Protocols for Data Extraction

Protocol 1: Extraction and Transformation of Dose-Response Data

This protocol standardizes the most common quantitative data in toxicology.

• Identify Source: Locate all reported doses and corresponding response metrics (e.g., percent inhibition, tumor incidence) for the relevant outcome.
• Extract Raw Data: Record the dose value, unit, response value, response unit, and sample size (n) for each data point. Note if doses are measured in compound concentration, administered amount, or absorbed dose.
• Apply Transformation Rules:
  • Unit Conversion: Convert all doses to a molar concentration (e.g., μM) for in vitro studies or to mg/kg body weight/day for in vivo studies using predefined conversion factors.
  • Response Normalization: If responses are given as absolute values (e.g., enzyme activity of 120 U/mg), recalculate as "percent of control mean" where the concurrent control group mean is set to 100%.
  • Data Structure: Reshape data into a standardized table: Study_ID | Test_System | Dose_Value_Standardized | Dose_Unit_Standard | Response_Value | Response_Unit_Standard | N.

Protocol 2: Coding Qualitative Histopathological Findings

This protocol standardizes descriptive pathology data.

• Extract Descriptive Text: From the results section, copy verbatim all text describing tissue observations in treated and control groups (e.g., "showed minimal multifocal hepatocellular hypertrophy").
• Primary Coding: Using a pre-defined coding framework based on a standard ontology (e.g., the Phenotype and Trait Ontology (PATO)), assign one or more codes to each text snippet. For example, "minimal multifocal hepatocellular hypertrophy" could be coded as: PATO:0000381 (hypertrophy), location: UBERON:0001172 (liver), severity: PATO:0002194 (minimal), pattern: PATO:0002256 (multifocal).
• Adversity Judgment: Apply pre-specified, objective criteria to code each finding as "adverse" or "non-adverse." Criteria may include severity, association with decreased organ function, or progression. This judgment is recorded as a separate standardized variable.

Protocol 3: Leveraging LLM-Assisted Extraction for Efficiency

Recent advancements show Large Language Models (LLMs) can semi-automate data extraction [51].

• Prompt Engineering: Develop and validate precise instruction prompts (e.g., "From the following text, extract the NOAEL value and its unit. If not stated, write 'NR'. Text: [Study Text]").
• LLM Execution & Output: Feed the text of included studies (typically the PDF converted to structured text) to the LLM using the engineered prompts. The LLM outputs structured data (e.g., JSON format).
• Human Validation & Correction: A human reviewer systematically checks 100% of the LLM's extractions against the source document. Errors are corrected, and the prompt is refined iteratively to improve performance. This creates a high-quality, standardized dataset more efficiently than fully manual extraction [51].

Transformation Pathways from Raw to Standardized Evidence

The core technical challenge is converting raw, heterogeneous data into a harmonized format for analysis. The following diagram details the common transformation pathways.

Data Transformation Pathways to Standardized Evidence

The Toxicologist's Standardization Toolkit

Implementing the above protocols requires a combination of curated resources and software tools.

Table 2: Essential Toolkit for Standardizing Toxicological Evidence

Tool Category	Specific Item / Solution	Function in Standardization
Standardized Vocabularies & Ontologies	Chemical Entities of Biological Interest (ChEBI)	Provides stable, unique identifiers and names for small chemical compounds, resolving synonyms and trade names to a standard term [48].
	Medical Subject Headings (MeSH)	A broad biomedical vocabulary for indexing disease, anatomy, and biological phenomena. Useful for standardizing reported health outcomes [48].
	Phenotype And Trait Ontology (PATO)	Provides standardized terms for describing qualities, phenotypes, and measurements (e.g., "increased," "severe," "focal") [48].
Data Transformation & Management	SQL / R / Python (Pandas)	Programming languages and libraries used to write scripts for automated data cleaning, unit conversion, and restructuring of extracted data [47].
	Electronic Data Capture (EDC) System	A pre-configured database (e.g., REDCap, systematic review software) that enforces data types and constraints during the manual extraction phase, reducing entry errors [49].
Reference Databases	Compiled Conversion Factors	An internal spreadsheet of molar masses and unit conversion factors (e.g., ppm to mg/m³) specific to the chemicals under review, ensuring consistent calculations.
	Study Design Codebook	A living document defining how specific study design elements (e.g., "subchronic," "Good Laboratory Practice (GLP)") are identified and coded for the review.
Emerging Technology	Large Language Models (LLMs)	Can be used as an assistive technology to extract structured data from PDF text, draft coding of qualitative findings, or identify inconsistencies, subject to rigorous human validation [51].

Step 6, Data Extraction and Management, is where the theoretical rigor of a systematic review protocol is translated into concrete, analyzable evidence. In toxicology, this demands a disciplined focus on standardization to bridge the inherent diversity of evidence streams. By adhering to a structured workflow—profiling sources, defining explicit rules, executing careful transformations, and validating outputs—reviewers construct a reliable foundation for evidence synthesis. The integration of quantitative unit conversion with qualitative semantic coding, supported by standardized vocabularies and emerging tools like LLMs, transforms disparate research reports into a coherent, comparable body of evidence. This meticulous process is indispensable for producing toxicological systematic reviews that are truly transparent, reproducible, and fit for informing scientific understanding and public health decision-making.

Within the framework of conducting a systematic review in toxicology, the synthesis of evidence represents the critical phase where collected data is integrated to form clear, evidence-based conclusions. This step moves beyond mere summarization to a rigorous evaluation and combination of findings, addressing the core research question with transparency and methodological rigor [1]. In toxicology, this process is fundamental to evidence-based toxicology (EBT), which aims to improve the field's objectivity, consistency, and reproducibility, thereby more effectively informing regulatory and risk management decisions [1].

Synthesis is typically bifurcated into qualitative and quantitative approaches. Qualitative synthesis involves a structured, narrative summary of the extracted data, often organized by key themes, study design, population, or outcome. Quantitative synthesis, or meta-analysis, employs statistical methods to combine numerical results from multiple independent studies, yielding a single pooled estimate of effect or association [52]. The choice and application of these methods are not mutually exclusive; a robust systematic review frequently employs both to provide a comprehensive answer [27]. The complexity of toxicological evidence—which may span human observational studies, controlled animal experiments, in vitro assays, and mechanistic data—poses unique challenges for synthesis, making the adoption of a structured, pre-defined protocol essential [1].

Foundational Protocols for Evidence Synthesis

The synthesis phase must be built upon meticulously executed preceding steps of the systematic review. The following protocols establish the necessary foundation.

Protocol 1: Developing the Analytic Framework and Data Extraction Model Before synthesis begins, a detailed plan for data extraction and organization is required. This is guided by the analytic framework established in the review protocol, which links the population, exposure, comparator, and outcomes (e.g., PECO or PICO question) [27]. For example, a protocol investigating environmental pollutants and left ventricular dysfunction would frame its question as: "What is the evidence on the effect of exposure to environmental pollutants (E) on left ventricular dysfunction (O) compared to non-exposure (C) in humans (P) from observational studies (S)?" [53]. Data extraction forms are then created to consistently capture information from each included study, such as study design, sample size, exposure metrics, outcome measures, effect estimates (e.g., odds ratios, hazard ratios), confidence intervals, and key confounders adjusted for [53].

Protocol 2: Assessing Study Quality and Risk of Bias (RoB) A critical prerequisite to synthesis is the evaluation of the internal validity of each included study. This involves a systematic assessment of risk of bias using domain-based tools. For toxicological reviews, common tools include those tailored for non-randomized studies of exposures (e.g., the OHAT tool) or for animal studies (e.g., SYRCLE's RoB tool) [53] [54]. Key domains assessed typically include:

• Bias due to confounding.
• Bias in selection of participants.
• Bias in classification of exposures.
• Bias due to departures from intended exposures.
• Bias due to missing data.
• Bias in measurement of outcomes.
• Bias in selection of the reported result [53]. The results of this assessment directly inform the synthesis by highlighting the strengths and weaknesses of the evidence base and can be used to conduct sensitivity analyses (e.g., synthesizing only low-bias studies) [27].

Methodologies for Qualitative Evidence Synthesis

Qualitative synthesis provides a narrative and thematic integration of findings where statistical pooling is inappropriate or impossible due to heterogeneity in study designs, exposures, or outcomes.

Methodology: Thematic Analysis and Evidence Grouping The process begins by grouping studies according to pre-specified categories, such as the type of toxicant (e.g., heavy metals, persistent organic pollutants), population (e.g., occupational, general), or outcome severity [53]. Within these groups, findings are analyzed for consistent patterns, discordances, and gaps. The Hill criteria (e.g., strength of association, consistency, temporality, biological gradient) are often applied as a framework for qualitatively assessing evidence for a causal relationship [27]. The synthesis should transparently describe the progression of effects, from molecular initiating events to adverse outcomes, potentially leveraging the Adverse Outcome Pathway (AOP) framework to organize mechanistic evidence [27] [54].

Output and Presentation The results of a qualitative synthesis are presented in structured evidence tables and summarized narratively in the review text. Tables comprehensively display key study characteristics and findings, allowing for direct comparison by readers. The narrative summary explains the weight of the evidence, notes consistencies and contradictions across studies, and links the findings back to the primary review question [1].

Table 1: Framework for Qualitative Synthesis: Grouping Studies and Assessing Causality

Synthesis Grouping Category	Description	Application Example	Causal Consideration (Hill Criteria)
By Toxicant Class	Groups studies based on the chemical or physical nature of the exposure.	Synthesizing all studies on "cadmium" or "particulate matter <2.5μm (PM2.5)" separately [53].	Consistency: Are effects similar across different studies on the same toxicant?
By Evidence Stream	Separates human epidemiological, in vivo animal, and in vitro mechanistic data.	Assessing human observational data separately from controlled animal toxicology studies [1].	Plausibility: Do mechanistic studies support the biological plausibility of observations in whole organisms?
By Outcome Severity	Organizes findings based on the progression of toxic effect.	Grouping studies on subclinical biomarker changes, organ dysfunction, and overt morbidity/mortality.	Biological Gradient: Is there evidence of a dose-response relationship?
By Population Susceptibility	Differentiates findings in general populations from those in vulnerable subgroups.	Comparing effects in healthy adults to those in children, the elderly, or individuals with pre-existing conditions [53].	Specificity: Is the association specific to a particular exposure and outcome?

Methodologies for Quantitative Evidence Synthesis (Meta-Analysis)

Meta-analysis is applied when a sufficient number of included studies report comparable effect estimates for a common outcome. It provides a quantitative summary that increases statistical power and precision.

Methodology 1: Data Preparation and Effect Measure Selection The first step involves ensuring all effect measures are comparable. For dichotomous outcomes (e.g., presence or absence of a lesion), odds ratios (OR) or risk ratios (RR) are commonly used [54]. For continuous outcomes (e.g., enzyme activity level), mean differences or standardized mean differences are used. Studies reporting different measures may need to be converted to a common metric, if possible. The unit of analysis must be clearly defined (e.g., the tissue-specific observation from an animal study) [54].

Methodology 2: Statistical Pooling and Model Selection The core of meta-analysis is the statistical combination of effect estimates. This requires choosing between a fixed-effect model (which assumes all studies estimate a single true effect) and a random-effects model (which assumes the true effect varies across studies due to heterogeneity). The random-effects model is generally more appropriate in toxicology due to expected variation in species, strain, exposure regimen, and laboratory methods [54]. The pooled effect estimate is calculated, often represented visually in a forest plot, which displays each study's estimate and confidence interval along with the final pooled result.

Methodology 3: Assessment of Heterogeneity and Sensitivity Analysis Statistical heterogeneity is quantified using the I² statistic, which describes the percentage of total variation across studies due to heterogeneity rather than chance. An I² value >50% indicates substantial heterogeneity [54]. Sources of heterogeneity are explored through subgroup analysis (e.g., pooling studies by animal species separately) or meta-regression. Sensitivity analyses test the robustness of the results by repeating the meta-analysis under different assumptions, such as excluding studies with high RoB or using an alternative statistical model.

Table 2: Quantitative Synthesis (Meta-Analysis) Models and Metrics

Component	Description	Formula/Interpretation	Application in Toxicology
Fixed-Effect Model	Assumes a single true effect size; weights studies primarily by inverse variance.	Pooled Estimate = Σ (wi * Yi) / Σ wi	Rarely appropriate; may be used if studies are virtually identical (e.g., same protocol).
Random-Effects Model	Assumes true effect varies across studies; incorporates between-study variance (τ²) into weights.	Pooled Estimate = Σ (wi* * Yi) / Σ wi*	Standard approach for toxicology meta-analysis to account for expected heterogeneity [54].
Heterogeneity (I² Statistic)	Measures the proportion of total variance due to between-study variance.	I² = (Q - df)/Q * 100%	I² > 50% suggests substantial heterogeneity warranting investigation into its sources [54].
Forest Plot	Visual display of individual study estimates and the pooled meta-analysis result.	Graphical summary with confidence intervals.	Essential for presenting meta-analysis results transparently.
Sensitivity Analysis	Re-running analysis under different conditions to assess result stability.	e.g., exclusion of high RoB studies, use of trim-and-fill method for publication bias.	Critical for testing the robustness of conclusions derived from the pooled data [27].

Integrated Synthesis: Combining Evidence Streams and Advanced Approaches

Modern toxicological reviews often require the integration of diverse data types, moving towards a systems toxicology perspective.

Approach 1: Weight-of-Evidence (WoE) and Confidence Assessment After qualitative and quantitative syntheses are complete, a final weight-of-evidence assessment is performed. This integrates findings across evidence streams, considers the RoB and relevance of the included studies, and evaluates the coherence of the entire body of evidence. Frameworks like GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) or its toxicology-specific adaptations are used to rate the overall confidence in the evidence (e.g., high, moderate, low, very low) [1] [27].

Approach 2: Systems Toxicology Meta-Analysis This advanced approach integrates high-throughput data (e.g., transcriptomics, metabolomics) with traditional toxicological endpoints using causal biological network models. For instance, a meta-analysis of independent studies on engineered nanomaterials can use predefined network models of pulmonary pathways to quantify the network perturbation amplitude (NPA) caused by each material. This allows for a mechanistic comparison of toxicants beyond simple endpoint aggregation, identifying key biological pathways consistently disrupted [55].

Approach 3: Large-Scale Data Mining and Hypothesis Generation In industrial and regulatory settings, large-scale meta-analysis of historical corporate or public databases is used for target safety characterization. One methodology involves aggregating data from hundreds of preclinical studies into tissue-target pairs and calculating the odds ratio for histopathological findings. This data-driven approach can generate statistically significant hypotheses about off-target toxicities associated with specific pharmacological targets, which can then be validated through targeted experimentation [54].

Evidence Synthesis Methodology Workflow

Table 3: Research Reagent Solutions for Evidence Synthesis

Tool Category	Specific Tool / Resource	Primary Function	Application in Synthesis
Review Management	Rayyan [53], CADIMA [56], SysRev [56]	Cloud-based platforms for collaborative screening, full-text review, and basic data extraction.	Facilitates team coordination during study selection and initial data organization prior to formal synthesis.
Bias Assessment	OHAT RoB Tool [53], SYRCLE's RoB Tool [54], Cochrane RoB 2.0	Structured checklists to evaluate risk of bias in different study designs (e.g., NRS, animal studies, RCTs).	Provides critical inputs for qualitative sensitivity analysis and informs confidence in the body of evidence.
Data Extraction & Mgmt	Custom Excel/Google Sheets templates, REDCap, RevMan [56]	Creation of structured, piloted forms for consistent data harvesting from included studies.	Ensures accuracy and consistency of data entered into qualitative evidence tables and quantitative meta-analysis models.
Statistical Analysis	R (metafor, meta packages), Stata, Comprehensive Meta-Analysis (CMA)	Performing meta-analysis calculations, generating forest and funnel plots, assessing heterogeneity.	Executes the core quantitative synthesis, including complex random-effects models and meta-regression [54].
Reporting & Visualization	PRISMA 2020 Checklist [52], PRISMA Flow Diagram Generator [56], GRADEpro GDT [56]	Guides transparent reporting of the review and creates summary of findings tables with confidence ratings.	Ensures the synthesized evidence is communicated clearly, and the overall confidence in findings is assessed and stated.

Synthesis Reporting and Critical Appraisal

The final step is the transparent reporting of the synthesis methods and results, guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [52]. The report must detail:

• The methods used for qualitative synthesis and data presentation.
• The rationale for performing or not performing a meta-analysis.
• All statistical methods used for meta-analysis (e.g., model selection, heterogeneity assessment).
• The results of all RoB assessments and sensitivity analyses.
• The results of any WoE or confidence rating assessments [27].

The quality of the completed systematic review itself can be appraised by users using tools like AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews), which checks for the presence of critical protocol, search, synthesis, and reporting elements [56].

Key Risk of Bias Assessment Domains

Within the structured framework of a toxicological systematic review, Step 8 represents the critical synthesis phase where evidence is integrated to form definitive hazard identification conclusions. This step follows the systematic evaluation of individual study quality and risk of bias, and the rating of confidence in the body of evidence for specific health outcomes [57]. The process transforms a collected dataset into a transparent, evidence-based judgment regarding the potential health hazards of a chemical agent, such as 1,1,2-trichloroethane [57]. Contemporary discussions, such as those at the TSRC 2025 conference, emphasize that this step must balance regulatory caution with scientific rigor, applying weight-of-evidence (WoE) approaches to avoid overinflating risk estimates from data-deficient or lower-quality studies [58]. The ultimate goal is to produce a decision-relevant assessment that informs both scientific understanding and regulatory action [58] [41].

Step 8 is the culmination of the systematic review process. It involves the formal integration of all appraised evidence to answer the primary problem formulation question: "What are the potential health hazards associated with exposure to the substance?" [57]. This is not a simple tally of positive and negative studies, but a structured qualitative synthesis that considers:

• The confidence ratings assigned to the body of evidence for each outcome (e.g., hepatic effects, neurological effects, cancer) [57].
• The consistency, coherence, and biological plausibility of effects across studies, species, and exposure routes.
• The magnitude and significance of the observed effects.
• The applicability of the evidence (from animal models or specific human populations) to the general human context.

The output is a hazard conclusion, which may categorize the evidence for a specific health outcome as sufficient, limited, inadequate, or evidence of no effect. For example, a review might conclude there is "sufficient evidence" of hepatic toxicity from oral exposure in animals but "inadequate evidence" for carcinogenicity in humans [57]. This conclusion directly informs the derivation of toxicity factors, such as reference values (ReVs) and unit risk factors (URFs), which are used in quantitative risk assessment [41].

Core Methodologies and Experimental Protocols

The execution of Step 8 relies on rigorous methodologies from preceding steps and specific integration protocols.

1. Evidence Collection and Extraction Protocol: Before integration, data must be systematically extracted from included studies using a standardized form. The Agency for Toxic Substances and Disease Registry (ATSDR) protocol, as applied in its toxicological profile for 1,1,2-trichloroethane, extracts the following key data points [57]:

• Study Identification: Citation, chemical form, species, strain.
• Exposure Regimen: Route (inhalation, oral, dermal), specific method (gavage, drinking water), duration, frequency, dose levels.
• Experimental Design: Number of subjects per group, parameters monitored.
• Outcomes: Key findings, No-Observed-Adverse-Effect Level (NOAEL), Lowest-Observed-Adverse-Effect Level (LOAEL), effect observed at LOAEL.
• Reviewer Assessment: Quality comments and outcome summary.

2. Study Quality and Risk of Bias Assessment Protocol: The validity of the integration depends on the critical appraisal of each study. This involves using design-specific tools to evaluate internal validity (risk of bias). Common tools include [59]:

• Cochrane Risk of Bias (RoB) 2.0 Tool: For randomized controlled trials (though less common in environmental toxicology).
• Newcastle-Ottawa Scale (NOS): For assessing the quality of nonrandomized studies, such as cohort and case-control studies, based on selection, comparability, and outcome/exposure assessment.
• Systematic Review Center for Laboratory animal Experimentation (SYRCLE) Risk of Bias Tool: Specifically designed for animal studies.

Assessment should be performed independently by two or more reviewers, with conflicts resolved by consensus or a third reviewer [60] [61].

3. Confidence Rating Protocol (Pre-Integration): Prior to final integration, the confidence in the body of evidence for each outcome is rated. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework is a widely adopted methodology for this purpose [62]. The protocol involves starting with a baseline confidence level (high for experimental studies, low for observational) and then rating down for limitations in five domains: risk of bias, imprecision, inconsistency, indirectness, and publication bias. Confidence can be rated up for a large magnitude of effect, a dose-response gradient, or if all plausible confounding would reduce the demonstrated effect [62].

Table 1: Key Steps in a Systematic Review Framework for Toxicology (Adapted from ATSDR and TCEQ) [57] [41]

Step	Title	Core Objective	Key Output
1	Problem Formulation	Define the scope, population, exposure, comparator, and outcomes (PECO).	Protocol with explicit inclusion/exclusion criteria [57].
2	Literature Search & Screen	Identify all potentially relevant studies through comprehensive, documented searches.	List of studies for full-text review [57] [61].
3	Data Extraction	Systematically collect relevant data from included studies.	Populated, standardized data extraction tables [57].
4	Identify Outcomes of Concern	Catalog all reported health effects from the extracted data.	Table of health outcomes by route and species [57].
5	Assess Risk of Bias / Study Quality	Critically appraise the internal validity of each study.	Quality rating for each study (e.g., low, moderate, high risk of bias).
6 & 7	Rate & Translate Confidence in Evidence	Evaluate the overall body of evidence for each outcome.	Confidence rating (e.g., High, Moderate, Low, Very Low) for each outcome [57] [62].
8	Integrate Evidence for Hazard ID	Synthesize all appraised evidence to draw hazard conclusions.	Hazard identification statements and toxicity factors (e.g., ReV, URF).

Table 2: Criteria for Rating Confidence in a Body of Evidence (Based on GRADE) [62]

Domain	Rating Down (Lower Confidence)	Rating Up (Higher Confidence)
Risk of Bias	Serious limitations in study design or execution across most evidence.	Not typically used for rating up.
Imprecision	Wide confidence intervals, small sample size, or few events.	Not applicable.
Inconsistency	Unexplained heterogeneity in results (e.g., variable effect direction, I² > 50%).	Not applicable.
Indirectness	Evidence is indirect regarding PECO (e.g., wrong population, surrogate outcome).	Not applicable.
Publication Bias	Evidence suggests unpublished studies exist that would change conclusions.	Not applicable.
Large Magnitude	Not applicable.	Very large relative risk or effect size (e.g., RR > 2 or < 0.5).
Dose-Response	Not applicable.	Presence of a clear gradient across exposure levels.
Plausible Confounding	Not applicable.	All plausible confounding would reduce an apparent effect.

Visualization of the Step 8 Workflow and Decision Pathway

The following diagram illustrates the logical flow and decision-making process within Step 8, integrating inputs from previous review stages to formulate final hazard conclusions.

Flowchart Title: Step 8 Workflow: From Evidence Synthesis to Hazard Conclusion

The Scientist's Toolkit: Essential Materials and Reagents for Systematic Review

Table 3: Research Reagent Solutions for Conducting Systematic Reviews in Toxicology

Tool / Resource	Category	Function / Purpose
GRADEpro GDT / Other GRADE Software [62]	Software	Facilitates the creation of evidence summaries (SoF tables) and guides the transparent application of the GRADE framework for rating confidence.
Covidence, Rayyan, DistillerSR [61]	Systematic Review Management Platform	Online platforms designed to manage the entire review process: de-duplication, title/abstract screening, full-text review, data extraction, and quality assessment.
Cochrane Risk of Bias (RoB) 2.0 Tool [59]	Quality Assessment Tool	Standardized tool for assessing risk of bias in randomized trials.
Newcastle-Ottawa Scale (NOS) [59]	Quality Assessment Tool	Validated tool for assessing the quality of nonrandomized studies (cohort and case-control) in meta-analyses.
PubMed, EMBASE, TOXLINE	Bibliographic Database	Core databases for conducting comprehensive literature searches to ensure all relevant primary studies are captured.
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Checklist & Flow Diagram [61]	Reporting Guideline	Provides a minimum set of items for transparent and complete reporting of a systematic review. The flow diagram tracks the study selection process.
AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) [61]	Appraisal Tool	Critical appraisal tool used to assess the methodological quality of a completed systematic review.
IARC Monographs Preamble, OHAT/NTP Handbook	Methodological Guidance	Provide authoritative, field-specific frameworks for hazard identification and systematic review in toxicology and cancer research.

Solving Common Problems: Optimizing Your Review for Efficiency and Reliability

In evidence-based toxicology, the systematic review is the cornerstone for integrating diverse data streams—from human observational studies and animal bioassays to in vitro and in silico models [1]. The validity of the entire synthesis is predicated on the first critical step: a comprehensive and unbiased literature search. An inadequate search strategy, characterized by a limited selection of databases and neglect of grey literature, constitutes a fundamental and pervasive pitfall. It irrevocably biases the evidence base, potentially leading to erroneous conclusions about chemical hazards and risks [1]. This pitfall undermines the core promise of systematic reviews: to provide a transparent, reproducible, and objective summary of all available evidence on a precisely framed question [1].

Empirical data reveals this is a widespread issue. An analysis of 817 systematic reviews and meta-analyses (SRMAs) found that while 95% searched Medline, only 44% included EMBASE and 41% the Cochrane Library [63]. More critically, searches were frequently limited to published literature, with underutilization of trial registries and grey literature sources [63]. This practice creates substantial risk of publication bias, as unpublished studies or those with null results are systematically omitted. The consequence is a synthesized evidence base skewed toward positive or statistically significant findings, compromising its reliability for regulatory and public health decision-making [63] [64].

Quantitative Analysis of Database Selection Patterns and Gaps

The selection of bibliographic databases directly determines the scope and representativeness of the identified evidence. Analysis reveals consistent patterns and significant gaps in current practice.

Table 1: Usage Frequency and Characteristics of Key Information Resources in Systematic Reviews

Resource Type	Example Resources	Typical Usage in SRMAs (2005-2016) [63]	Primary Function & Coverage	Association with Reduced Publication Bias [63]
Major Biomedical Databases	Medline (PubMed), EMBASE, Cochrane CENTRAL	Medline: 95%, EMBASE: 44%, Cochrane: 41%	Index peer-reviewed journal literature. EMBASE has stronger European/ pharmacological coverage. Cochrane specializes in clinical trials.	Scopus (when added to Medline) showed a negative association.
Multidisciplinary / Citation Databases	Scopus, Web of Science	Not quantified in cited study, but recommended as supplements [65].	Broad interdisciplinary coverage, includes citation tracking to find related work.	Scopus showed a significant negative association with publication bias.
Trial Registries	ClinicalTrials.gov, WHO ICTRP Portal	Used more frequently in SRMAs published in methods journals [63].	Prospectively register trial protocols and results, including unpublished findings.	ClinicalTrials.gov (for safety outcomes) showed a negative association.
Grey Literature Sources	Regulatory reports (FDA), dissertations, conference abstracts	Underutilized; guideline publication (2013) did not substantially increase use [63].	Provide unpublished, non-commercial, or hard-to-find data. Crucial for balanced evidence.	Not specifically quantified, but essential to mitigate publication bias [63].
Toxicology-Specialized Resources	TOXLINE, ECOTOX, HSDB	Use is field-dependent; essential for comprehensive toxicological reviews.	Cover specialized literature on chemical properties, toxicology, and environmental effects.	Critical for capturing domain-specific evidence not in biomedical databases.

A 2024 case study starkly illustrates the consequence of limited searching. Two systematic reviews addressing the same clinical question, published within six months of each other, used different database combinations (PubMed/Embase vs. PubMed/Cochrane). Their final included studies overlapped by only 4 out of 27 total unique studies, demonstrating that each review missed a majority of eligible studies [64]. This resulted in differing data on primary outcomes, rendering neither review reliable for decision-making [64].

Experimental Protocols: Methodologies for Studying Search Adequacy

The quantitative insights on search inadequacy are derived from rigorous, reproducible study designs. The following protocol details the methodology from a key large-scale analysis [63].

Protocol: Analyzing Trends and Impact of Database Selection in Systematic Reviews

• Objective: To examine trends in databases searched from 2005–2016 and associations between resources searched and evidence of publication bias in SRMAs [63].
• Study Design: Retrospective, cross-sectional analysis of a randomly selected sample of published SRMAs [63].
• Eligibility Criteria:
  • Population: SRMAs with human subjects authored by US-affiliated investigators (to ensure comparability over time) [63].
  • Intervention/Exposure: Self-reported search strategy detailing electronic databases, registries, and grey literature sources used [63].
  • Comparator: Comparisons across publication years and between different journal types (e.g., methods journals vs. specialized journals) [63].
  • Outcome: 1) Frequency of resource usage. 2) Network analysis of co-searched resources. 3) Association (via logistic regression) between resources searched and a lower chance of finding statistical evidence of publication bias (e.g., via funnel plot asymmetry) [63].
• Search Strategy for Identification of SRMAs:
  • Database: PubMed [63].
  • Search Filter: A pre-validated high-sensitivity filter for systematic reviews (systematic[sb]) combined with the publication type Meta-Analysis[ptyp], filters for author affiliation (USA[ad]), human subjects, and publication date ranges for each year from 2005–2016 [63].
• Study Selection Process:
  • Random Sampling: 100 SRMA records were randomly selected from the search results for each calendar year [63].
  • Manual Review & Screening: Full-text articles were reviewed to confirm they met the operational Cochrane definition of an SRMA (explicit search, defined selection, formal statistical synthesis) [63].
  • Exclusion: Articles were excluded for inadequate methodological detail or out-of-scope methods [63].
  • Final Sample: 817 SRMA articles were included for analysis [63].
• Data Extraction & Analysis:
  • Extracted variables included: journals searched, use of registries (e.g., ClinicalTrials.gov), use of grey literature, journal type, and statistical indicators of publication bias [63].
  • Trend Analysis: Calculated proportional use of each resource over time [63].
  • Network Analysis: Mapped which resources were searched simultaneously to identify clusters of common practice [63].
  • Regression Analysis: Used logistic models to identify information sources whose use was associated with a lower likelihood of the SRMA reporting significant publication bias [63].

Visualizing the Systematic Review Workflow and the Pitfall

Diagram 1: Systematic review workflow with search pitfall.

Diagram 2: How search strategy impacts the evidence base.

A robust search strategy for toxicology systematic reviews must extend beyond general biomedical databases to capture the field's diverse evidence streams [1]. The following toolkit categorizes essential resources.

Table 2: Research Reagent Solutions for Comprehensive Toxicology Searches

Resource Category	Specific Resource Examples	Primary Function in Toxicology SR	Key Consideration
Core Biomedical Databases	PubMed/Medline, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL)	Foundational search for peer-reviewed human, animal, and mechanistic studies. EMBASE is critical for pharmacological literature.	Searching only these is inadequate [64]. Use both Medline and Embase for overlap and unique coverage [65].
Multidisciplinary Databases	Scopus, Web of Science Core Collection	Broad coverage across sciences. Essential for finding interdisciplinary environmental health, chemistry, and engineering literature. Citation tracking finds related studies.	Associated with lower publication bias [63].
Toxicology-Specialized Databases	TOXLINE, ECOTOX (EPA), HSDB (Hazardous Substances Data Bank), PubMed's TOXNET subset	Capture specialized toxicology, hazard, risk, and environmental fate literature not fully indexed in core biomedical databases.	Non-negotiable for chemical-specific reviews.
Trial & Study Registries	ClinicalTrials.gov, WHO ICTRP, EU Clinical Trials Register	Identify ongoing, completed, and unpublished human clinical trials of toxicological agents (e.g., chemotherapies). Mitigate publication bias.	Required by PRISMA 2020 for interventional reviews [19].
Grey Literature Sources	Regulatory Agency Websites (EPA, EFSA, FDA, ECHA), ProQuest Dissertations & Theses, conference proceedings, OpenGrey	Access to unpublished study reports, regulatory assessments, academic theses, and preliminary findings crucial for balanced hazard assessment.	Requires methodical, source-specific search strategies [66].
Reference Management & Screening Software	EndNote, Zotero, Rayyan, Covidence	Manage large search results, remove duplicates, and facilitate blinded screening by multiple reviewers.	Essential for ensuring the screening process is systematic and reproducible [66] [65].
Reporting Guideline	PRISMA 2020 Statement & Flow Diagram [19]	Provides a structured checklist and flow diagram template to ensure transparent reporting of the search and selection process.	Journal requirement; use the flow diagram to document search yield [67].

The pitfall of inadequate literature search is not merely a procedural error but a critical threat to the scientific integrity of systematic reviews in toxicology. It introduces selection bias at the very origin of the evidence synthesis pipeline, predetermining potentially skewed and unreliable outcomes. The solution is a mandatory, protocol-driven approach to searching that embraces resource diversity. This entails combining core biomedical and multidisciplinary databases, diligently searching toxicology-specific resources, and systematically integrating trial registries and grey literature. As evidenced, comprehensive searches utilizing resources like Scopus and ClinicalTrials.gov are demonstrably associated with a reduced risk of publication bias [63]. For toxicology, a field where decisions impact public health and environmental policy, committing to such rigorous search methodology is an ethical and scientific imperative. Overcoming this first pitfall lays the only credible foundation for the subsequent steps of appraisal, synthesis, and interpretation that define a high-quality, trustworthy systematic review.

Within the rigorous domain of toxicology research—encompassing hazard identification, risk assessment, and the evaluation of New Approach Methodologies (NAMs)—systematic reviews are foundational for evidence-based decision-making [68]. The validity of such reviews is contingent upon the completeness of the literature search; missing relevant studies can lead to biased conclusions, misinformed safety assessments, and flawed regulatory policies. A persistent challenge for researchers and drug development professionals is identifying the most efficient combination of bibliographic databases to ensure comprehensive coverage without incurring impractical screening burdens.

This guide frames the implementation of an optimal database search strategy within the broader thesis of conducting a high-quality systematic review in toxicology. It moves beyond theoretical coverage of databases to present an evidence-based, practical methodology proven to maximize recall of relevant references.

Core Evidence: The Bramer Study on Database Performance

The foundational evidence for the recommended database combination comes from a prospective, exploratory study by Bramer et al. (2017) [69] [70]. This research departed from previous analyses of database coverage by instead analyzing actual retrieval—the references found by real search strategies for published systematic reviews.

Methodology: The study analyzed 58 published systematic reviews (containing 1,746 relevant references identified via database searches) for which complete search records were available [70]. For each review, the researchers identified which of the finally included references were retrieved by searches in each database used (e.g., Embase, MEDLINE, Web of Science, Google Scholar). They then calculated performance metrics—recall, precision, and number needed to read—for individual databases and for combinations.

Key Quantitative Findings: The study yielded critical data on the unique contributions and combined performance of major databases, as summarized in the tables below.

Table 1: Unique Contribution of Individual Databases [70]

Database	Number of Unique Included References Retrieved	Percentage of Total Unique References (n=291)
Embase	132	45.4%
MEDLINE	68	23.4%
Web of Science Core Collection	46	15.8%
Google Scholar	26	8.9%
Cochrane CENTRAL	11	3.8%
Other Specialized Databases	8	2.7%

Table 2: Performance of Optimal Database Combination [69] [70] [71]

Database Combination	Overall Recall	Reviews with 100% Recall	Reviews with ≥95% Recall
Embase + MEDLINE + Web of Science + Google Scholar	98.3%	72%	93%

Conclusion: The research demonstrated that 16% of all included references were found in only a single database, underscoring the risk of relying on a limited search. The combination of Embase, MEDLINE (including Epub ahead of print), Web of Science Core Collection, and Google Scholar was identified as optimal, achieving near-complete recall (98.3%) efficiently. The study estimated that approximately 60% of published systematic reviews fail to retrieve 95% of available relevant references due to insufficient database searching [69] [70].

Integrating the Optimal Combination into a Systematic Review Workflow for Toxicology

Conducting a systematic review is a multi-stage process where the literature search is a critical, formative component [72] [73]. The optimal database combination must be integrated systematically.

Protocol Development and Search Strategy Translation

Before searching, a detailed protocol must be developed, specifying the research question, inclusion/exclusion criteria, and the planned search strategy for each database [72] [66]. The search strategy should be developed with high sensitivity, using a broad range of synonyms and both controlled vocabulary (e.g., MeSH in MEDLINE, Emtree in Embase) and free-text terms [74].

A core challenge is the accurate translation of the search strategy across databases, as syntax, field codes, and controlled vocabularies differ. For example, a proximity operator may be ADJ3 in Ovid but NEAR/3 in Web of Science. Using macros or careful manual adaptation is essential [70]. Collaboration with a research librarian is highly recommended at this stage to ensure search quality and reproducibility [74] [66].

Search Execution for the Core Combination

• Embase (via embase.com): Searches both Embase and MEDLINE records. Its extensive coverage of European and Asian journals and conference abstracts, coupled with the deep indexing of the Emtree thesaurus (especially for drugs and chemicals), makes it the highest-yield single source [70] [75].
• MEDLINE (via Ovid or PubMed): The premier biomedical database. When searching via PubMed, it is crucial to supplement the search with the publisher[sb] filter to capture recent Epub-ahead-of-print records not yet fully indexed [70].
• Web of Science Core Collection: Provides broad multidisciplinary coverage, capturing high-impact journals in toxicology, environmental sciences, and chemistry that may be peripheral to strictly biomedical databases. It also offers cited reference searching [74] [75].
• Google Scholar: Serves as a supplementary source that searches the full text of articles, potentially retrieving references missed in bibliographic databases. Best practice is to screen the first 200-400 results sorted by relevance [70] [74] [75]. Exporting results requires careful use of tools like Publish or Perish.

All results should be collected in a reference manager (e.g., EndNote, Zotero) for deduplication and screening.

Toxicology-Specific Adaptations and Grey Literature

While the core four-database combination provides excellent coverage for biomedical topics, toxicological systematic reviews often require targeted adaptations.

Specialized Databases: Depending on the review's focus, supplementary searches in subject-specific databases are warranted. For example:

• Chemical & Regulatory: TOXLINE, Chemical Abstracts Service (SciFinder), EPA databases.
• Environmental Health: GreenFILE, Environmental Sciences and Pollution Management.
• Occupational Health: NIOSHTIC-2, OSH-UPDATE.

Grey Literature: In toxicology and risk assessment, where publication bias is a significant concern (e.g., negative or null results may be under-published), proactively searching grey literature is mandatory [74]. Key sources include:

• Trial Registries: ClinicalTrials.gov, WHO ICTRP for unpublished study data.
• Government & Regulatory Reports: Websites of the U.S. EPA, FDA, ECHA, EFSA.
• Theses and Dissertations: ProQuest Dissertations & Theses Global.
• Conference Proceedings: Often indexed within Embase and Web of Science.

A systematic approach to grey literature, such as using the CADTH Grey Matters checklist, is recommended to ensure transparency and comprehensiveness [74] [75].

The Scientist's Toolkit for Systematic Reviews in Toxicology

Table 3: Essential Research Reagent Solutions for Toxicology Systematic Reviews

Tool / Resource Name	Function / Purpose	Key Notes for Toxicology
Optimal Database Combination	Core search engines to ensure ~98% recall of published literature.	Embase, MEDLINE, Web of Science Core Collection, Google Scholar. The foundational set for any biomedical toxicology review [69] [74].
Reference Management Software	Stores, deduplicates, and organizes search results; facilitates screening.	EndNote, Zotero, Mendeley. Critical for handling large result sets from multiple databases.
Grey Literature Checklist	Provides a structured guide to searching non-traditional publication sources.	CADTH Grey Matters. Helps minimize publication bias by identifying regulatory reports, dissertations, and trial registries [74].
Systematic Review Management Platform	Supports collaborative screening, data extraction, and quality assessment.	Rayyan, Covidence. Essential for managing the review process with multiple reviewers, reducing error and bias.
Reporting Standards Checklist	Ensures the complete and transparent reporting of the review methodology.	PRISMA (Preferred Reporting Items for Systematic Reviews) and PRISMA-S (for search methods). Required for publication in high-quality journals [74] [66].
Toxicology-Specific Data Sources	Provides chemical-specific data, regulatory information, and specialized literature.	TOXLINE, EPA CompTox Chemicals Dashboard, NTP reports. Necessary for reviews on data-poor chemicals or regulatory assessments [68].
Protocol Registry	Publicly registers the review plan to reduce duplication of effort and bias.	PROSPERO. The international register for systematic review protocols with health-related outcomes [66].

Implementing the optimal database combination of Embase, MEDLINE, Web of Science, and Google Scholar is not an arbitrary choice but an evidence-based strategy to maximize the recall and validity of a systematic review. For toxicology researchers and drug development professionals, this approach forms the robust core of a comprehensive search. It must be expertly executed through careful strategy translation, supplemented with targeted toxicological resources and a rigorous grey literature search, and integrated into the wider systematic review process—from protocol to publication. Adopting this methodology addresses the documented shortcomings in current review practices and establishes a foundation for trustworthy, actionable evidence synthesis in the field.

In the context of a systematic review in toxicology research, the selection of primary studies is the methodological cornerstone that determines the validity and reliability of the entire synthesis. Unlike a narrative literature review, which can be flexible and descriptive, a systematic review requires a structured, rigorous, and transparent process to minimize bias and provide evidence-based answers [76]. Unclear or biased study selection undermines this foundation, introducing systematic errors that can lead to overestimation or underestimation of true toxicological effects, such as a compound's hazard potential or a therapeutic agent's safety profile [77]. This guide details the origins of this pitfall, provides protocols to prevent it, and offers tools for its identification and correction.

The Problem: Origins and Consequences of Selection Bias

Selection bias in a systematic review occurs when the process of identifying and including studies is influenced by factors other than the pre-defined, objective criteria aligned with the research question. In toxicology, this can have direct implications for chemical risk assessment and drug safety profiles.

Primary Origins:

• Vague Inclusion/Exclusion Criteria: Criteria that use ambiguous terms like "significant toxicity," "standard exposure," or "relevant model" without operational definitions allow for subjective interpretation.
• Inadequate Search Strategy: Relying on a single database, using restrictive search strings, or excluding non-English literature or grey literature (e.g., regulatory reports, conference abstracts) leads to a non-representative sample of evidence.
• Unreliable Screening Process: Conducting title/abstract or full-text screening by a single reviewer, or with multiple reviewers without calibration and conflict resolution procedures, introduces inconsistency.
• Selective Outcome Reporting Tendency: An unconscious preference for studies that report positive or statistically significant findings, while overlooking studies with null or negative results, skews the evidence base.

Toxicology-Specific Consequences: The result is a synthesized evidence pool that may not reflect the true biological effect. For example, a review concluding a chemical is "safe" based only on high-dose, short-term rodent studies while excluding chronic low-dose or in vitro mechanistic data provides a flawed foundation for human health risk assessment. This compromises the review's utility for informing regulatory decisions or clinical guidelines.

Quantitative Analysis of Bias Assessment Tools

Selecting an appropriate, validated tool is critical for transparently assessing the risk of bias in included studies, which directly informs conclusions about the strength of evidence [78]. The following table compares widely used tools relevant to toxicology study designs.

Table 1: Risk of Bias Assessment Tools for Toxicology Systematic Reviews

Tool Name	Primary Study Design	Key Domains Assessed	Output / Scoring	Key Reference & Source
Cochrane RoB 2	Randomized Controlled Trials (RCTs)	Bias from randomization, deviations, missing data, measurement, selective reporting	Judgment (Low/High/Some concerns) per domain & overall	Cochrane Handbook [77]
ROBINS-I	Non-Randomized Studies of Interventions (e.g., cohort, case-control)	Bias from confounding, participant selection, intervention classification, departures, missing data, outcome measurement, selective reporting	Judgment (Low/Moderate/Serious/Critical) per domain & overall	Cochrane Collaboration [77]
SYRCLE's RoB	Animal Intervention Studies	Selection, performance, detection, attrition, reporting, other biases	Signaling questions (Yes/No/Unclear)	Derived from Cochrane RoB
OHAT RoB	Human & Animal Observational Studies	Participant selection, exposure assessment, confounding, outcome assessment, selective reporting, other biases	Guidance for judgment across domains	NTP Office of Health Assessment and Translation
QUADAS-2	Diagnostic Accuracy Studies	Patient selection, index test, reference standard, flow & timing	Judgment (High/Low/Unclear) & concerns regarding applicability	University of Bristol

Experimental Protocols to Mitigate Selection Bias

Implementing a standardized, pre-published protocol is the most effective defense against selection bias. The following methodologies should be detailed in the protocol.

Protocol 3.1: Developing A Priori Inclusion/Exclusion Criteria

• Population (P): Define the biological system with precise terminology (e.g., "Sprague-Dawley rats, male, 8-10 weeks old," "human primary hepatocytes," "population living within 5km of a lead smelter").
• Exposure/Intervention (I): Specify the toxicant or therapeutic agent, including analogs, formulations, and routes of administration (e.g., "oral gavage," "inhalation," "ppm in drinking water").
• Comparator (C): Define the control condition (e.g., "vehicle control," "placebo," "background population exposure levels").
• Outcome (O): Objectively define the measured endpoints (e.g., "serum alanine aminotransferase (ALT) levels ≥ 2x control mean," "histopathological evidence of hepatocellular adenoma," "incidence of neurodevelopmental disorder").
• Study Design (S): Specify eligible designs (e.g., "randomized controlled trials," "prospective cohort studies," "in vivo studies with n≥5 per group").

Protocol 3.2: Executing a Comprehensive Search Strategy

• Database Selection: Search multiple, discipline-specific databases (e.g., PubMed/MEDLINE, Embase, Scopus, TOXLINE, Web of Science).
• Search String Development: Use controlled vocabulary (MeSH, Emtree) and free-text terms for P/I/C/O concepts, combined with Boolean operators. Avoid overly restrictive filters.
• Grey Literature Search: Include clinical trial registries (ClinicalTrials.gov), regulatory agency websites (EPA, ECHA, FDA), and conference proceedings.
• Reference Mining: Manually screen reference lists of included studies and relevant review articles.

Protocol 3.3: Conducting a Blinded, Duplicate Screening Process

• Pilot Calibration: Before formal screening, all reviewers independently screen a random sample of 50-100 records using the criteria. Calculate inter-rater reliability (e.g., Cohen's kappa). Discuss discrepancies until consensus is reached and criteria are refined.
• Dual Independent Screening: At least two reviewers screen each title/abstract and subsequent full-text report independently, blinded to each other's decisions.
• Conflict Resolution: All conflicts are resolved through discussion between the two reviewers. If consensus cannot be reached, a third senior reviewer arbitrates.
• Documentation: Use systematic review software (e.g., Rayyan, Covidence, DistillerSR) to track decisions and maintain an audit trail. Record reasons for exclusion at the full-text stage.

Table 2: Example Inclusion/Exclusion Criteria for a Toxicology Review

Criterion	Category	Inclusion	Exclusion
Population	Species & Model	In vivo mammalian models (rodents, primates)	In vitro studies, non-mammalian models
Intervention	Exposure	Chronic oral exposure (≥90 days) to Compound X	Acute exposure, non-oral routes (e.g., dermal, inhalation)
Comparator	Control Group	Vehicle control or untreated control group	Studies with no internal control group
Outcome	Measured Endpoint	Hepatic steatosis confirmed by histopathology	Studies only reporting serum lipids without histology
Study Design	Publication Type	Primary research articles in peer-reviewed journals	Reviews, editorials, conference abstracts without full data

Research Reagent Solutions for Unbiased Selection:

Item	Function & Rationale
Pre-registered Protocol (PROSPERO)	Publicly registers the review plan (PICO, methods) to lock in criteria and analysis, preventing data-driven changes [76].
Bibliographic Software (EndNote, Zotero)	Manages large citation libraries, removes duplicates, and facilitates sharing among reviewers.
Dedicated Screening Software (Rayyan, Covidence)	Platforms designed for blind duplicate screening, conflict highlighting, and decision tracking, essential for Protocol 3.3 [78].
Risk of Bias Visualization (ROBVIS)	A web app that generates standardized "traffic light" and weighted bar plots from RoB assessment data, aiding transparent reporting [77].
Reporting Guideline (PRISMA 2020)	Provides a checklist and flow diagram framework to ensure complete and transparent reporting of the study selection process [76].

Visualizing the Study Selection and Bias Assessment Workflow

A standardized, multi-stage workflow is critical to minimize bias. The following diagram maps the process from initial identification to final inclusion and quality assessment.

Systematic Review Study Selection and Bias Assessment Workflow

After studies are included, a rigorous, tool-based assessment is conducted to evaluate their internal validity. The following diagram details this critical appraisal process.

Risk of Bias Assessment and Judgment Process

In the methodological framework of systematic review (SR) for toxicology, the pre-specification and piloting of inclusion and exclusion criteria are foundational to ensuring scientific rigor and reliability. These criteria define the exact scope of evidence that will be synthesized to answer a precisely formulated research question, acting as the primary filter against bias and arbitrariness in study selection [79] [80].

The adoption of SR methodology, pioneered in clinical medicine, represents a significant advancement for toxicological risk assessment and evidence integration. It provides a transparent, methodologically rigorous, and reproducible means to summarize available evidence, which is central to the principles of evidence-based toxicology [81]. This guide details the technical process of developing and validating these critical criteria, framing them within the essential steps of conducting a toxicological SR.

Theoretical Foundations and Core Principles

Defining Inclusion and Exclusion Criteria

Inclusion and exclusion criteria are collectively known as eligibility criteria [79].

• Inclusion Criteria are the characteristics that a study must possess to be considered for the review. They are derived directly from the key elements of the research question—typically the Population, Exposure/Intervention, Comparator, and Outcome (PECO framework in toxicology) [81] [80].
• Exclusion Criteria are characteristics that disqualify a study, even if it meets the inclusion criteria. They identify studies with features that could interfere with the outcome, introduce excessive risk of bias, or make synthesis impractical (e.g., unsuitable study design, co-exposures to confounding agents, inadequate reporting) [79] [80].

The Imperative for Pre-Specification and Piloting

Pre-specifying criteria in a publicly accessible protocol before beginning the formal screening mitigates selection bias and ensures the review's reproducibility, a core tenet of the SR process [81]. Piloting, or testing, these criteria on a sample of the retrieved literature is a critical validation step that is often overlooked. It serves to:

• Identify Ambiguities: Uncover vague terms or concepts that different reviewers may interpret differently.
• Assess Feasibility: Determine if the criteria are so restrictive that they yield no studies or so broad that they yield an unmanageable number.
• Calibrate the Review Team: Ensure consistent application of criteria across all reviewers, a prerequisite for reliable screening [80].

Structured Methodology for Criteria Development and Piloting

Step 1: Drafting Criteria from the PECO Framework

The first step translates the SR question into a structured draft of criteria. The PECO framework is standard:

• Population (P): Define the biological system (e.g., human, in vivo mammalian, in vitro cell line, specific animal model like Sprague-Dawley rat). Include relevant descriptors (e.g., age, sex, strain, disease state) [79].
• Exposure (E): Specify the toxicant(s), including forms (e.g., Bisphenol A, cadmium chloride), routes of administration (e.g., oral gavage, inhalation, drinking water), durations, and relevant dose ranges.
• Comparator (C): Define the acceptable control groups (e.g., vehicle control, sham-exposed, background exposure level).
• Outcome (O): List the toxicological endpoints of interest (e.g., clinical observation, organ weight, histopathology, biomarker level like serum ALT, omics data, apical endpoints like mortality or tumor incidence).

Table 1: Core Components of Inclusion/Exclusion Criteria for a Toxicology SR

Component	Description	Toxicology-Specific Examples & Considerations
Population (P)	Defines the biological system under investigation.	Inclusion: Primary hepatocytes from human or rat; Male C57BL/6 mice. Exclusion: Non-mammalian systems (e.g., zebrafish) if not relevant; genetically modified models unless specifically studied.
Exposure (E)	Specifies the agent, route, duration, and dose.	Inclusion: Oral exposure to arsenic (as NaAsO₂) for >28 days. Exclusion: Co-exposure with other known hepatotoxicants; studies using non-relevant forms (e.g., arsenobetaine).
Comparator (C)	Defines the acceptable control/reference group.	Inclusion: Vehicle control (e.g., corn oil); matched sham-exposed group. Exclusion: Historical controls; control groups exposed to a different vehicle.
Outcome (O)	Lists the measurable endpoints relevant to the question.	Inclusion: Quantitative data on liver necrosis, serum alanine aminotransferase (ALT) activity. Exclusion: Solely qualitative descriptions (e.g., "mild inflammation"); unrelated endpoints (e.g., neurobehavioral scores).
Study Design	Specifies acceptable types of evidence.	Inclusion: Randomized controlled trials (for clinical tox), controlled in vivo studies, dose-response studies. Exclusion: Case reports, narrative reviews, studies without a control group, in silico-only studies (if not the focus).
Data Accessibility	Ensures the study report contains necessary information.	Inclusion: Studies reporting mean, measure of variance (SD, SEM), and group size (n). Exclusion: Studies where only a graphical representation of data is provided and numerical data cannot be extracted or reliably estimated.

Step 2: The Pilot Testing Protocol

A formal pilot phase is conducted after the literature search is performed but before full-text screening begins.

• Random Sample Selection: Randomly select a sample of citations and/or full-text articles (typically 1-3% of the total, or 50-100 records) from the search results [81].
• Independent Dual Review: At least two reviewers independently apply the draft criteria to this sample, classifying each record as "include," "exclude," or "uncertain," and documenting the specific reason for exclusion.
• Calculate Inter-Rater Reliability: Use a statistic like Cohen's Kappa (κ) to quantify agreement beyond chance. A κ ≥ 0.6 indicates substantial agreement; ≥ 0.8 is excellent [82].
• Resolve Discrepancies & Refine Criteria: Reviewers meet to discuss every discrepancy. Disagreements often reveal ambiguities in the criteria (e.g., "Does 'chronic exposure' include 21-day studies?"). The criteria are then refined to resolve these ambiguities.
• Re-pilot (if necessary): If major changes are made, the revised criteria should be tested on a new sample until satisfactory agreement is achieved.

Table 2: Quantitative Analysis of a Pilot Test for Eligibility Criteria

Pilot Metric	Calculation Formula	Target Value	Outcome Example & Interpretation
Raw Agreement	(Number of agreements / Total records screened) x 100	> 80%	85% agreement indicates good initial consistency between reviewers.
Cohen's Kappa (κ)	Measures agreement corrected for chance. Calculated using standard statistical software.	κ ≥ 0.6 (Substantial)	κ = 0.72. Indicates substantial agreement beyond chance.
Major Conflict Rate	(Records with conflicting "Include"/"Exclude" decisions / Total records) x 100	< 10%	7% major conflicts. These are the focus of the consensus discussion.
Refinement Outcome	Qualitative summary of criteria changes post-pilot.	N/A	Clarified "chronic exposure" to mean "≥ 28 days in rodents." Added specific exclusion for studies using propylene glycol as vehicle.

Step 3: Finalizing and Documenting the Criteria

The finalized criteria must be documented with operational clarity. Each criterion should be unambiguous, measurable, and leave minimal room for subjective judgment. This final set is locked and used for the entire screening process, with any deviations documented as protocol amendments.

Toxicology-Specific Considerations and Challenges

Toxicology SRs face unique challenges that must be reflected in the criteria [81]:

• Evidence Stream Diversity: Criteria must account for heterogeneous study types, from human epidemiological studies and controlled in vivo animal tests to in vitro mechanistic assays. Separate criteria streams or a hierarchical approach may be needed.
• Dose-Response and Study Duration: Explicit thresholds for minimum duration or relevant dose ranges are crucial. A study on acute cytotoxicity may be excluded from a review of chronic carcinogenicity.
• Model System Relevance: Justifying the inclusion or exclusion of specific models (e.g., transgenic animals, particular cell lines) is essential for the review's external validity.
• Risk of Bias Assessment Integration: Eligibility criteria should align with planned risk of bias/study quality tools. For example, if "blinding of outcome assessment" is a domain in the risk of bias tool, the team must be prepared to screen for and extract this information.

Visualizing the Workflow: From Protocol to Finalized Criteria

The following diagram illustrates the iterative, systematic workflow for developing and validating inclusion/exclusion criteria within a toxicological systematic review.

Table 3: Research Reagent Solutions for Systematic Review Methodology

Tool / Resource Category	Specific Examples & Functions	Relevance to Criteria Development & Piloting
Protocol & Reporting Guides	PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols): Provides a checklist for items to include in a protocol, ensuring comprehensive pre-specification [81].	Ensures all necessary components of the PECO framework and eligibility criteria are documented prospectively.
Reference Management & Screening Software	Rayyan, Covidence, DistillerSR: Web-based tools designed for collaborative systematic review screening. Features include blinded dual review, conflict highlighting, and pilot mode.	Facilitates the independent pilot screening process, tracks decisions, and automatically calculates inter-rater reliability metrics.
Toxicology-Focused Guidance	NHTSA's Systematic Review Methodology, EFSA's Guidance on SR for Food Safety: Provide field-specific advice on handling evidence from animal toxicology, in vitro studies, and human data [81].	Informs the development of realistic, fit-for-purpose criteria for diverse toxicological evidence streams.
Inter-Rater Reliability Calculators	Online Kappa Calculators (e.g., GraphPad), Statistical Software (R, SPSS): Quantify the level of agreement between reviewers during the pilot phase [82].	Provides objective data (Cohen's Kappa) to validate the clarity and applicability of the drafted criteria.
Color Contrast Checkers	WebAIM Contrast Checker: Online tool to verify that color contrast ratios meet WCAG accessibility standards (minimum 4.5:1 for text) [83].	Essential for ensuring that any color coding used in screening spreadsheets or visual workflow diagrams is accessible to all team members.

In the field of toxicology, where evidence informs critical decisions in chemical risk assessment, drug safety, and public health policy, the systematic review (SR) is an indispensable tool for synthesizing often complex and conflicting data. The integrity of an SR's conclusions is wholly dependent on the rigor of its critical appraisal process—the systematic evaluation of the validity, reliability, and relevance of the individual studies it incorporates [84]. Inconsistent or poor-quality appraisal represents a fundamental pitthal that can fatally undermine a review, leading to biased, inaccurate, or misleading conclusions [84].

This pitfall manifests when reviewers apply appraisal tools haphazardly, lack training in methodological assessment, or fail to transparently report their judgments. In toxicology, the stakes are particularly high. An overly lenient appraisal may grant undue weight to a methodologically flawed animal toxicology study or an epidemiological analysis with uncontrolled confounding, skewing the understanding of a compound's hazard. Conversely, overly stringent or inconsistent criteria may unjustly exclude valid evidence, creating a distorted evidence base. This guide provides a detailed technical framework for executing consistent, high-quality critical appraisal within toxicological SRs, ensuring that the resulting evidence synthesis is a reliable foundation for scientific and regulatory decision-making [85].

Methodological Protocols for Rigorous Appraisal

A robust critical appraisal protocol must be pre-specified in the SR's methodology to prevent ad-hoc decisions and minimize reviewer bias. The following workflow details the essential components.

Pre-Appraisal Planning and Tool Selection

Before evaluating the first study, the review team must establish a standardized appraisal framework.

• Defining the Research Question and Relevance Criteria: The appraisal must be anchored to the SR's focused research question, typically structured using the PICO (Patient/Problem, Intervention, Comparison, Outcome) or similar framework (e.g., PECO for exposure) [84]. A study's relevance is judged first: does it directly address the PICO question? [85].
• Selecting Appropriate Critical Appraisal Tools: The choice of tool is dictated by study design. Using a tool for randomized controlled trials (RCTs) on an observational cohort study will yield meaningless results. Standardized, validated tools should be selected [86] [85].
  • For animal studies: Tools like the SYRCLE's risk of bias tool are specifically designed for in vivo experiments.
  • For human observational studies (cohort, case-control): The Newcastle-Ottawa Scale (NOS) is commonly used [85].
  • For human intervention studies (RCTs): The Cochrane Risk of Bias (RoB 2) tool is the current standard [84] [85].
  • For the overall SR: AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews) is used to appraise reviews of interventions [84] [85].
• Developing a Coding and Extraction Guide: Create a detailed manual operationally defining how each item in the chosen tool(s) will be applied to the specific context of the review (e.g., what constitutes "adequate blinding" in a rodent histopathology assessment?). This guide ensures consistent interpretation across reviewers.

The Dual-Reviewer Process with Calibration

Critical appraisal should never be conducted by a single individual. A minimum two-reviewer process with reconciliation is mandatory to reduce random error and subjective bias [85].

• Reviewer Calibration: Reviewers independently appraise the same 2-3 studies using the coding guide. Their results are compared to calculate inter-rater reliability (e.g., using Cohen's kappa statistic). Discrepancies are discussed, and the coding guide is refined until acceptable agreement (e.g., kappa > 0.6) is achieved.
• Independent Appraisal: Reviewers then appraise studies independently, blinded to each other's judgments and often to the study journal and authors to mitigate potential bias.
• Reconciliation of Discrepancies: All disagreements are documented and resolved through consensus discussion. If consensus cannot be reached, a third senior reviewer adjudicates.
• Piloting the Search Strategy: The search strategy must be piloted and refined across multiple relevant databases (e.g., PubMed/MEDLINE, Embase, TOXLINE, Web of Science) to ensure it captures a comprehensive and unbiased set of literature [84]. The syntax must be adapted for each database's unique search language [84].

Table 1: Common Critical Appraisal Tools for Toxicology Evidence Synthesis

Study Design	Recommended Tool	Primary Appraisal Focus	Source/Authority
In Vivo (Animal) Studies	SYRCLE's Risk of Bias Tool	Selection, performance, detection, attrition, reporting bias specific to animal models	SYRCLE
Randomized Controlled Trials (Human)	Cochrane RoB 2 Tool	Randomization, deviations from intervention, missing data, outcome measurement, selective reporting	Cochrane Collaboration [85]
Cohort & Case-Control Studies	Newcastle-Ottawa Scale (NOS)	Selection of cohorts, comparability, assessment of outcome/exposure	University of Ottawa/Oxford [85]
Systematic Reviews (of Interventions)	AMSTAR 2	Comprehensiveness of search, study selection, data extraction, risk of bias assessment, meta-analysis methods	AMSTAR [84] [85]
Qualitative Studies	CASP Qualitative Checklist	Study aims, methodology, design, recruitment, data collection, reflexivity, ethical issues	Critical Appraisal Skills Programme [85]

Data Synthesis Informed by Appraisal

The results of the critical appraisal must directly inform the data synthesis and conclusions.

• Stratified Analysis: Present results stratified by risk of bias (e.g., high vs. low risk). A sensitivity analysis, where studies at high risk of bias are excluded, should be performed to see if the overall conclusion changes.
• Grading the Overall Evidence: Use a framework like GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) to rate the overall confidence in the body of evidence. Risk of bias from the appraisal is a key downgrading factor [85].

Results: Quantitative Insights and Common Deficiencies

Quantitative analysis of the appraisal process and outcomes is vital for transparency. The following metrics should be reported.

Table 2: Key Metrics from the Critical Appraisal Process

Metric	Description	Calculation/Example	Interpretation in Toxicology Context
Inter-Rater Reliability	Agreement between independent reviewers before reconciliation.	Cohen's Kappa (κ) = 0.85	κ > 0.8 indicates excellent agreement, reducing concern for subjective bias.
Percentage Agreement per Domain	Agreement on specific risk-of-bias domains (e.g., randomization, blinding).	90% agreement on "Selective Reporting" domain.	Highlights domains where appraisal criteria were most/least clear.
Distribution of Risk of Bias	Proportion of studies judged as low, some concerns, or high risk.	15% Low, 60% Some Concerns, 25% High Risk.	Characterizes the overall methodological quality of the evidence base.
Primary Sources of Bias	Most frequently identified methodological flaws.	"Lack of Blinding" in 70% of in vivo studies; "Inadequate Confounder Control" in 40% of cohort studies.	Identifies systemic methodological weaknesses in the primary research field.

Common critical appraisal deficiencies identified in SRs include selective outcome reporting, where only favorable or significant toxicological endpoints are published; inadequate blinding during outcome assessment (e.g., in histopathology slides); and poor accounting for confounding factors in epidemiological studies (e.g., smoking status, co-exposures) [84]. Furthermore, inconsistent application of the tool across studies, where similar methodological flaws are judged differently, is a frequent failing that invalidates the synthesis.

Visualizing the Appraisal Workflow

A standardized, diagrammatic representation of the appraisal workflow ensures all reviewers and end-users understand the process.

Diagram 1: Dual-Reviewer Critical Appraisal Workflow (77 characters)

The logical relationships between appraisal results and their impact on the evidence synthesis are equally critical to visualize.

Diagram 2: Impact Pathway of Appraisal on Synthesis (58 characters)

The Scientist's Toolkit for Critical Appraisal

Table 3: Essential Toolkit for Executing Critical Appraisal

Tool/Resource Category	Specific Item/Software	Function & Role in Appraisal	Key Considerations
Protocol & Project Management	Pre-registration on PROSPERO	Publicly documents appraisal plan (tools, process) before review begins, mitigating reporting bias.	Mandatory for high-quality SRs.
	Covidence, Rayyan, DistillerSR	Web-based platforms for managing dual blinding, conflict resolution, and data extraction during appraisal.	Streamlines the logistical process, ensures audit trail.
Critical Appraisal Instruments	Cochrane RoB 2, SYRCLE's RoB, Newcastle-Ottawa Scale (NOS)	Validated checklists/questionnaires to systematically assess methodological quality and risk of bias.	Core tool. Must match study design. Pre-pilot the tool.
	AMSTAR 2 (for appraising other SRs)	Checklist to appraise the methodological quality of a systematic review being considered for inclusion.	Used when conducting an umbrella review or including SRs as evidence.
Reference & Support	Cochrane Handbook for Systematic Reviews	The definitive methodological guide; Chapter 8 details risk of bias assessment.	Essential reference for resolving complex appraisal questions [84].
	Agency-specific Guidelines (e.g., EFSA, EPA)	Provide toxicity-specific guidance on evaluating study reliability (e.g., Klimisch scoring).	Crucial for regulatory toxicology reviews.
Data Synthesis & Visualization	RevMan, R (metafor package), Stata	Statistical software to perform meta-analyses stratified by risk of bias and create summary plots (e.g., forest plots colored by RoB).	Enables quantitative integration of appraisal results.
	GRADEpro GDT	Software to create 'Summary of Findings' tables and apply the GRADE framework, integrating RoB judgments.	Systematically translates appraisal into an evidence grade.

Within the framework of a thesis on conducting systematic reviews in toxicology, the assessment of risk of bias (RoB) is a fundamental, non-negotiable step. It is the methodological process of evaluating a study's internal validity—the degree to which its design, conduct, and analysis have minimized systematic errors that could distort the true effect of an exposure or intervention [87]. This is distinct from random error (imprecision) and general study quality, which may include aspects like reporting completeness [87]. In toxicology, where research directly informs chemical risk assessments and public health policies, failing to account for bias can lead to erroneous conclusions about hazard and safety [87].

The landscape of available tools is vast and often inconsistent. A systematic review of 230 assessment tools published from 1995 to 2023 found that 93% addressed concepts beyond pure risk of bias, such as statistical appropriateness (65%) and reporting quality (64%) [88]. Furthermore, 25% employed numerical scoring systems, a practice generally discouraged as it can oversimplify complex methodological critiques and be misleading [88]. Therefore, selecting a disciplined-appropriate tool is not a trivial task; it requires understanding the specific biases pertinent to toxicological study designs and choosing a framework focused squarely on internal validity.

The Critical Role of Risk of Bias Assessment in Toxicology

Toxicological evidence synthesis relies on diverse study types, from in vivo animal studies and in vitro assays to human observational studies. Each design is susceptible to a core set of biases:

• Selection Bias: Arises from systematic differences in baseline characteristics between compared groups, often due to inadequate randomization in experimental studies or confounding in observational studies [87].
• Performance Bias: Results from systematic differences in the care provided to groups, aside from the intervention under study (e.g., differences in handling of animal treatment groups) [87].
• Detection Bias: Stems from systematic differences in how outcomes are assessed, often related to a lack of blinding of outcome assessors [87].
• Attrition Bias: Occurs from systematic differences in withdrawals or exclusions of participants from the analysis [87].
• Reporting Bias: Arises from the selective reporting of outcomes based on the nature of the results [87].

A rigorous RoB assessment directly impacts the thesis's credibility. It determines the confidence in individual study results and dictates the weight they are given in the overall synthesis. Studies with a high risk of bias may justifiably be discounted or subjected to sensitivity analysis. Furthermore, systematic assessment helps explain heterogeneity across studies and informs the design of future, more robust toxicology research [87].

Comparative Analysis of Primary Risk of Bias Tools

Selecting the correct tool is paramount. The following table summarizes key features of major tools relevant to toxicology and related fields.

Table 1: Comparison of Core Risk of Bias Assessment Tools

Tool Name	Primary Study Design	Core Construct	Domains of Bias	Output & Strengths	Key Considerations
SYRCLE's RoB Tool [87]	Animal intervention studies	Internal validity	Selection, Performance, Detection, Attrition, Reporting, Other.	Domain-level judgments (Low/High/Unclear). Field-specific for animal studies.	Does not generate a composite score. Requires understanding of animal experimental methods.
OHAT (Office of Health Assessment and Translation) Tool [87]	Human & animal studies for hazard identification.	Risk of bias/ internal validity.	Adapted from Cochrane; covers selection, performance, detection, attrition, reporting.	Domain-level judgments. Integrates directly with evidence integration for hazard assessment.	Designed for environmental health and toxicology assessments.
Cochrane RoB 2 [77] [89]	Randomized Controlled Trials (RCTs).	Risk of bias.	Bias from randomization, deviations, missing data, outcome measurement, result selection.	Algorithm-driven domain & overall judgment. Detailed guidance for RCTs.	Gold standard for clinical RCTs. Less directly applicable to non-randomized toxicology studies.
ROBINS-I [77] [89]	Non-randomized studies of interventions.	Risk of bias.	Bias due to confounding, participant selection, intervention classification, deviations, missing data, outcome measurement, result selection.	Domain-level judgments. Critical for evaluating observational or non-randomized intervention data.	Conceptually aligns with causal questions in toxicology but can be complex to apply.

Protocol for Applying Risk of Bias Tools in a Systematic Review

The following workflow provides a detailed methodology for integrating RoB assessment into a toxicological systematic review.

Tool Selection & Customization

• Match Tool to Design: Align the primary study design in your review with the appropriate tool (see Table 1). A review of rodent studies would mandate SYRCLE's RoB, while a review of human occupational cohorts might use ROBINS-I or OHAT.
• Pilot the Tool: Develop a standardized guidance document. Two reviewers should independently apply the tool to the same 5-10 studies, calibrating their understanding of signaling questions and judgment criteria. Refine guidance based on disagreements [87] [90].

Conducting the Assessment

• Dual Independent Review: At least two trained reviewers assess each study independently. This minimizes subjective error.
• Source Information Judgments: Base judgments solely on information reported in the study and any associated protocols or registries. Do not assume unreported practices are adequate.
• Follow the Algorithm: For tools like RoB 2 and ROBINS-I, follow the prescribed algorithm of signaling questions to arrive at a domain judgment (e.g., "Low," "Some concerns," "High" for RoB 2) [77] [89].
• Document Supporting Rationale: For every judgment, record the relevant text from the source publication and a brief rationale. This ensures transparency and consistency.

Data Synthesis & Visualization

• Tabulate Assessments: Compile all judgments into a structured table for the manuscript supplementary materials.
• Generate Visualizations: Use tools like robvis to create "traffic light" plots (domains per study) and weighted bar charts (distribution of judgments per domain) [77] [89]. These provide an immediate visual summary of the strengths and weaknesses of the evidence base.
• Incorporate into Synthesis: Use the RoB assessments to grade the overall certainty of evidence (e.g., using GRADE). Plan sensitivity or meta-regression analyses to explore the impact of high-risk domains on pooled effect estimates.

Emerging Protocol: Integration of Artificial Intelligence

Recent advancements demonstrate that Large Language Models (LLMs) can significantly enhance efficiency. A 2025 study showed that LLM-assisted RoB assessment achieved 97.3% accuracy and reduced average processing time to 5.9 minutes per study, compared to 10.4 minutes for conventional methods [90].

• Protocol for AI-Assisted Assessment:
  • AI First Pass: Use a validated LLM (e.g., Claude-3.5-sonnet, Moonshot-v1-128k) with a structured prompt to extract methodological data and provide a preliminary RoB judgment for each domain [90].
  • Human Expert Review: A reviewer critically evaluates the LLM's extractions and judgments against the source PDF, correcting errors. The most significant improvements are seen in domains like sequence generation [90].
  • Adjudication: A second reviewer verifies the corrected assessments. This human-in-the-loop model leverages AI for speed while maintaining expert oversight for accuracy and nuanced judgment [90].

Diagram 1: Workflow for risk of bias assessment in toxicology reviews.

Visualizing the Logic of Risk of Bias Assessment

Understanding the conceptual relationship between study conduct, reporting, and the resulting risk of bias is crucial for accurate application.

Diagram 2: Relationship between study conduct, reporting, and risk of bias judgment.

The Scientist's Toolkit for Risk of Bias Assessment

Table 2: Essential Resources for Conducting Risk of Bias Assessment

Tool/Resource	Type	Primary Function in RoB Assessment	Key Features
SYRCLE's RoB Tool	Assessment Framework	Assessing internal validity in animal intervention studies.	Provides signaling questions for 10 domains specific to animal research (e.g., baseline characteristics, random housing) [87].
OHAT Tool	Assessment Framework	Assessing risk of bias in human & animal studies for hazard identification.	Tailored for environmental health; integrates with evidence mapping and strength-of-body assessment [87].
Cochrane RoB 2 & ROBINS-I [77] [89]	Assessment Framework	Gold-standard tools for randomized (RoB 2) and non-randomized (ROBINS-I) studies.	Detailed algorithms with explicit guidance. Supported by extensive tutorials.
robvis [77] [89]	Visualization Software	Creating publication-quality "traffic light" and bar plots from RoB data.	Web app and R package. Accepts direct input from common RoB tools.
LLMs (e.g., Claude-3.5-sonnet) [90]	AI Assistant	Accelerating data extraction and providing preliminary RoB judgments.	Can process large volumes of text quickly. Requires careful human verification and prompt engineering.
Quality Assessment Tool Repository (Duke Univ.) [77]	Online Repository	Aiding in the initial selection of an appropriate RoB or quality appraisal tool.	Searchable database of tools filtered by study design and discipline.

Within the framework of conducting a systematic review (SR) in toxicology, heterogeneity is not merely a statistical nuisance but a fundamental characteristic of the evidence base. A SR aims to synthesize findings from multiple independent studies to arrive at a more precise and generalizable conclusion [91]. In toxicology, these studies invariably involve diverse species (e.g., rodents, rabbits, dogs, in vitro models), a wide array of toxicological endpoints (e.g., median lethal dose (LD₅₀), no-observed-adverse-effect level (NOAEL), histopathological scores), and varied experimental designs (e.g., administration routes, exposure durations, control groups) [92]. Failing to adequately recognize, characterize, and handle this heterogeneity can lead to misleading pooled estimates, obscure critical patterns in the data, and ultimately generate flawed conclusions that misdirect regulatory decisions or drug development pathways [91]. This guide provides a technical roadmap for proactively managing heterogeneity, transforming it from a pitfall into a source of deeper insight within a toxicological SR.

Conceptual Foundations of Heterogeneity

Heterogeneity in a meta-analysis refers to the variability in study outcomes that extends beyond what would be expected from random chance alone [91]. This variability arises from genuine differences in the studies being synthesized. It is a pervasive and unavoidable feature of evidence synthesis in preclinical and toxicological research [91].

• Clinical vs. Statistical Heterogeneity: It is crucial to distinguish between clinical (or methodological) heterogeneity and statistical heterogeneity. Clinical heterogeneity refers to differences in the PICO elements of the included studies: Population (e.g., species, strain, sex), Intervention/Exposure (e.g., compound, dose, route), Comparator, and Outcomes (e.g., specific endpoint, measurement method, time of assessment) [93]. Statistical heterogeneity is the quantitative manifestation of this clinical diversity, representing the degree of variation in effect sizes across studies [91].
• Quantifying Statistical Heterogeneity: Common metrics include:
  • Cochran’s Q-test: A null hypothesis test for the presence of heterogeneity. A p-value < 0.10 is often used to indicate significant heterogeneity [94] [91].
  • I² Statistic: This describes the percentage of total variation across studies that is due to heterogeneity rather than chance. It is more interpretable than the Q-test. Common thresholds are: <30% (low), 30-60% (moderate), >60% (substantial) [94] [91].
  • τ² (Tau-squared): This estimates the variance of the true effect sizes across studies. Its square root (τ) is expressed in the same units as the outcome measure, making it intuitive for understanding the absolute scope of heterogeneity [91].

Table 1: Metrics for Quantifying Heterogeneity in Meta-Analysis

Metric	Interpretation	Calculation/Note	Common Thresholds
Cochran’s Q	Tests the null hypothesis that all studies share a common effect size.	Derived from the weighted sum of squared differences between study estimates and the pooled estimate.	p < 0.10 suggests significant heterogeneity.
I² Statistic	Percentage of total variability attributable to heterogeneity between studies.	I² = (Q - df)/Q × 100%, where df = degrees of freedom (n_studies - 1).	Low: <30%; Moderate: 30-60%; Substantial: >60% [94].
τ² (Tau-squared)	Estimated variance of the true effect sizes across the population of studies.	Calculated using iterative methods (e.g., DerSimonian-Laird, REML). Basis for the random-effects model.	Larger values indicate greater dispersion of true effects.
Prediction Interval	Range within which the effect size of a future, similar study is expected to fall.	Incorporates τ² to account for heterogeneity. Provides a more realistic scope for application than a confidence interval alone [91].	A 95% prediction interval is wider than the 95% confidence interval when τ² > 0.

Methodological Framework for Systematic Reviews

A rigorous, pre-defined protocol is the primary defense against mishandling heterogeneity. Adherence to established guidelines like PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ensures transparency and completeness [94].

Protocol Development and Registration

The process begins with a publicly registered protocol (e.g., on PROSPERO), which locks in the analysis plan to minimize bias [94].

• PECO(S) Framework for Toxicology: A tailored variant of the clinical PICO framework is essential for structuring the review question and eligibility criteria [94].

  • Population (P): Specify species (e.g., "Rattus norvegicus"), strain, age, sex, and health status.
  • Exposure (E): Define the chemical/compound, dose ranges, administration route (oral, dermal, inhalation), frequency, and duration.
  • Comparator (C): Detail the control group (e.g., vehicle control, sham control).
  • Outcome (O): List the toxicological endpoints of interest (e.g., liver weight change, serum ALT level, histopathology score for necrosis).
  • Study Design (S): Specify eligible designs (e.g., randomized controlled trial in animals, dose-response study).

• Comprehensive Search Strategy: Develop a sensitive search string using controlled vocabularies (e.g., MeSH terms like "Animal Experimentation," "Models, Animal") and free-text keywords related to the compound, species, and endpoints [93]. Searches should span multiple databases (PubMed, Embase, Web of Science, TOXRIC [92]) and include scrutiny of gray literature.

Study Selection, Data Extraction, and Quality Assessment

A reproducible, multi-phase screening process (title/abstract → full-text) conducted by independent reviewers minimizes selection bias [93] [94].

• Structured Data Extraction: Extract data into a pre-piloted form that captures all PECO(S) elements and quantitative results. This should include details that are potential sources of heterogeneity: exact species/strain, dosing regimen, endpoint measurement methodology, and study duration [94].
• Risk of Bias (RoB) Assessment: Use domain-based tools specific to preclinical research (e.g., SYRCLE’s RoB tool, ROBINS-E [94]) to evaluate methodological quality. Domains include selection bias, performance bias, detection bias, attrition bias, and reporting bias [93]. RoB is a key source of methodological heterogeneity and must be analyzed as such.
• Certainty of Evidence: Use the GRADE framework for preclinical evidence to rate the overall confidence in the synthesized findings, considering RoB, inconsistency (heterogeneity), indirectness, imprecision, and publication bias [94].

Diagram 1: Systematic Review Workflow for Handling Heterogeneity

Quantitative Synthesis and Heterogeneity Management Strategies

When sufficient, comparable data are available, meta-analysis is performed.

• Model Selection: The choice between a fixed-effect model (assumes a single true effect size) and a random-effects model (assumes true effect sizes follow a distribution) is critical. In toxicology, where clinical heterogeneity is the norm, the random-effects model is generally more appropriate as it explicitly accounts for between-study variance (τ²) [91].
• Investigating Sources of Heterogeneity: When significant heterogeneity (I² > 50%) is detected, pre-planned analyses should investigate its sources [94] [91].
  • Subgroup Analysis: Stratify studies by categorical variables (e.g., species, sex, high vs. low RoB) and calculate pooled estimates for each subgroup. Formal tests for subgroup differences (e.g., ANOVA analog) determine if effect sizes differ significantly between categories.
  • Meta-Regression: A more powerful technique that explores the relationship between continuous or categorical study-level covariates (e.g., dose level, animal body weight, year of publication) and the observed effect size. It quantifies how much heterogeneity is explained by the covariate.
• Sensitivity Analysis: Tests the robustness of the pooled result by iteratively removing studies (e.g., those with high RoB, outliers identified via Galbraith plots) or switching statistical models [94].
• Handling Scarce Endpoint Data: For data-scarce human endpoints, advanced computational methods like the ToxACoL (Adjoint Correlation Learning) framework can be applied. It models relationships between multiple toxicity endpoints (e.g., LD₅₀ across species) using graph topology, allowing knowledge transfer from data-rich endpoints (e.g., rat oral LD₅₀) to predict data-scarce ones (e.g., human oral TDLo) [92].

Table 2: Performance of ToxACoL vs. Benchmark Models on Data-Scarce Human Endpoints [92]

Target Endpoint	Description	Performance Improvement (ToxACoL vs. SOTA)	Data Requirement Reduction
Human-Oral-TDLo	Human low toxic dose via oral route.	+56%	~70-80% less training data required.
Women-Oral-TDLo	Human female low toxic dose via oral route.	+87%	~70-80% less training data required.
Man-Oral-TDLo	Human male low toxic dose via oral route.	+43%	~70-80% less training data required.

Diagram 2: ToxACoL Adjoint Correlation Learning Architecture

The Scientist's Toolkit: Research Reagent Solutions

The following table details essential materials and tools for conducting and synthesizing toxicology research, with a focus on managing experimental variability.

Table 3: Essential Research Reagents and Tools for Toxicological Studies

Item	Function/Application	Relevance to Heterogeneity Management
In Vivo Animal Models	Provide whole-organism systemic toxicity data. Species (rat, mouse, rabbit, dog) and strain selection are major sources of heterogeneity. Standardized strains (e.g., Sprague-Dawley rats) reduce genetic variability.
Vehicle Controls	The substance (e.g., corn oil, saline, carboxymethyl cellulose) used to administer the test compound. Inconsistent vehicle use across studies introduces confounding variability.	Critical for defining the Comparator (C) in PECO(S).
Biomarker Assay Kits	Quantify specific biochemical endpoints (e.g., ELISA for serum alanine aminotransferase (ALT) for hepatotoxicity, kits for creatinine kinase). Different kit manufacturers/sensitivities are a source of measurement heterogeneity.	Defines the Outcome (O) measurement. Standardized protocols are essential.
Histopathology Scoring System	A semi-quantitative framework for grading tissue damage (e.g., NAFLD Activity Score). Inter-pathologist variability is a key source of heterogeneity; use of validated, published scoring systems improves consistency.	Critical for Outcome (O) standardization. Blind assessment reduces bias.
Chemical Databases	Resources like TOXRIC [92] and PubChem [92] provide curated, machine-learning-ready toxicity data across species and endpoints, enabling computational approaches to bridge data gaps.	Source of data for computational modeling (e.g., ToxACoL) to address data scarcity.
Meta-Analysis Software	Tools like STATA [94] or R (with metafor, meta packages) perform random-effects models, calculate I²/τ², and conduct subgroup/meta-regression analyses.	Essential for quantifying and exploring statistical heterogeneity.
Systematic Review Platforms	Online tools like SyRF (Systematic Review Facility) [93] facilitate collaborative screening, data extraction, and management for multi-reviewer teams, reducing process-based errors.	Manages workflow heterogeneity and ensures reproducible screening/data extraction.

This technical guide details the integration of methodologically rigorous subgroup analysis and transparent reporting within systematic reviews for toxicology research. Subgroup analysis is essential for understanding heterogeneity in toxicological responses across species, strains, exposure scenarios, and population demographics, moving beyond average effects to inform precise risk assessments. However, such analyses are prone to false-positive findings from multiple testing and false negatives from inadequate power unless pre-specified and evaluated with stringent criteria [95] [96]. This whitepaper, framed within the broader thesis of conducting systematic reviews in toxicology, provides a structured framework for the pre-planned design, credibility assessment, and transparent reporting of subgroup analyses. It adapts advanced clinical methodologies, such as cumulative subgroup analysis and credibility checklists, to address toxicology's unique challenges, including integrating multiple evidence streams and translating findings from animal models to human health [1]. The goal is to enhance the objectivity, reproducibility, and utility of toxicological evidence synthesis for researchers, scientists, and drug development professionals.

Core Concepts in Subgroup Analysis for Systematic Reviews

In evidence-based toxicology, systematic reviews provide a transparent and reproducible method to synthesize studies on a precisely framed question [1]. A core challenge is heterogeneity—variability in effect sizes due to differences in species, experimental design, exposure pathways, or genetic backgrounds. Subgroup analysis is the primary tool to investigate this heterogeneity, testing whether toxicological outcomes differ across defined subsets of the evidence base.

The fundamental shift advocated here is from post hoc, exploratory subgroup analyses to pre-planned, hypothesis-driven investigations. Exploratory analyses, often conducted after data collection, carry high risks of spurious findings [95] [96]. In contrast, pre-planned analyses are defined in the systematic review protocol before data extraction, specifying the subgroup variable (e.g., rodent strain, sex, exposure duration), the biological rationale, and the statistical method for interaction testing. This approach aligns with the rigorous methodology of systematic reviews, which are characterized by explicit, pre-specified plans to minimize bias [1].

Credible subgroup analysis in toxicology must address two key questions: 1) Is the observed difference in effects between subgroups (subgroup effect) statistically reliable? and 2) Is it clinically or biologically significant? A framework developed for clinical guidelines emphasizes three criteria for credibility: a significant overall treatment effect in the main analysis, subgroup variables defined at baseline (pre-randomization), and a statistically significant interaction test [95]. In toxicology, "baseline" translates to factors inherent to the study system before exposure, such as species, sex, or genetic strain.

Failing to properly investigate heterogeneity has consequences. It can obscure important risks for vulnerable subpopulations or lead to inappropriate extrapolation of animal data to humans [1]. Transparent reporting of both the conduct and the limitations of subgroup analyses is therefore not optional but a cornerstone of scientific integrity and utility for risk assessment.

Quantitative Data on Review Methods and Reporting Practices

Table 1: Comparison of Narrative vs. Systematic Review Methodology in Toxicology

Feature	Narrative (Traditional) Review	Systematic Review
Research Question	Broad and informal, often not explicit [1].	Specified, focused, and explicit (PICO format) [1].
Literature Search	Sources and strategy usually not specified; risk of selective citation [1].	Comprehensive, multi-database search with explicit, reproducible strategy [1].
Study Selection	Criteria usually not specified [1].	Explicit inclusion/exclusion criteria applied consistently [1].
Quality Assessment	Informal or absent [1].	Critical appraisal using explicit risk-of-bias tools [1].
Data Synthesis	Often qualitative summary [1].	Qualitative summary plus quantitative synthesis (meta-analysis) where appropriate [1].
Time & Resources	Months; lower direct costs [1].	Often >1 year; moderate to high resource requirement [1].
Key Strength	Provides expert perspective; useful when time is limited [1].	Minimizes bias, enhances reproducibility, and provides a definitive summary of evidence [1].

Table 2: Credibility Assessment Criteria for Subgroup Analyses (Adapted for Toxicology) [95]

Criterion	Definition & Rationale	Application in Toxicology Reviews
1. Overall Effect	The primary pooled analysis shows a statistically significant and biologically meaningful effect.	The meta-analysis must show a significant adverse (or protective) effect for the agent before subgroup exploration.
2. A Priori Specification	The subgroup hypothesis and analysis plan were pre-specified in the review protocol.	The subgroup variable (e.g., "rat strain") and analysis method are documented before data extraction begins.
3. Baseline Characteristic	The subgroup variable is a characteristic measured at baseline, prior to exposure/intervention.	Factors like species, sex, genotype, or pre-existing disease status, not outcomes measured post-exposure.
4. Significant Interaction	A formal statistical test for interaction is significant (p < 0.05).	The test confirms the difference in effect size between subgroups is unlikely due to chance.
5. Biological Plausibility	A convincing biological mechanism explains the differential effect.	Supported by existing pharmacokinetic, metabolic, or mechanistic data (e.g., known metabolic differences between species).

Table 3: Reporting of Subgroup Analyses in Health Equity-Relevant Trials (Baseline Data) [97]

PROGRESS-Plus Characteristic	Percentage of Trials Reporting Subgroup Analysis (n=200)
Sex/Gender	19%
Race/Ethnicity/Culture	9%
Socioeconomic Status	4%
Education	0%
Occupation	0%
Place of Residence	0%
Religion	0%
Social Capital	0%
Any PROGRESS-Plus Factor	37%

Note: This data, though from clinical trials, underscores the common under-reporting of subgroup analyses relevant to vulnerable populations—a critical concern in toxicology for identifying susceptible groups [97].

Experimental Protocols for Subgroup Analysis

Protocol for Credibility Assessment of a Subgroup Analysis

This protocol adapts a clinical oncology algorithm for use in toxicological systematic reviews [95].

Objective: To systematically evaluate the credibility of a hypothesized subgroup effect within a body of evidence. Materials: Extracted data from included studies, pre-defined subgroup variable, statistical software (e.g., STATA, R). Procedure:

• Extraction: Identify the subgroup analysis of interest from the forest plot or study reports. Document whether it was pre-specified in the original study or review protocol or conducted post hoc [95].
• Credibility Assessment (Core Check): Apply the five criteria in Table 2 sequentially [95].
  • If all five criteria are met, the subgroup effect is deemed credible. The conclusion can state that the evidence suggests a differential effect.
  • If criterion #4 (significant interaction) is not met, but others are, the analysis is inconclusive; no differential effect can be claimed.
  • If any of criteria #1, #2, #3, or #5 are not met, the subgroup finding has low credibility and should be interpreted as exploratory, generating hypotheses for future research.
• Clinical/Biological Assessment: For credible findings, assess the real-world significance. Is the magnitude of difference between subgroups large enough to influence risk assessment or regulatory decisions? Is the susceptible subgroup identifiable and meaningful in a public health context?
• Transparent Reporting: Report the results of this assessment in the review's "Results" and "Limitations" sections. State clearly the credibility level and its implications for interpretation [95].

Protocol for Cumulative Subgroup Meta-Analysis

This advanced method pools subgroup-level data chronologically to identify when a subgroup effect became detectable, potentially reducing research waste [96].

Objective: To determine the earliest point at which sufficient evidence accumulated to demonstrate a credible subgroup effect. Materials: Individual participant or study-level data from multiple studies, ordered by publication year. Procedure:

• Data Preparation: For each study, calculate the effect size (e.g., standardized mean difference, risk ratio) and its variance for each subgroup. Ensure the subgroup variable is consistent across studies.
• Sequential Pooling: Perform a meta-analysis of the subgroup effect (i.e., the interaction). Start with the first published study. Then, iteratively add data from the next study in chronological order, repeating the meta-analysis each time [96].
• Analysis & Stopping Point: Plot the cumulative pooled estimate of the subgroup effect (e.g., ratio of odds ratios) and its 95% confidence interval over time. The point where the confidence interval first excludes the null value (e.g., 1 for a ratio of ratios) and remains excluded in subsequent updates is the estimated detection point [96].
• Interpretation: Compare this detection point to when the effect was actually reported in the literature. As demonstrated in a case study, this method can detect a subgroup effect 15 years earlier, using 71% fewer subjects, than a traditional individual patient data (IPD) meta-analysis [96]. This highlights the value of prospectively planning and reporting subgroup data.

Visualizing Workflows and Methodologies

Systematic Review Workflow with Subgroup Analysis Integration

Subgroup Analysis Credibility Assessment Algorithm

Table 4: Key Resources for Conducting Systematic Reviews with Subgroup Analysis in Toxicology

Resource Category	Specific Item/Software	Function & Application in Subgroup Analysis
Protocol & Reporting Guidelines	PRISMA-P & PRISMA 2020 [98]	Standards for drafting a review protocol and reporting the final review. Essential for pre-specifying subgroup hypotheses and analysis plans.
Systematic Review Handbook	Cochrane Handbook [1] [98]; OHAT Handbook [98]	Foundational methodological guidance. The OHAT handbook is specifically tailored for environmental health/toxicology evidence integration.
Statistical Software	R (metafor, meta packages), STATA [95] [96]	Conducting meta-analysis, formal interaction tests for subgroups, and cumulative meta-analysis.
Risk of Bias Tools	OHAT Risk of Bias Tool, SYRCLE's RoB tool	Assessing internal validity of individual animal studies. Bias at the study level can distort subgroup findings.
Data Extraction & Management	Covidence, Rayyan, DistillerSR	Managing the screening and data extraction process, including coding for subgroup variables.
Equity & Relevance Framework	PROGRESS-Plus [97]	A checklist for considering socially stratifying factors (Place, Race, Occupation, etc.) that may define susceptible subgroups in human evidence.

Conducting a systematic review (SR) in toxicology represents a formidable undertaking characterized by significant temporal demands, complex resource allocation, and intricate teamwork challenges. Unlike narrative reviews, which may be completed in months, SRs typically require over a year and demand specialized expertise in science, review methodology, literature search, and data analysis [1]. This whitepaper delineates the core scale-related pitfalls within the SR framework, including managing multiple evidence streams, integrating omics and computational data, and coordinating multidisciplinary teams. We provide detailed experimental protocols for key phases, quantitative comparisons of resource needs, and evidence-based strategies for implementing effective team temporal leadership and resource management to enhance rigor, transparency, and reproducibility in evidence-based toxicology.

Systematic reviews are the cornerstone of evidence-based toxicology (EBT), offering a transparent, methodologically rigorous alternative to traditional narrative reviews [1]. The adaptation of this methodology from clinical medicine to toxicological questions introduces unique and scaling challenges. Toxicology SRs must integrate diverse evidence streams—from human observational studies and animal bioassays to in vitro mechanistic data and in silico models—to answer questions about hazard identification, dose-response, and risk [1] [99]. This integration occurs across multiple biological scales, from molecular pathway perturbations to population-level health outcomes.

The process is inherently resource-intensive. A comparative analysis highlights that while narrative reviews might be completed within months, SRs generally extend beyond one year and require a broader, more specialized team [1]. The core challenge, or "pitfall," lies in underestimating the logistical, temporal, and human resource demands of this comprehensive process. Failure to proactively manage these dimensions risks project failure, team burnout, and reviews that are neither reproducible nor conclusive, ultimately undermining the goal of informing sound regulatory and public health decisions [1] [100].

Temporal Demands and Project Management

The SR timeline is protracted due to its iterative and exhaustive nature. Key phases—protocol development, literature search, multi-stage screening, data extraction, risk-of-bias assessment, and evidence synthesis—each consume substantial time [1] [27]. Unrealistic deadlines, often set without accounting for protocol refinement, iterative screening, or unanticipated complexities like managing thousands of citations, lead to rushed work, stress, and compromised scientific quality [101] [102].

Table 1: Comparative Timeline and Resource Profile of Review Types in Toxicology

Feature	Narrative Review	Systematic Review
Typical Timeframe	Months	>1 Year [1]
Primary Expertise Required	Subject matter science	Science, SR methodology, literature search, data analysis/statistics [1]
Cost Level	Low	Moderate to High [1]
Key Scalability Limitation	Author capacity and bias	Coordinated team effort, software, and process management

Resource Allocation and Visibility

Resource management extends beyond budgetary constraints to encompass human capital, software tools, and data. A prevalent problem is lack of resource visibility, where project leads cannot accurately see team members' skills, ongoing workloads, and availability [101] [102]. This leads to inefficient allocation: overloading experts, creating bottlenecks, or underutilizing talent. In client-facing or multi-project research environments, this results in "resource chaos," with simultaneous burnout and idle time within the same team [100]. Furthermore, inadequate forecasting of needs for specialized skills (e.g., biostatisticians, information specialists) or software (e.g., for meta-analysis or machine learning-based screening) can halt progress [102].

Teamwork and Multidisciplinary Coordination

Toxicology SRs require a team with diverse expertise: subject matter experts, methodologists, librarians, data analysts, and project managers [27]. Scaling this team effectively is critical. Common mistakes include hiring or assembling teams too quickly without clear role definition, leading to poor skill fit and cohesion [103]. Inadequate onboarding of new team members into the SR's rigid protocols causes inconsistencies in screening or data extraction [103]. Perhaps most critically, poor communication and collaboration in growing teams lead to misalignment, duplicated efforts, and errors [103]. The absence of a shared leadership model that explicitly manages time (team temporal leadership) exacerbates these issues under pressure, reducing innovation and performance [104].

Experimental Protocols for Managing Scale

This section outlines detailed methodologies for two resource-intensive phases of a toxicology SR.

Protocol: Development and Registration

A pre-registered, detailed protocol is non-negotiable for managing scale as it prevents mission creep and aligns the team.

• Formulate the Review Question: Define a precise PECO/PICO question (Population, Exposure/Intervention, Comparator, Outcome) [27].
• Develop Analytic Framework: Create a visual framework linking exposures, key events in adverse outcome pathways (AOPs), and health outcomes to guide evidence integration [27] [99].
• Establish Team Structure & Roles: Document the core team, advisory group, and conflict-of-interest statements. Define decision-making hierarchies for inclusion/exclusion conflicts [27].
• Design Comprehensive Search Strategy: Collaborate with an information specialist. Search multiple databases (e.g., PubMed, Embase, TOXLINE, Web of Science). Use controlled vocabulary and free-text terms. Document the full strategy for reproducibility [1] [27].
• Define Screening & Data Extraction Forms: Pilot-test inclusion/exclusion criteria on a sample of articles. Develop and standardize electronic data extraction templates in tools like DistillerSR or Rayyan to ensure consistency across reviewers [27].
• Specify Risk-of-Bias & Evidence Assessment Methods: Select and adapt tools (e.g., OHAT, Cochrane RoB) for toxicological study designs (e.g., animal, in vitro). Define criteria for assessing confidence in the body of evidence (e.g., GRADE, WOE) [1] [27].
• Publish Protocol: Register on PROSPERO or similar platform and publish in a journal to ensure transparency [1].

Protocol: Data Integration for Quantitative Systems Toxicology (QST)

Integrating diverse data streams for computational modeling is a major scaling challenge [105].

• Define the System and Toxicity Pathway: Identify the molecular initiating event and key relationships in the relevant AOP [99] [105].
• Assemble and Curate Heterogeneous Data: Systematically gather data from the SR output: in vitro concentration-response, in vivo toxicity endpoints, toxicokinetic (TK) parameters, and human exposure estimates. Curate for consistency in units and formats [105].
• Develop Computational Architecture:
  • Pharmacokinetic (PK) Component: Build a physiological-based PK (PBPK) model to translate external exposure to target site concentration.
  • Pharmacodynamic/Toxicodynamic (PD/TD) Component: Use a network-based or quantitative systems model to link target site concentration to pathway perturbation and cellular/organ response [105].
• Calibrate and Validate the Model: Calibrate model parameters using a subset of the curated data. Validate predictions against an independent set of in vivo or epidemiological data not used in calibration [105].
• Perform Sensitivity and Uncertainty Analysis: Identify key model parameters driving uncertainty in predictions. Quantify overall uncertainty in the predicted points of departure (e.g., benchmark doses) [105].
• Contextualize for Risk Assessment: Use the validated QST model to simulate human-relevant exposure scenarios, propose safe exposure levels, and identify critical data gaps [105].

Visualization of Systematic Review Workflow and Data Integration

The following diagrams map the complex workflows and relationships involved in managing a large-scale SR.

Diagram 1: Systematic Review Workflow with Management Levers (99 characters)

Diagram 2: Data Integration for Predictive Toxicology Modeling (71 characters)

The Scientist's Toolkit: Essential Research Reagent Solutions

Effectively scaling an SR requires leveraging specific tools and materials to standardize work and manage complexity.

Table 2: Key Research Reagent Solutions for Scaling Toxicology Systematic Reviews

Tool/Reagent Category	Specific Examples	Primary Function in Managing Scale
Protocol & Project Management	PRISMA-P Checklist, PROSPERO Registry, Gantt Charts, Teamwork.com, Rocketlane [1] [100] [102]	Ensures transparency, pre-defines methods, manages timelines, and provides visibility into team workload and project portfolios.
Literature Management	DistillerSR, Rayyan, Covidence, EndNote	Enables blinding, de-duplication, and collaborative multi-reviewer screening of thousands of citations with audit trails.
Risk-of-Bias Assessment	OHAT Tool, SYRCLE's RoB tool, Cochrane RoB, QUADAS-2 [1] [27]	Provides standardized, structured criteria to consistently assess study quality across a large body of evidence.
Data Extraction & Curation	Custom electronic data extraction forms, OECD eChemPortal, EPA CompTox Chemicals Dashboard	Standardizes data collection into structured formats (e.g., for meta-analysis or QST modeling) and aids chemical identifier curation.
Quantitative Synthesis & Modeling	R (metafor, meta), Python, MATLAB, SimBiology, NONMEM, PBPK/PD platforms [105] [106]	Enables statistical meta-analysis and the development of integrative computational models (QST) for prediction and uncertainty quantification.
Team Communication & Docs	Slack, Microsoft Teams, Wiki platforms (e.g., Confluence), GitHub	Facilitates real-time communication, document version control, and centralizes standard operating procedures (SOPs) for a dispersed team.

Quantitative Analysis of Scale Management Challenges

The data from operational research highlights the concrete costs of poor scale management.

Table 3: Quantified Impact of Resource and Teamwork Challenges

Challenge Area	Quantitative Metric / Finding	Source / Context
Project Failure & Burnout	41% of service leaders cite bad planning as the main reason projects fail. 80% of managers blame resource constraints for burnout and turnover.	Analysis of client-service organizations [100].
Technology Blockade	Outdated tools (e.g., spreadsheets) are the biggest operational blocker for nearly 4 in 10 agencies.	Teamwork.com State of Agency Operations Report (2024) [100].
Efficiency Gain from Tools	Using a dedicated platform (Teamwork.com) for one year improved billable utilization by 22% for client-service organizations.	Case study on resource management ROI [100].
Time Pressure & Leadership	Team Temporal Leadership (TTL) has a significant positive impact on Team Innovation Performance (TIP). Time Pressure positively moderates the TTL-Team Learning Behavior relationship.	Survey of 163 R&D teams [104].
Data Complexity in Modeling	In clinical toxicology PK/PD modeling, dose and timing are "uncertain" or "unknown" variables, treated as random variables within bounds.	Analysis of overdose and envenomation studies [106].

Integrated Strategies for Mitigation

To navigate Pitfall 5, an integrated strategy addressing all three dimensions is essential.

• Implement Proactive Temporal Leadership: Designate a leader responsible for scheduling (clear milestones), synchronization (aligning team rhythms), and allocating time buffers for unforeseen tasks [104]. This leadership is most critical under high time pressure [104].
• Adopt a Centralized Resource Management Platform: Move beyond spreadsheets to software that provides a single source of truth for team skills, availability, and real-time workload [101] [100] [102]. Use it for forecasting and to avoid over-promising.
• Build the Team with Intentionality:
  • Define Roles First: Clearly outline required expertise before recruiting [103].
  • Invest in Structured Onboarding: Use mentors and detailed SOPs to integrate new members [103].
  • Foster Psychological Safety: Encourage open feedback and learning behavior to improve innovation performance [103] [104].
• Automate and Standardize Processes: Use SR software for screening and data extraction. Automate repetitive tasks like citation downloading and report formatting. Document all workflows [103] [27].
• Plan for Data Complexity from the Start: For reviews aiming at quantitative integration, engage modeling experts early. Design data extraction forms compatible with QST/PBPK model inputs and plan for rigorous data curation [105] [106].

The scale of a modern toxicology systematic review—encompassing its temporal span, multidisciplinary resource needs, and teamwork complexity—is its defining challenge. As the field moves towards integrating high-throughput in vitro data, omics, and computational models, these demands will only intensify [99] [105]. Success is not merely a function of scientific expertise but of deliberate project management, strategic resource allocation, and adaptive team leadership. By recognizing "Managing the Scale" as a critical, addressable pitfall and implementing the integrated strategies outlined here, research teams can enhance the efficiency, reliability, and impact of their systematic reviews, strengthening the foundation of evidence-based toxicology and risk assessment.

Ensuring Rigor and Looking Ahead: Validation, Comparison, and Future Directions

The conduct of systematic reviews (SRs) represents a cornerstone of evidence-based toxicology (EBT), a discipline dedicated to applying transparent, objective, and methodologically rigorous principles to the synthesis of toxicological evidence [1]. This movement addresses significant limitations inherent in traditional narrative reviews, which often lack explicit methodologies, risk selective citation, and yield conclusions that are difficult to reproduce [1]. For researchers, scientists, and drug development professionals, navigating the landscape of authoritative SR frameworks is essential for producing high-quality syntheses that can reliably inform chemical risk assessment, drug safety evaluation, and regulatory decision-making.

This whitepaper provides an in-depth technical guide to three preeminent frameworks for evidence synthesis: the Office of Health Assessment and Translation (OHAT)/National Toxicology Program (NTP) approach, the European Food Safety Authority (EFSA) risk assessment paradigm, and the Cochrane methodology for systematic reviews. Framed within the broader context of conducting a systematic review in toxicology, this document benchmarks these frameworks against one another, detailing their core methodologies, experimental and analytical protocols, and their specific applications to toxicological questions.

The OHAT, EFSA, and Cochrane frameworks, while sharing a foundation in rigorous evidence synthesis, were developed for distinct primary contexts: environmental health toxicology, food and feed safety, and clinical healthcare interventions, respectively. This origin shapes their methodological emphasis and terminology.

NTP/OHAT Approach: The OHAT handbook provides standard operating procedures for conducting evidence evaluations to identify the state of the science or reach hazard conclusions [12]. It is a living document, updated to improve reliability and efficiency, with recent clarifications on reaching hazard conclusions from human data alone and developing confidence ratings across multiple outcomes [12]. Its process is tailored for evaluating environmental exposures and their potential health hazards.

EFSA Risk Assessment Framework: EFSA defines risk assessment as a specialized field involving the review of scientific data to evaluate risks, structured around four core steps: hazard identification, hazard characterization, exposure assessment, and risk characterization [107]. EFSA's guidance, particularly in areas like risk-benefit assessment of foods, emphasizes a stepwise approach, dose-response modelling, and the integration of variability and uncertainty [108]. Its work extends to environmental risk assessment for regulated products like pesticides, GMOs, and feed additives [109].

Cochrane Methodology: Cochrane is a global leader in SR methodology for healthcare. Its cornerstone is the Cochrane Handbook for Systematic Reviews of Interventions, which provides exhaustive guidance on review conduct [110]. Cochrane actively evolves its methods, with recent initiatives including new random-effects meta-analysis methods in RevMan, leadership in the responsible use of artificial intelligence (AI) in evidence synthesis, and a strong focus on integrating equity considerations and patient involvement into all new reviews [111].

Table: Core Characteristics of Authoritative Systematic Review Frameworks

Framework (Primary Context)	Defining Methodology	Core Output	Key Toxicological Application
NTP/OHAT (Environmental Health)	Adapted systematic review for hazard identification & assessment. Transparent, protocol-driven, uses structured evidence integration.	Hazard identification conclusion, level of evidence rating (e.g., "known to be a hazard").	Evaluation of human & animal evidence on environmental chemicals, pharmaceuticals, etc. [12].
EFSA (Food & Feed Safety)	Formal chemical risk assessment process: Hazard ID, Hazard Char., Exposure Assessment, Risk Char. [107].	Risk characterization (e.g., margin of exposure, health-based guidance values).	Safety of food additives, pesticide residues, contaminants, GMOs, feed additives [108] [109].
Cochrane (Clinical Healthcare)	Gold-standard systematic review/meta-analysis of interventions. PRISMA/GRADE integration. Focus on bias minimization.	Systematic review with quantitative synthesis (where possible), 'Summary of Findings' table.	Efficacy & safety of clinical interventions for poisoning/toxic exposure; evidence on adverse drug effects [1].

Practical Implementation: Workflows and Experimental Protocols

Conducting a review under each framework follows a structured sequence. The following diagrams and protocols outline the key stages.

3.1 The OHAT/NTP Systematic Review Workflow The OHAT approach breaks down the SR process into discrete, sequential steps to ensure transparency and reproducibility [1].

Key Protocol: Hazard Conclusion Integration (OHAT Step 9) This critical phase integrates human and animal evidence streams to answer the review question.

• Objective: To transparently integrate findings from synthesized evidence and confidence ratings into a final hazard conclusion.
• Procedure:
  • Display Evidence: Create a structured summary (e.g., table) presenting the direction of effect, confidence rating (e.g., high, moderate, low, very low), and key study limitations for each outcome and evidence stream (human, animal).
  • Apply Pre-defined Logic Framework: Use a decision matrix (often provided in OHAT guidance) to combine confidence ratings across streams. For example, "high" confidence in human evidence may be sufficient for a "known hazard" conclusion, whereas "low" confidence in animal evidence may only support a "suspected hazard" conclusion [12].
  • Consider Mechanistic Data: Evaluate supporting in vitro or mechanistic data to assess biological plausibility, but typically as supplemental rather than primary evidence.
  • Document Rationale: Explicitly document the reasoning for the final conclusion, noting any areas of inconsistency or uncertainty.
• Outcome: A definitive hazard conclusion statement (e.g., "known to be a hazard," "not classifiable," "not identified to be a hazard") supported by a clear audit trail [12].

3.2 The EFSA Risk Assessment Paradigm EFSA's process is defined by four formal steps, which can be applied within a systematic review context.

Key Protocol: Dose-Response Analysis & Benchmark Dose (BMD) Modeling (EFSA Step 2) Hazard characterization often involves quantifying the relationship between exposure and toxic effect.

• Objective: To determine a point of departure (POD), such as a BMD, for establishing a health-based guidance value (e.g., Acceptable Daily Intake - ADI).
• Procedure:
  • Select Critical Data: From the synthesized evidence, identify the most relevant, reliable dose-response datasets for critical effects (often from animal studies).
  • Model Fitting: Fit a range of mathematical dose-response models (e.g., exponential, polynomial) to the data using specialized software (e.g., EPA’s BMDS, PROAST).
  • Calculate BMD/BMDL: For a given benchmark response (BMR, e.g., 10% extra risk), calculate the BMD (the dose associated with the BMR) and its lower confidence limit, the BMDL, which is typically used as the POD.
  • Model Averaging: When multiple models fit adequately, apply model averaging to derive a more robust BMDL that accounts for model uncertainty.
  • Apply Assessment Factors: The POD (BMDL) is divided by composite assessment factors (for interspecies differences, human variability, database deficiencies, etc.) to derive a health-based guidance value like an ADI or Tolerable Daily Intake (TDI) [108].
• Outcome: A quantitative safe exposure level for humans, central to EFSA’s risk characterization.

3.3 The Cochrane Systematic Review Process Cochrane's detailed workflow is the international benchmark for intervention reviews, adaptable to toxicological questions, particularly on therapeutic interventions for toxicity or drug safety.

Key Protocol: Meta-Analysis Using RevMan with Random-Effects Models Cochrane's software, RevMan, is central to conducting meta-analysis.

• Objective: To statistically synthesize quantitative data from multiple studies to produce an overall estimate of effect.
• Procedure:
  • Data Preparation: Enter extracted outcome data (e.g., means and standard deviations for continuous data, event counts for dichotomous data) for each study and comparison group into RevMan.
  • Model Selection: Choose a random-effects model, which assumes the true effect varies between studies, as it is often more appropriate for toxicological data than a fixed-effect model. Cochrane has implemented updated random-effects methods, including new heterogeneity estimators and prediction intervals [111].
  • Effect Measure Selection: For dichotomous data (e.g., presence/absence of a lesion), use Risk Ratio (RR) or Odds Ratio (OR). For continuous data (e.g., enzyme activity level), use Mean Difference (MD) or Standardized Mean Difference (SMD).
  • Execute Analysis: RevMan calculates the pooled effect estimate, 95% confidence interval (CI), and provides forest plot visualization.
  • Assess Heterogeneity: Interpret the I² statistic (percentage of total variability due to between-study heterogeneity) and the prediction interval, which estimates the range in which the effect of a new study would fall.
• Outcome: A quantitative summary effect measure with a measure of its precision and an assessment of between-study consistency, forming the core of the results section in a Cochrane review.

Quantitative Benchmarking and Data Integration

The performance and application of these frameworks can be compared across measurable dimensions. Furthermore, modern toxicology leverages large-scale databases and computational tools that interface with these review processes.

Table: Quantitative Benchmarking of Framework Attributes and Outputs

Metric / Dimension	NTP/OHAT	EFSA	Cochrane
Typical Review Timeline	>1 year (often 1.5-2 years for complex assessments) [1].	Often multi-year for comprehensive chemical assessments.	>1 year (for full review) [1]; Rapid review formats emerging [111].
Primary Synthesis Method	Qualitative evidence integration with optional quantitative support.	Quantitative dose-response analysis (BMD modeling); probabilistic exposure assessment.	Quantitative meta-analysis as standard where possible [111].
Confidence/Certainty Rating Tool	OHAT-based rating (considering risk of bias, consistency, directness, etc.).	Integrated assessment of uncertainty within each step.	GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) [1].
Key Software Tools	DistillerSR, HAWC (Health Assessment Workspace Collaborative).	BMD software (e.g., BMDS, PROAST), Monte Carlo simulation for exposure.	RevMan (for analysis), Rayyan (for screening), Covidence.
Benchmark Computational Tool Performance	Integrated use of tools like OPERA (QSAR models for physicochemical properties) [112].	Reliance on predictive tools for TK properties (e.g., GastroPlus, Simcyp) validated against data from sources like TOXRIC [113] [112].	Less emphasis on computational toxicology; focus on statistical analysis tools.

Integration of Computational Toxicology (In Silico) Benchmarks: Systematic reviews increasingly inform and are informed by New Approach Methodologies (NAMs). For instance, a 2024 benchmarking study evaluated 12 software tools for predicting physicochemical and toxicokinetic properties, crucial for EFSA's hazard characterization and exposure assessment. The study reported average R² values of 0.717 for physicochemical properties and 0.639 for toxicokinetic regression models, identifying robust tools for integration into risk assessment workflows [112]. Databases like TOXRIC, which contains over 113,000 compounds and 1,474 toxicity endpoints, provide the large-scale, curated data needed to train and validate such computational models, thereby enriching the evidence base for systematic reviews [113].

The Scientist's Toolkit: Essential Research Reagent Solutions

Conducting a high-quality systematic review in toxicology requires leveraging specialized tools and databases.

Table: Key Research Reagent Solutions for Systematic Reviews in Toxicology

Tool / Resource Name	Type	Primary Function in Review Process	Relevant Framework
DistillerSR	Web-based Software	Literature screening and data extraction management with AI-assisted prioritization.	All (OHAT, EFSA, Cochrane)
HAWC (Health Assessment Workspace Collaborative)	Open-source Web Platform	Modular tool for developing assessment components: literature inventory, data extraction, visualizations (e.g., evidence maps).	OHAT, EFSA
RevMan (Review Manager)	Desktop Software	Protocol development, risk-of-bias assessment, meta-analysis, and 'Summary of Findings' table generation.	Cochrane
Rayyan	Web-based Tool	Blinded collaborative screening of abstracts and titles using AI to highlight potential exclusions.	All
TOXRIC Database [113]	Public Database	Repository of toxicological data (compounds, endpoints, features) for retrieving ML-ready datasets, benchmarking, and understanding molecular representations.	OHAT, EFSA (for data sourcing)
OPERA QSAR Suite [112]	Open-source Software	Predicts physicochemical properties and toxicity endpoints; provides applicability domain assessment for reliable predictions.	OHAT, EFSA (for filling data gaps)
BMDS (Benchmark Dose Software)	Desktop Software	Fits statistical models to dose-response data to calculate BMD and BMDL values.	EFSA
GRADEpro GDT	Web-based Tool	Develops transparent 'Summary of Findings' and 'Evidence Profile' tables to present quality of evidence and findings.	Cochrane (increasingly OHAT)

The choice of framework for a systematic review in toxicology is dictated by the review's primary objective. The OHAT/NTP approach is the specialist tool for hazard identification and assessment, offering a transparent path from evidence to a public health-oriented hazard conclusion. The EFSA framework is the comprehensive engine for full chemical risk assessment, essential when quantitative safety thresholds (like ADIs) and exposure scenarios are required for regulation. The Cochrane methodology remains the gold standard for questions of clinical intervention efficacy and safety, including treatments for toxic exposures or adverse drug reaction profiles.

The future of evidence synthesis in toxicology lies in the strategic integration of these frameworks and the tools they employ. A review might use a Cochrane-grade search and screening protocol, apply OHAT principles for risk of bias assessment and evidence integration, and utilize EFSA-endorsed BMD modeling for dose-response analysis. This is further augmented by leveraging curated databases like TOXRIC and validated computational tools identified through benchmarking studies [113] [112]. By understanding the strengths and protocols of each authoritative framework, researchers can design maximally robust, credible, and impactful systematic reviews to advance the science of toxicology and protect public health.

In the hierarchy of scientific evidence, systematic reviews and meta-analyses occupy the highest level, serving as the cornerstone for evidence-based decision-making in fields ranging from clinical medicine to toxicology [11]. Their value, however, is entirely contingent upon the clarity, transparency, and completeness of their reporting. Without a full and accurate account of the methods and findings, the reliability and utility of a systematic review are compromised. This is where reporting guidelines fulfill a critical role. They are structured checklists designed to ensure that manuscripts provide the minimum information necessary to be understood, appraised, and replicated [114].

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement is the preeminent reporting guideline for this type of research [115]. It is crucial to distinguish between a methodological handbook, which provides guidance on how to conduct a review, and a reporting guideline like PRISMA, which provides a framework for how to report what was done [114]. PRISMA 2020 is the current iteration, offering an updated 27-item checklist and a flow diagram to guide authors in comprehensively documenting their review process [115]. While its initial focus was on reviews of healthcare interventions, its principles are broadly applicable, providing a foundation for a growing family of specialized extensions tailored to specific review types and fields, including toxicology [116].

The Core PRISMA 2020 Statement: Structure and Key Items

The PRISMA 2020 statement is built around a 27-item checklist organized into seven key sections: Title, Abstract, Introduction, Methods, Results, Discussion, and Other Information [115]. Adherence to this structure ensures that every critical component of the systematic review process is documented for the reader.

Table 1: Core Sections and Selected Key Items from the PRISMA 2020 Checklist

Section	Item #	Reporting Requirement	Rationale and Application
Methods	6	Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility.	Defines the scope of the review. In toxicology, this explicitly states the population (e.g., specific animal model, cell line), exposure (e.g., chemical, dose, duration), comparator, and outcomes (e.g., mortality, tumor incidence, biomarker change) [11].
Methods	8	Search strategy: Present the full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Ensures reproducibility. A complete strategy includes databases searched (e.g., PubMed, Embase, TOXLINE), date of search, and the full syntax of search terms and Boolean operators [11].
Methods	12	Risk of bias assessment: Describe methods used for assessing risk of bias of individual studies.	Critical for interpreting the strength of evidence. Toxicological reviews may adapt tools like the SYRCLE's risk of bias tool for animal studies or assess reporting completeness against guidelines like ARRIVE.
Results	17	Study selection: Use a flow diagram to present numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions.	The PRISMA flow diagram provides a transparent, visual summary of the screening process, documenting the attrition of records at each stage [115].
Results	21	Results of syntheses: For all syntheses, present summary estimates, confidence/credible intervals, and measures of statistical heterogeneity.	For meta-analyses, this includes forest plots with pooled effect estimates. For narrative syntheses, a structured summary of findings is required.
Discussion	23	Certainty of evidence: Provide an overall assessment of certainty (or confidence) in the body of evidence.	Often performed using frameworks like GRADE, which can be adapted for pre-clinical and toxicological evidence to grade confidence in predictions of human health risk.

A foundational step covered by the PRISMA methods section is formulating the research question, often using a structured framework. The PICO framework (Population, Intervention, Comparator, Outcome) is the most common, though for toxicology, "Intervention" is frequently replaced by "Exposure" [11]. A well-defined PICO/E question directly informs the eligibility criteria (Item 6) and the search strategy (Item 8).

PRISMA 2020 Flow Diagram Process

PRISMA Extensions for Specialized Review Types

The standard PRISMA checklist provides an excellent foundation, but certain specialized forms of evidence synthesis require additional reporting standards. To address this, the PRISMA framework has been extended through a formal consensus process to create domain-specific guidelines [116] [117].

Table 2: Selected PRISMA Extensions Relevant to Toxicology and Environmental Health Research

Extension Name	Primary Purpose	Key Additional/Modified Reporting Items	Relevance to Toxicology
PRISMA-NMA (Network Meta-Analysis) [117] [118]	Reporting systematic reviews incorporating network meta-analysis to compare multiple interventions/exposures simultaneously.	Geometry of the network (S1): Describe methods to explore the treatment network. Assessment of inconsistency (S2): Describe methods to evaluate agreement between direct and indirect evidence. Presentation of network structure (S3): Provide a network graph.	Vital for comparing the relative toxicity or therapeutic efficacy of multiple chemicals or drugs. A 2025 scoping review is actively working to update this guideline [119].
PRISMA-ScR (Scoping Reviews) [117]	Reporting scoping reviews that aim to map key concepts and evidence gaps in a field.	Indicate the review question and key elements (e.g., PCC: Population, Concept, Context). Explain the choice of evidence source selection. Present the characteristics of the evidence sources.	Useful for broad landscape assessments in toxicology, e.g., mapping all studies on a class of emerging contaminants before a focused systematic review.
PRISMA-P (Protocols) [117]	Reporting protocols for systematic reviews and meta-analyses.	Provides a checklist for pre-defining the review's objectives and methods, promoting transparency and reducing bias from post-hoc changes.	Essential first step. Registering a protocol (e.g., in PROSPERO) is considered best practice and is required by many journals [120].
Extension for Preclinical Animal Studies [116]	Reporting systematic reviews of preclinical, in vivo animal experiments. (Under development)	Expected to address items specific to animal research, such as detailed reporting of animal models, husbandry, experimental procedures, and translational considerations.	Directly applicable to the core of toxicological hazard identification. Aims to improve the reliability and translational value of preclinical evidence synthesis.
PRISMA-COSMIN for OMIs [117]	Reporting systematic reviews of outcome measurement instruments.	Focuses on the systematic assessment of an instrument's measurement properties (e.g., reliability, validity).	Critical for reviews synthesizing evidence on biomarkers of exposure, effect, or susceptibility in toxicology.

The development of these extensions follows a rigorous methodology. As illustrated by the ongoing update for PRISMA-NMA, the process typically involves a scoping review of the literature to identify reporting gaps, followed by a Delphi survey with international experts to reach consensus on new items, culminating in a guideline publication and dissemination effort [119].

Development Process for a PRISMA Extension

Experimental Protocols: Methodological Case Studies

The following protocols illustrate the application of PRISMA principles in active research settings, highlighting detailed methodologies.

Case Study 1: Evaluating AI Tools Against the PRISMA Method A 2025 study designed a content analysis to evaluate the performance of AI tools in replicating key stages of a PRISMA-based systematic review [121].

• Objective: To compare AI platforms against the PRISMA benchmark for literature search, data extraction, and study composition in glaucoma systematic reviews.
• Intervention/Test Methods: Four AI platforms were tested: Connected Papers and Elicit for literature search; Elicit and ChatPDF for data extraction; Jenni AI for manuscript composition.
• Reference Standard: Four published, peer-reviewed glaucoma systematic reviews conducted using the full PRISMA method served as the reference benchmark.
• Experimental Procedure:
  • Literature Search Simulation: The exact keywords from each reference review were input into Connected Papers and Elicit. The resulting lists of papers were compared to the studies included in the original PRISMA reviews.
  • Data Extraction Test: PDFs of the studies included in the reference reviews were uploaded to Elicit and ChatPDF. The AI was instructed to extract specific data (e.g., main findings, outcomes, study design). Extracted data were compared line-by-line against manual extraction from the original reviews.
  • Composition Test: Instructions were given to Jenni AI to write sections of a review based on provided PDFs. Output was evaluated for methodological completeness, result elaboration, and conclusion strength.
• Outcome Measures: For searches, the percentage of included studies successfully retrieved. For data extraction, accuracy was categorized as "accurate," "imprecise," "missing," or "incorrect." For composition, qualitative assessment of content sufficiency.
• Key Result: The PRISMA method demonstrated clear superiority. AI tools failed to retrieve all relevant studies, and data extraction accuracy ranged from 51.4% to 60.3%, with significant rates of missing or incorrect information [121].

Case Study 2: Updating the PRISMA-NMA Guideline A 2025 protocol outlines the methods for updating the PRISMA extension for Network Meta-Analysis [119].

• Objective: To conduct a scoping review informing the update of the PRISMA-NMA reporting guideline to address evolving methodology and reporting gaps.
• Search Strategy: Comprehensive searches of multiple databases (e.g., MEDLINE, EMBASE) and grey literature for two document types: 1) Methodological guidance documents on NMA, and 2) Overviews of reviews evaluating NMA reporting quality.
• Study Selection: Independent screening by two reviewers against pre-defined eligibility criteria focused on documents published after the original 2015 PRISMA-NMA.
• Data Extraction: A standardized form was used to extract data on proposed or identified reporting items, methodological challenges, and recommendations.
• Synthesis: Extracted items were collated, categorized, and used to generate a comprehensive list of candidate reporting items. This list directly feeds the next stage of the guideline development process: a Delphi consensus exercise [119].
• Outcome: The review identified 37 new candidate items for consideration in the updated PRISMA-NMA checklist, highlighting areas like the assessment of transitivity (comparability of studies in a network) and statistical model selection [119].

The Scientist's Toolkit: Essential Materials for PRISMA-Compliant Reviews

Conducting and reporting a systematic review requires a suite of conceptual and software tools. The following table details key components of this toolkit.

Table 3: Research Reagent Solutions for Systematic Reviews

Tool Category	Specific Tool/Resource	Function	Relevance to PRISMA Reporting
Question Formulation	PICO/PECO Framework [11]	Structures the research question into Population, (Exposure)/Intervention, Comparator, Outcome.	Directly informs Item 4 (Objectives) and Item 6 (Eligibility criteria) of the PRISMA checklist.
Protocol Registration	PROSPERO Registry	Public, prospective registration platform for systematic review protocols.	Fulfills Item 5 (Protocol and registration), enhancing transparency and reducing duplication of effort.
Search Management	Bibliographic Databases (PubMed, Embase, etc.) [11]	Host peer-reviewed literature. A comprehensive search across multiple databases is mandatory.	Required for Item 7 (Information sources) and Item 8 (Search strategy).
Study Screening	Covidence, Rayyan [11]	Web-based tools for managing title/abstract and full-text screening by multiple reviewers, including conflict resolution.	Supports the process reported in Item 9 (Study selection) and generates data for the PRISMA flow diagram (Item 17).
Risk of Bias Assessment	Cochrane RoB 2, SYRCLE's RoB Tool, Newcastle-Ottawa Scale	Standardized tools to evaluate the methodological quality (risk of bias) of included studies.	The tool used and its results must be described per Item 12 (Risk of bias assessment) and presented per Item 19.
Data Synthesis	R (metafor package), RevMan, Stata	Statistical software for performing meta-analysis, generating forest plots, and assessing heterogeneity.	Essential for executing and reporting Item 21 (Results of syntheses).
Certainty of Evidence	GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) Framework	A systematic approach to rate the overall confidence in an estimate of effect across studies.	Increasingly required by journals and used to satisfy Item 23 (Certainty of evidence) in the discussion.
Reporting Guideline	PRISMA 2020 Checklist & Flow Diagram [115]	The core checklist and template for documenting the review process.	The foundational tool for ensuring the manuscript itself is complete and transparent.

PRISMA in Practice: Application to Toxicology Research

Conducting a systematic review in toxicology within the PRISMA framework involves addressing field-specific challenges at each stage.

• Protocol & Question (PICO/E): The protocol must pre-specify the exposure of interest with precise chemical identifiers (e.g., CAS number), relevant toxicological outcomes (e.g., carcinogenicity, neurotoxicity, endocrine disruption), and appropriate model systems (in vivo, in vitro, in silico) [11]. A protocol for a review on "The association between glyphosate exposure and non-Hodgkin lymphoma in human epidemiological studies" would clearly define these elements.
• Search & Selection: Searches must extend beyond biomedical databases to include toxicology-specific resources like TOXLINE. Eligibility criteria must account for different study designs (cohort, case-control, cross-sectional for human data; guideline-compliant vs. exploratory studies for animal data).
• Risk of Bias & Evidence Grading: Standard tools like the Cochrane RoB tool are designed for clinical trials and may not be fully appropriate. Toxicologists must select or adapt tools fit-for-purpose, such as the Office of Health Assessment and Translation (OHAT) tool for human and animal studies or SYRCLE's tool specifically for animal research. Grading the certainty of evidence may require adaptations of GRADE for pre-clinical data.
• Synthesis & Reporting: For human health risk assessment, a dose-response meta-analysis may be the goal. For hazard identification based on animal studies, a review may focus on narrative synthesis and reporting consistency with OECD Test Guidelines. Journals like Environment International now enforce strict PRISMA or ROSES reporting standards for systematic reviews, mandating completed checklists upon submission [120].

The PRISMA framework, through its core principles and specialized extensions, provides the essential architecture for conducting transparent, reproducible, and high-impact systematic reviews in toxicology. Its ongoing evolution, as seen in the development of extensions for preclinical studies and the update of PRISMA-NMA, ensures it remains relevant to the methodological needs of the field [116] [119]. Adherence to PRISMA is not merely a publishing formality but a fundamental practice in rigorous evidence-based toxicological science.

The adoption of systematic review methodology represents a paradigm shift in toxicology, moving the field toward greater objectivity, transparency, and reproducibility [1]. Historically, toxicological assessments have relied heavily on narrative reviews, where an expert summarizes a field without explicit, documented methods for literature search, study selection, or evidence synthesis [1]. This traditional approach carries a significant risk of bias and is difficult to reproduce or validate [1]. In contrast, evidence-based toxicology (EBT) applies formal, systematic, and transparent methods to identify, select, appraise, and synthesize all relevant evidence on a precisely framed question [1]. This rigorous process is essential for informing robust regulatory decisions and health risk assessments, minimizing the potential for error or selective use of data [1].

This guide frames the comparative analysis of review methodologies within the essential process of conducting a systematic review. A systematic review is a core evidence-based tool characterized by a protocol-driven, multi-step process designed to comprehensively locate and synthesize all available evidence while minimizing bias [1]. The following sections will detail this process, compare it with alternative review types, and provide the technical protocols and resources necessary for its execution in toxicological research.

Core Methodologies: A Comparative Framework

Toxicological evidence synthesis can be approached through several distinct review methodologies, each with defined strengths, limitations, and appropriate applications. The choice of methodology is fundamentally driven by the specific research question [122]. The table below provides a comparative analysis of key review types relevant to toxicology.

Table: Comparative Analysis of Toxicological Review Methodologies

Review Type	Primary Objective & Description	Key Strengths	Key Limitations	Typical Time/Resource Commitment
Systematic Review [1] [122]	To systematically search, appraise, and synthesize research evidence on a specific question using a pre-defined, protocol-driven process.	High methodological rigor, transparency, and reproducibility. Minimizes bias. Provides definitive summary of knowns/unknowns.	Resource-intensive (often >1 year). Requires multidisciplinary expertise. Complex for multiple evidence streams [1].	High (Costly and time-consuming)
Narrative (Traditional) Review [1]	To provide a broad, expert-led summary or commentary on a topic, often without explicit methods.	Flexible and broad in scope. Can provide quick expert insight. Useful for exploring nascent fields.	Lack of transparent methods increases risk of bias. Not comprehensive or reproducible. Qualitative summary only [1].	Variable (Months to years)
Meta-Analysis [122]	A statistical technique to quantitatively combine and analyze results from multiple independent studies (often conducted within a systematic review).	Increases statistical power and precision of effect estimates. Allows exploration of heterogeneity across studies.	Dependent on quality/comparability of included studies (garbage in, garbage out). Cannot compensate for flawed primary studies.	High (Requires statistical expertise)
Scoping Review [122]	To map the key concepts, evidence types, and gaps in a broad or complex field. Identifies the nature and extent of available evidence.	Ideal for clarifying complex or emerging topics. Useful for planning a full systematic review. Faster than a full systematic review.	Does not assess quality of evidence or synthesize results. Outcome is a map of literature, not an answer to a specific risk question.	Moderate
Rapid Review [122]	To provide a timely evidence synthesis using streamlined systematic review methods under time constraints (e.g., for urgent policy decisions).	Accelerates the review process. Balances rigor with practicality for decision deadlines.	Streamlining (e.g., limited search, single reviewer) may increase risk of bias. Transparency about limitations is critical.	Low to Moderate

The Systematic Review Process: A Ten-Step Workflow for Toxicology

Conducting a systematic review in toxicology involves a sequence of deliberate, documented steps. The following diagram illustrates this core workflow, adapted for toxicological evidence [1].

Step 1: Plan and Frame the Question The process begins with formulating a specific, answerable research question. The PICOS framework (Population, Intervention/Exposure, Comparator, Outcome, Study design) is commonly adapted for toxicology (e.g., replacing "Intervention" with "Chemical Exposure") [1]. A detailed, publicly registered protocol is then developed, specifying the methods for all subsequent steps to ensure transparency and reduce bias [1].

Step 2: Conduct a Systematic Search A comprehensive, reproducible literature search is performed across multiple databases (e.g., PubMed, TOXCENTER, Embase) using a pre-defined strategy with explicit search terms and filters [1]. The goal is to identify all potentially relevant published and, where feasible, unpublished evidence to mitigate publication bias.

Step 3: Screen Studies for Eligibility Identified records are screened against pre-defined eligibility criteria (aligned with PICOS) in two phases: title/abstract screening and full-text review [1]. Screening is typically performed by two independent reviewers to minimize error, with conflicts resolved by consensus or a third reviewer.

Step 4: Critically Appraise Included Studies The methodological quality and risk of bias of each included study are assessed using standardized tools (e.g., OHAT Risk of Bias Tool, SYRCLE's tool for animal studies) [1]. This appraisal informs the interpretation of findings and can be used to weight studies in the synthesis or conduct sensitivity analyses.

Step 5: Extract Relevant Data Data pertaining to the research question and study characteristics are extracted from each included study into structured forms or tables. Key data include study design, subject characteristics, exposure parameters, outcome measures, results, and funding sources [1]. Dual extraction with verification is recommended.

Step 6: Synthesize the Evidence Extracted data are synthesized to summarize the body of evidence. This involves narrative synthesis (descriptive summary), often accompanied by tabular presentation (e.g., summary of findings tables) and graphical displays (e.g., forest plots, LSE figures) [122] [123]. For suitable quantitative data, a meta-analysis may be performed to statistically combine results across studies [122].

Step 7: Interpret Findings and Report The synthesized evidence is interpreted, considering the strength, relevance, and biological plausibility of findings. Conclusions are drawn, and implications for risk assessment, regulation, or future research are stated [1]. The final Step 8 involves preparing a complete report following guidelines like PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [1].

Experimental & Analytical Protocols for Included Evidence

The validity of a systematic review depends on the quality of the primary studies it includes. This section outlines standard experimental designs and statistical analysis protocols commonly encountered in toxicological evidence.

4.1 Standardized Data Presentation: The LSE Table To enable consistent comparison across studies, data from in vivo toxicity studies are often summarized in a Levels of Significant Exposure (LSE) table. This format, used by agencies like ATSDR, organizes key data points [123].

Table: Structure and Interpretation of an LSE Table [123]

Column/Element	Description	Purpose in Evidence Synthesis
Route & Exposure Period	Route (oral, inhalation, dermal) and duration (acute, intermediate, chronic).	Allows grouping and comparison of studies by relevant exposure scenario.
Key Number & Species	Unique study ID and test species/strain/group size.	Links data points between tables and figures; identifies model system.
Exposure Parameters	Detailed dosing regimen (dose, frequency, medium).	Enables assessment of dosing relevance and comparison across studies.
Parameters Monitored	Health effect categories examined (e.g., hematology, hepatic).	Identifies the scope of the investigation and potential for missed effects.
Critical Effect Endpoint	Specific adverse effect observed.	Identifies the most sensitive or relevant toxicological outcome.
NOAEL (mg/kg/day)	No Observed Adverse Effect Level – highest dose with no adverse effect.	Key point of departure for risk assessment; used to derive safety thresholds.
LOAEL (mg/kg/day)	Lowest Observed Adverse Effect Level – lowest dose with a measured adverse effect.	Identifies the threshold of toxicity; serious vs. less serious categorizations are critical [123].
CEL (mg/kg/day)	Cancer Effect Level – doses associated with neoplastic effects.	Used specifically for carcinogenicity assessment.
Figure Reference	Links tabular data to a graphical LSE figure plotting dose vs. effect.	Provides visual intuition for dose-response relationships and confidence [123].

4.2 Statistical Analysis Protocols for Toxicity Data Selecting the correct statistical method is crucial, as different methods can lead to different conclusions from the same data [124]. The decision is based on data distribution, study design, and the specific comparisons of interest.

• Parametric vs. Nonparametric Tests: The foundational choice. Parametric tests (e.g., Student's t-test, ANOVA) assume data follow a normal distribution and are generally more powerful when this assumption holds. Nonparametric tests (e.g., Wilcoxon rank-sum, Kruskal-Wallis) do not assume normality and are suitable for skewed data, ordinal data (like pathology severity scores), or small sample sizes [124].
• Correcting for Multiple Comparisons: In standard toxicity study designs with a control and several dose groups, comparing each dose to the control involves multiple simultaneous statistical tests. Performing multiple tests without adjustment inflates the probability of a false positive (Type I error) [124]. Therefore, specialized multiple comparison procedures must be used:
  • Dunnett's Test (Parametric) / Steel's Test (Nonparametric): Used when the primary interest is comparing each treatment group to a single control group, without assuming a dose-response trend [124].
  • Williams' Test (Parametric) / Shirley-Williams Test (Nonparametric): Used specifically when a monotonic dose-response trend (either increasing or decreasing) is expected, offering greater statistical power to detect such trends [124].
  • Tukey's Test (Parametric) / Steel-Dwass Test (Nonparametric): Used for comparing all possible pairs of groups when there is no single control [124].

Advanced and Emerging Methodologies

5.1 Computational Toxicology and High-Throughput Evidence Modern toxicology increasingly integrates data from high-throughput screening (HTS) assays and computational models. Systematic reviews can incorporate this evidence stream, which includes:

• ToxCast/Tox21 Data: Results from HTS assays profiling thousands of chemicals for biological activity [125].
• High-Throughput Toxicokinetics (HTTK): Data and models predicting internal dose from external exposure [125].
• In Silico Predictions: QSAR (Quantitative Structure-Activity Relationship) models and read-across predictions [125].
• Virtual Tissue Models: Computational simulations of biological systems to predict organ-level toxicity [125].

Systematic review frameworks like the OHAT/NTP approach are evolving to integrate these diverse evidence streams, assessing their reliability and relevance alongside traditional in vivo studies.

5.2 The Role of Umbrella and Living Reviews As the number of systematic reviews grows, umbrella reviews (reviews of systematic reviews) become valuable for synthesizing findings across multiple reviews on a broad topic (e.g., the toxicity of a chemical class) [122]. Furthermore, the concept of living systematic reviews—continuously updated as new evidence emerges—is gaining traction to keep high-priority assessments current in a rapidly evolving scientific landscape [1].

Table: Key Research Reagent Solutions and Resources

Resource Category	Specific Tool / Database	Primary Function in Review Process	Key Utility
Protocol & Reporting	PRISMA Guidelines (prisma-statement.org)	Planning & Reporting	Provides checklist and flow diagram for transparent reporting of systematic reviews [1].
Systematic Review Software	Rayyan, Covidence, DistillerSR	Study Screening & Data Extraction	Facilitates blinded duplicate screening, conflict resolution, and data management for review teams.
Toxicology Databases	PubMed, TOXCENTER, Embase	Literature Searching	Core databases for comprehensive identification of toxicological literature.
Chemical/Toxicity Data	EPA CompTox Chemicals Dashboard [125]	Evidence Identification & Data Extraction	Central hub for chemical identifiers, properties, and curated in vivo/HTTox data (ToxValDB, ToxCast) [125].
Animal Toxicity Data	ToxRefDB [125]	Data Extraction & Synthesis	Provides curated in vivo toxicity data from guideline studies for hazard assessment [125].
Ecotoxicology Data	ECOTOX Knowledgebase [125]	Evidence Identification	Source for adverse effects data on aquatic and terrestrial species.
Risk of Bias Assessment	OHAT Risk of Bias Tool, SYRCLE's Tool	Critical Appraisal	Standardized tools for evaluating methodological quality of human and animal studies.
Statistical Analysis	R, SAS, GraphPad Prism	Data Synthesis	Software for performing meta-analysis, complex statistics, and generating forest plots and graphics.
Literature Management	EndNote, Zotero, Mendeley	Reference Management	Essential for storing, deduplicating, and organizing large numbers of citations.
Literature Mining	Abstract Sifter [125]	Screening Acceleration	Excel-based tool to triage and prioritize PubMed search results using keyword highlighting [125].

The field of toxicology research is defined by a constant influx of new data—from novel chemical entities and nanomaterials to evolving epidemiological studies on chronic exposures. Traditional systematic reviews (SRs), while foundational for evidence-based decision-making in chemical risk assessment and drug development, struggle with this velocity. By the time a conventional review is published, its conclusions risk obsolescence [126]. This inherent limitation underscores the critical need for dynamic evidence synthesis methodologies within toxicology.

Living Systematic Reviews (LSRs) represent a transformative solution. An LSR is a systematic review that is continually updated, incorporating new evidence as it becomes available [126] [127]. This model is particularly suited for high-priority, fast-moving areas such as the toxicology of emerging contaminants or the safety profile of new pharmaceutical adjuvants. Concurrently, artificial intelligence (AI) and machine learning (ML) are emerging as powerful aids to overcome the resource-intensive bottlenecks of the review process, from screening thousands of abstracts to extracting complex dose-response data [128]. When integrated, LSRs and ML create a synergistic framework for maintaining a current, rigorous, and actionable evidence base, which is essential for informing real-time public health guidelines and precision toxicology.

The Evolving Landscape of Living Systematic Reviews

The adoption of LSRs has accelerated markedly, driven by the need for timely evidence during the COVID-19 pandemic. A 2025 methodological survey identified 168 individual LSRs across health fields, with 92 newly detected since May 2021 [126] [127]. This growth signals a paradigm shift in evidence synthesis.

Table 1: Characteristics and Uptake of Living Systematic Reviews (as of March 2023) [126] [127]

Characteristic	Finding	Implication for Toxicology
Total LSRs Identified	168 individual LSRs (549 records)	Demonstrates established methodology; a model for toxicology topics with rapid evidence generation.
New LSRs (May 2021-Mar 2023)	92 LSRs	Indicates accelerating adoption beyond the initial pandemic-driven surge.
Update Frequency	Highly variable; COVID-19 LSRs update more frequently.	Toxicology LSRs on fast-moving topics (e.g., vaping toxicity) may require frequent, triggered updates.
Use of GRADE	58.5% of LSRs with results used GRADE.	Highlights the importance of transparent, systematic assessment of the certainty of evidence in toxicological findings.
Centralized Platforms	More common among funded, non-COVID, Cochrane LSRs.	Suggests dedicated resources and platforms are key for sustainable toxicology LSRs to share live findings.

The survey revealed significant methodological diversity, particularly in update triggers and frequencies. While some LSRs update on a schedule (e.g., monthly), others use value-of-information analysis or threshold-based triggers [126]. For toxicology, potential triggers could include the publication of a major animal bioassay, a new epidemiological cohort analysis, or a regulatory agency's release of new data. A key finding was that fewer LSRs than expected leveraged interactive, web-based dissemination platforms, pointing to a major area for future innovation to maximize impact [127].

Core Methodology: Transitioning from Static to Living Reviews in Toxicology

Conducting an LSR in toxicology builds upon the rigorous, protocol-driven steps of a standard systematic review but introduces critical living components [66] [129]. The workflow is a cycle rather than a linear project.

1. Foundational Protocol & Registration: The process begins with a meticulously defined protocol, even more crucial for an LSR. The research question, framed using toxicology-specific frameworks (e.g., PECO: Population, Exposure, Comparator, Outcome), must be both focused and adaptable [129]. The protocol explicitly prescribes the methods for the initial review and the living updates, including search frequency, update triggers, and decision rules for modifying the review question itself. Registration in PROSPERO is mandatory to ensure transparency and prevent duplication [129].

2. Living Search & Screening: Instead of a single search, searches are run repeatedly at intervals defined in the protocol. Machine learning tools become indispensable here. AI-based classifier models, trained on the team's initial screening decisions, can prioritize or exclude records in subsequent update searches, dramatically reducing the screening burden [128]. Tools like Rayyan or ASReview integrate these features, allowing reviewers to focus on the marginal, uncertain citations.

3. Continuous Data Extraction & Risk-of-Bias Assessment: As new studies are included, data extraction and quality assessment (using tools like the OHAT Risk of Bias Tool or SYRCLE's RoB tool for animal studies) must be performed iteratively. Natural Language Processing (NLP) models show promise for automating the extraction of specific data points (e.g., LD₅₀, NOAEL, confidence intervals) from text and tables [128].

4. Dynamic Synthesis & Dissemination: The statistical and narrative synthesis is updated with each cycle. A dedicated, version-controlled web platform is the ideal medium for dissemination, allowing users to view the latest findings, explore interactive evidence maps, and access previous versions [126]. This moves beyond static PDFs to a dynamic evidence resource.

Diagram 1: The Living Systematic Review (LSR) Workflow Cycle

Machine Learning as a Catalytic Aid in the Review Process

ML is not a replacement for expert judgment but a tool to amplify human efficiency and consistency. Its applications map directly onto the most labor-intensive stages of a review.

Priority Screening & Deduplication: Supervised ML models (e.g., logistic regression, support vector machines) can be trained on a sample of manually screened titles and abstracts. The model then scores the remaining and new records, presenting reviewers with those most likely to be relevant first. This saves up to 50% of screening time without compromising sensitivity [128]. Similarly, advanced deduplication algorithms go beyond exact matches to identify near-duplicate records from different databases.

Automated Data Extraction: This is a frontier in ML for toxicology reviews. NLP models, including more advanced transformer-based architectures, can be trained to locate and extract specific toxicological endpoints, study population details, and exposure parameters from PDFs. For example, a model can be trained to identify sentences containing "NOAEL" and extract the associated numerical value and unit. Experimental protocols show that creating a high-quality, annotated training dataset is the most critical step for success [128].

Risk of Bias Prediction: Early research explores using ML to predict the risk-of-bias ratings of studies based on their textual features, potentially serving as a consistency check for human reviewers.

Table 2: Experimental Protocol for Training an ML Model for Priority Screening [128]

Step	Action	Tool / Method Example	Outcome
1. Initial Manual Screening	Two independent reviewers screen a random sample (e.g., 1,000-2,000) of the initial search results.	Rayyan, Covidence	A labeled dataset (Include/Exclude) with human-coded decisions.
2. Feature Engineering	Convert text data (title/abstract) into numerical features.	TF-IDF (Term Frequency-Inverse Document Frequency) or sentence embeddings.	A feature matrix representing the textual content of each citation.
3. Model Training & Validation	Train a classifier (e.g., Random Forest, SVM) on 80% of the labeled data. Test performance on the held-out 20%.	Scikit-learn (Python), R Caret package.	A trained model with measured performance metrics (e.g., recall >99%, precision ~30-40%).
4. Integration & Active Learning	Integrate model into screening workflow. The model scores all unscreened records. Reviewers screen high-probability records first. Continuously feed new decisions to retrain and improve model.	Custom script linking ASReview API to reference manager.	A continuously learning system that reduces total screening burden over successive review cycles.

The Integration Pathway: ML-Enhanced LSRs in Practice

The true power of innovation is realized when ML is seamlessly integrated into the LSR pipeline. This creates a semi-automated, scalable evidence synthesis engine. For a toxicology LSR on "Hepatotoxicity of Novel Antifungal Agents," the integrated workflow would function as follows:

The LSR protocol is published on a platform like Open Science Framework (OSF). Initial searches in PubMed, Embase, and Toxline are run, and results are imported into an ML-screening tool. After training on a pilot set, the model prioritizes the remaining abstracts. As new studies are published, automated search alerts feed into the same platform. The ML model, now retrained on all previous decisions, screens the monthly update in minutes, flagging a handful for expert review. NLP-assisted extraction populates the data table with new study findings, and the meta-analytic model is rerun automatically. The updated forest plot and revised hazard conclusion are pushed to the live project website, alerting subscribers.

Diagram 2: Integrated ML-Enhanced LSR Pipeline for Toxicology

The Scientist's Toolkit: Essential Solutions for Implementation

Table 3: Research Reagent Solutions for ML-Enhanced LSRs in Toxicology

Tool / Resource Category	Specific Examples	Primary Function in LSR Workflow
Protocol Registration & Project Management	PROSPERO, Open Science Framework (OSF), Cochrane's RevMan	Hosts the a priori protocol, manages version control, and coordinates team data and files for the entire lifecycle of the LSR.
Bibliographic & Study Management	Rayyan, Covidence, DistillerSR, EPPI-Reviewer	Manages search results, facilitates blinded screening (title/abstract, full-text), deduplication, and often includes basic data extraction forms. Some integrate ML prioritization.
Dedicated AI/ML Screening Engines	ASReview, RobotAnalyst, SWIFT-Review	Open-source or commercial platforms specifically designed to apply active learning or other ML models to prioritize citations for systematic review screening.
Data Extraction & NLP Assistants	SysRev, ExaCT, free-text data extraction models (spaCy, BERT custom models)	Assist in extracting structured data (PECO elements, outcomes, numerical results) from PDFs and text, reducing manual transcription error.
Dynamic Dissemination & Visualization Platforms	SRDR+, meta.org, Shiny (R), Observable (JavaScript)	Hosts living review data, allowing for interactive visualization of findings (e.g., updated forest plots, evidence maps) and public access to the latest version.

The convergence of Living Systematic Reviews and machine learning marks a decisive step toward a more agile, responsive, and intelligent ecosystem for toxicology research. LSRs address the core challenge of evidence currency, while ML provides the scalable tools necessary to make the living model sustainable. For researchers and drug development professionals, embracing this integrated approach means moving from producing static, point-in-time documents to stewarding dynamic, authoritative evidence resources. The future of evidence synthesis in toxicology is not merely updated—it is continuously evolving, intelligently assisted, and immediately accessible, providing a robust foundation for safeguarding public health in a world of constant chemical innovation.

Systematic reviews represent the cornerstone of evidence-based toxicology (EBT), offering a transparent and reproducible method to summarize evidence for informing regulatory decisions and policy [130]. Historically, toxicology has relied on narrative reviews, which are often opaque in their methodology and susceptible to selective citation and bias, potentially leading to misleading conclusions and inconsistent risk management [130]. The adaptation of systematic review methodology from clinical medicine addresses these flaws by mandating explicit, pre-defined protocols, comprehensive searches, and critical appraisal of included studies [130]. This guide, framed within a broader thesis on conducting systematic reviews in toxicology, details methodologies to identify and correct common systemic flaws, thereby strengthening the validity and reliability of future evidence syntheses in the field.

Identifying and Characterizing Systemic Flaws

A critical first step in improving review validity is recognizing recurring methodological weaknesses. These flaws compromise the objectivity, consistency, and reproducibility that define evidence-based toxicology [130].

Table 1: Comparative Analysis of Review Types and Common Flaws

Feature	Traditional Narrative Review	Ideal Systematic Review	Associated Systemic Flaw
Question Formulation	Broad, often implicit [130].	Specified and specific using frameworks (e.g., PICO, PEO) [84] [11].	Unfocused questions lead to ambiguous inclusion criteria and selective evidence gathering.
Search Strategy	Usually not specified or comprehensive [130].	Comprehensive, multi-database, explicit strategy with documented syntax [84].	Incomplete retrieval of relevant evidence, introducing selection bias.
Study Selection & Appraisal	Implicit, informal [130].	Explicit criteria; critical appraisal using validated tools [130] [84].	Unreported bias and uncritical inclusion of methodologically weak studies.
Synthesis Process	Qualitative summary [130].	Structured synthesis (narrative, quantitative, or meta-analysis) [130] [131].	Subjective interpretation and failure to quantitatively integrate data where possible.
Protocol & Reporting	Rarely published.	Published a priori protocol; adherence to PRISMA guidelines [84].	"Moving goalposts," hindsight bias, and lack of transparency.

A primary flaw is the lack of a pre-registered protocol, which allows for subjective, post-hoc decisions that inflate bias [84]. Furthermore, inadequate search strategies limited to one or two databases fail to capture the full evidence base, as different databases index unique journals and conference proceedings [84]. Uncritical inclusion of studies without robust quality assessment propagates errors from primary research into the synthesis [86]. Finally, toxicology faces specific challenges like integrating multiple evidence streams (e.g., in vitro, animal, human) and extrapolating findings, which are often poorly addressed [130].

Methodological Corrections: Protocols and Standardization

Implementing rigorous, standardized methodologies at each review stage is the most effective correction for identified flaws.

3.1 Framing the Research Question and Protocol Development Every review must begin with a structured research question. Frameworks like PICO (Population, Intervention, Comparator, Outcome) for interventions or PEO (Population, Exposure, Outcome) for toxicological exposures provide essential structure [84] [11]. The question must be precisely articulated in a publicly accessible protocol, which details the planned methods for searching, selection, data extraction, and synthesis. This practice, as demonstrated by the Paracetamol Workgroup's pre-defined consensus definitions for poisoning types, locks in methodology and reduces bias [132].

3.2 Comprehensive Search Strategy & Study Management A replicable search strategy is non-negotiable. It should be developed with a librarian or information specialist, using controlled vocabularies (e.g., MeSH) and free-text terms combined with Boolean operators [84]. Searches must be run across multiple relevant databases (e.g., PubMed/MEDLINE, Embase, Scopus, Web of Science, TOXLINE) to minimize coverage bias [84] [11]. The use of specialized software like Covidence or Rayyan to manage references, screen titles/abstracts, and resolve conflicts between reviewers is a best practice that enhances efficiency and accuracy [11].

Diagram Title: Systematic Review Workflow with Bias Control Checkpoints

3.3 Critical Appraisal and Risk of Bias Assessment Formal quality assessment of included studies is essential. This involves evaluating the methodological rigor and risk of bias in each primary study, not simply excluding studies based on a quality "score" [86]. Tools are design-specific:

• Cochrane Risk of Bias (RoB) tools: For randomized and non-randomized controlled trials [84].
• Newcastle-Ottawa Scale: For cohort and case-control studies [11].
• SYRCLE's RoB tool: Specifically for animal studies in toxicology. The outcomes of this assessment should directly inform the data synthesis and the strength of evidence conclusions [84].

Diagram Title: Role of Bias Assessment in Evidence Interpretation

Data Synthesis and Analysis Strategies

The synthesis strategy must be chosen a priori and align with the nature of the extracted data [131].

Table 2: Data Synthesis Strategies for Systematic Reviews

Synthesis Type	Description	Typical Data Input	Common Outputs	Toxicology Application
Narrative Synthesis	Textual summary and thematic analysis of findings.	Qualitative data; heterogeneous quantitative data.	Summary tables, conceptual maps.	Integrating evidence across diverse study designs (e.g., in vitro, animal, epidemiological) [131].
Quantitative Synthesis (Meta-Analysis)	Statistical pooling of effect estimates from comparable studies.	Homogeneous quantitative data (e.g., odds ratios, mean differences).	Forest plot, pooled effect estimate (with CI), heterogeneity statistics (I²).	Quantifying a specific toxicological effect (e.g., hepatotoxicity odds) from similar animal studies [11].
Emerging Synthesis	Integrates diverse data types to develop new models or frameworks.	Mixed qualitative/quantitative studies, policy docs, theoretical work.	Conceptual models, decision frameworks, new hypotheses.	Developing integrated testing strategies or adverse outcome pathways (AOPs) [131].

A major threat to synthesis validity is publication bias. Statistical (e.g., funnel plots, Egger's test) and graphical methods should be used to assess it, and techniques like trim-and-fill may be employed to adjust for it [11]. When meta-analysis is performed, exploring sources of heterogeneity (e.g., via subgroup analysis by species, strain, or exposure duration) is more informative than ignoring it [11].

Adopting the following tools and resources standardizes the review process and mitigates common flaws.

Table 3: Research Reagent Solutions for Systematic Reviews

Tool Category	Specific Tool / Resource	Primary Function	Relevance to Addressing Flaws
Protocol & Reporting	PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement [84].	Checklist and flow diagram for transparent reporting.	Corrects incomplete reporting and enhances reproducibility.
Guidance Handbook	Cochrane Handbook for Systematic Reviews [84]; EFSA/OHAT Guidance for toxicology [130].	Definitive methodological guidance.	Provides standardized, evidence-based methods for all stages.
Quality Appraisal	Cochrane RoB tools; SYRCLE's RoB tool; Newcastle-Ottawa Scale [84] [11] [86].	Assess risk of bias in included studies.	Corrects uncritical inclusion of flawed primary studies.
Reference Management & Screening	Covidence; Rayyan; EndNote [11].	Manages citations, facilitates blinded screening, resolves conflicts.	Reduces human error in selection and improves process rigor.
Data Analysis & Synthesis	RevMan; R packages (metafor, meta); Stata [11].	Conducts meta-analysis, generates forest/funnel plots.	Enables robust quantitative synthesis and bias assessment.
Database	PubMed/MEDLINE; Embase; Scopus; Web of Science; TOXLINE [84] [11].	Sources for comprehensive literature searching.	Mitigates selection bias from inadequate searches.

The validity of future systematic reviews in toxicology depends on a conscious departure from informal, narrative practices and the rigorous adoption of evidence-based methodology. This requires: 1) acknowledging and understanding common systemic flaws, such as protocol deviations and uncritical appraisal; 2) implementing corrective methodologies at every stage, from protocol registration to bias-aware synthesis; and 3) leveraging an evolving toolkit of guidelines, software, and critical appraisal instruments. By adhering to these principles, reviewers will produce syntheses that truly fulfill the promise of evidence-based toxicology: transparent, reproducible, and robust foundations for scientific and regulatory decision-making [130].

Conclusion

Conducting a systematic review in toxicology is a demanding but indispensable process for generating reliable, transparent, and actionable evidence for human health protection and chemical risk assessment. By adhering to a structured, protocol-driven methodology—from formulating a precise question to grading the confidence in the evidence—researchers can overcome the field's inherent complexities, such as integrating diverse data streams and extrapolating across species. While challenges in resource allocation and methodology persist, the ongoing harmonization of frameworks (like OHAT), the adoption of living review models, and the critical awareness of common pitfalls are driving the field toward greater robustness. The future of evidence-based toxicology hinges on the widespread adoption and continuous refinement of these systematic approaches, which are crucial for building scientific consensus, underpinning credible regulations, and guiding the safe development of new chemicals and pharmaceuticals.

References

• 1. A primer on systematic reviews in toxicology - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC5489636/]
• 2. What are systematic reviews? [https://library-guides.ucl.ac.uk/systematic-reviews/what]
• 3. Systematic review [https://en.wikipedia.org/wiki/Systematic_review]
• 4. What is a Systematic Review? - Guides - Duke University [https://guides.mclibrary.duke.edu/sysreview]
• 5. Introduction to systematic review and meta-analysis - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC5903119/]
• 6. Top Systematic Review Software Tools Compared in 2025 [https://blog.hifivestar.com/posts/top-systematic-review-software-2025]
• 7. Software and Tools - Systematic Reviews and Meta Analysis [https://guides.library.harvard.edu/meta-analysis/software]
• 8. Software Comparison - Systematic Review Toolbox [https://hslib.jabsom.hawaii.edu/systematicreview/softwarecomparison]
• 9. Software Tools to Manage Your Review - Systematic Reviews [https://prattlibrary.cchmc.org/systematicreviews/software]
• 10. Exploring experiences of the regulatory toxicology system [https://pubmed.ncbi.nlm.nih.gov/40925984/]
• 11. A comprehensive guide to conduct a systematic review and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12366998/]
• 12. Handbook for Conducting Systematic Reviews for Health ... [https://ntp.niehs.nih.gov/research/assessments/noncancer/handbook]
• 13. 2025 Annual Meeting Report: Transparency and AI ... [https://toxchange.toxicology.org/blogs/kel-deshong/2025/05/01/2025-annual-meeting-report-transparency-and-ai-and]
• 14. Systematic Reviews: Data Extraction [https://med.cornell.libguides.com/systematicreviews/dataextraction]
• 15. Significant New Use Rules on Certain Chemical ... [https://www.federalregister.gov/documents/2025/11/03/2025-19755/significant-new-use-rules-on-certain-chemical-substances-25-15e]
• 16. Systematic Review and Evidence Integration for Literature- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4080517/]
• 17. A UK framework for the assessment and integration of ... [https://www.sciencedirect.com/science/article/pii/S027323002400093X]
• 18. Recommendations for the conduct of systematic reviews in ... [https://www.sciencedirect.com/science/article/pii/S016041202031881X]
• 19. PRISMA 2020 flow diagram [https://www.prisma-statement.org/prisma-2020-flow-diagram]
• 20. LibGuides: Creating a PRISMA flow diagram: PRISMA 2020 [https://guides.lib.unc.edu/prisma]
• 21. Systematic Reviews: Step 7: Extract Data from Included Studies [https://guides.lib.unc.edu/systematic-reviews/extract-data]
• 22. 8. Synthesize Your Results - Systematic Reviews [https://hslguides.osu.edu/systematic_reviews/synthesize]
• 23. Differentiating between mapping reviews and scoping ... [https://pubmed.ncbi.nlm.nih.gov/35636593/]
• 24. Reviews and Evidence Syntheses: Scoping or Mapping Review [https://libguides.utoledo.edu/es/scoping]
• 25. A primer on systematic reviews in toxicology [https://link.springer.com/article/10.1007/s00204-017-1980-3]
• 26. Applying Evidence-Based Methods to the Development ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9394185/]
• 27. Systematic Reviews and Evidence-Based Toxicology [https://toxstrategies.com/services/systematic-reviews-and-evidence-based-toxicology/]
• 28. A proposed framework for the systematic review and ... [https://ehjournal.biomedcentral.com/articles/10.1186/s12940-016-0156-6]
• 29. Ozone exposure and health effects: a protocol for an umbrella ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7430459/]
• 30. Preferred reporting items for systematic review and meta ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4320440/]
• 31. 3. Write and Register a Protocol - Systematic Reviews - Guides [https://guides.mclibrary.duke.edu/sysreview/protocol]
• 32. Protocols — PRISMA statement [https://www.prisma-statement.org/protocols]
• 33. A Protocol for the Use of Case Reports/Studies and ... [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.708380/full]
• 34. Guidance on assessing the methodological and reporting ... [https://www.sciencedirect.com/science/article/pii/S0160412016300903]
• 35. Protocols - Systematic Reviews, Scoping Reviews & Other ... [https://guides.rosalindfranklin.edu/sysreviews/protocols]
• 36. SYSTEMATIC LITERATURE SEARCH METHODS ... - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK601288/]
• 37. Searching the scientific literature: Implications for ... [https://www.sciencedirect.com/science/article/abs/pii/S0272735812000967]
• 38. Literature searching methods or guidance and their ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9300102/]
• 39. Using text mining for study identification in systematic reviews [https://pmc.ncbi.nlm.nih.gov/articles/PMC4320539/]
• 40. Appraising systematic reviews: a comprehensive guide to ... [https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2023.1268045/full]
• 41. Guidelines for performing systematic reviews in the ... [https://www.sciencedirect.com/science/article/pii/S0273230017303100]
• 42. Advancing systematic-review methodology in exposure ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8215717/]
• 43. How to structure your Table for Systematic Review and ... [https://pubrica.com/academy/literature-review/how-to-structure-your-table-for-systematic-review-and-meta-analysis/]
• 44. Critical Appraisal - Systematic Reviews and Meta-Analyses [https://guides.lib.vt.edu/SRMA/appraisal]
• 45. Assessing risk of bias in toxicological studies in the era of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12367879/]
• 46. Presenting data in tables and charts - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4008059/]
• 47. Data Standardization - an overview | ScienceDirect Topics [https://www.sciencedirect.com/topics/computer-science/data-standardization]
• 48. Data Standardization – OHDSI [https://www.ohdsi.org/data-standardization/]
• 49. What Is Database Standardization: Formula, Tools, Benefits | Airbyte [https://airbyte.com/data-engineering-resources/how-to-standardize-data]
• 50. Qualitative Vs Quantitative Data: Key Differences [https://www.datastackhub.com/compare/qualitative-data-vs-quantitative-data/]
• 51. Large Language Models for Data Extraction in Toxicology [https://zenodo.org/records/14893134]
• 52. Systematic Reviews: A Comprehensive Guide | PPTX [https://www.slideshare.net/slideshow/systematic-reviews-a-comprehensive-guide/273730719]
• 53. Protocol for a Systematic Review and Meta-Analysis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9223820/]
• 54. Large scale meta-analysis of preclinical toxicity data for target ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252533]
• 55. Systems toxicology meta-analysis—From aerosol exposure ... [https://www.sciencedirect.com/science/article/pii/S2468202018300962]
• 56. Systematic Review: Managing the Process - Research Guides [https://lib.guides.umd.edu/SR/managing]
• 57. Toxicological Profile for 1,1,2-Trichloroethane - NCBI Bookshelf [https://www.ncbi.nlm.nih.gov/books/NBK590701/]
• 58. TSRC 2025 Tox Wrap Up: Risk Assessment Takes Center ... [https://labstat.com/tsrc-2025-wrap-up-key-takeaways-from-the-risk-assessment-session-panel/]
• 59. Systematic Reviews: Step 6: Assess Quality of Included Studies [https://guides.lib.unc.edu/systematic-reviews/assess-quality]
• 60. Criteria Used in Quality Assessment of Systematic Reviews [https://www.ncbi.nlm.nih.gov/books/NBK242394/]
• 61. Chapter 6: Systematic Review Overview | ACIP GRADE ... [https://www.cdc.gov/acip-grade-handbook/hcp/chapter-6-systemic-review-overview/index.html]
• 62. GRADE handbook [https://gradepro.org/handbook]
• 63. Inadequate diversity of information resources searched in US ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6250602/]
• 64. Literature search in systematic reviews: How much is good ... [https://www.sciencedirect.com/science/article/pii/S2213398423002725]
• 65. Systematic Review: Select databases & save results [https://guides.lib.monash.edu/systematic-review/select-databases-and-grey-literature]
• 66. Steps of a Systematic Review - Research Guides [https://lib.guides.umd.edu/SR/steps]
• 67. How to Create an Effective PRISMA Flow Diagram [https://www.aje.com/arc/how-to-create-prisma-flow-diagram]
• 68. Integration of new approach methods for the assessment ... [https://pubmed.ncbi.nlm.nih.gov/39969258/]
• 69. Optimal database combinations for literature searches in ... [https://pubmed.ncbi.nlm.nih.gov/29208034/]
• 70. Optimal database combinations for literature searches in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5718002/]
• 71. Optimise Database Combinations in Systematic Reviews [https://marksmanhealthcare.com/2019/04/09/how-to-optimise-database-combinations-for-literature-searches-in-systematic-reviews/]
• 72. What are the Steps of a Systematic Review? [https://hslguides.osu.edu/systematic_reviews/steps]
• 73. Five steps to conducting a systematic review - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC539417/]
• 74. Step 3: Conduct Literature Searches - Systematic Reviews [https://guides.library.uab.edu/systematicreviewsnew/step3]
• 75. Databases and Sources - Systematic Reviews and Meta ... [https://guides.library.harvard.edu/meta-analysis/databases]
• 76. Literature review and systematic : What you need to know review [https://www.litmaps.com/articles/literature-review-and-systematic-review-what-you-need-to-know]
• 77. Risk of Bias Tools - Systematic Review Guide [https://beckerguides.wustl.edu/SystematicReviews/riskofbias]
• 78. Systematic Review and Evidence Synthesis: Risk of Bias ... [https://libguides.umn.edu/c.php?g=1264119&p=9285838]
• 79. Inclusion and Exclusion Criteria | Examples & Definition [https://www.scribbr.com/methodology/inclusion-exclusion-criteria/]
• 80. Inclusion and exclusion criteria in research studies [https://pmc.ncbi.nlm.nih.gov/articles/PMC6044655/]
• 81. A primer on systematic in reviews toxicology [https://pubmed.ncbi.nlm.nih.gov/28501917/]
• 82. Sample tables - APA Style - American Psychological Association [https://apastyle.apa.org/style-grammar-guidelines/tables-figures/sample-tables]
• 83. Data Visualizations, Charts, and Graphs - Digital Accessibility [https://accessibility.huit.harvard.edu/data-viz-charts-graphs]
• 84. Appraising systematic reviews: a comprehensive guide to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10764628/]
• 85. Describing and appraising studies - Systematic reviews [https://library-guides.ucl.ac.uk/systematic-reviews/describing-appraising]
• 86. Critical Appraisal tools [https://www.cebm.ox.ac.uk/resources/ebm-tools/critical-appraisal-tools]
• 87. Assessing risk of bias in toxicological studies in the era ... [https://link.springer.com/article/10.1007/s00204-025-03978-5]
• 88. Risk of bias assessment tools often addressed items not ... [https://www.sciencedirect.com/science/article/pii/S0895435625000174]
• 89. Risk of bias tools [https://www.riskofbias.info/]
• 90. Language models for data extraction and risk of bias ... [https://www.nature.com/articles/s41746-025-01457-w]
• 91. Heterogeneity in meta-analyses: an unavoidable challenge ... [https://pubmed.ncbi.nlm.nih.gov/39956636/]
• 92. ToxACoL: an endpoint-aware and task-focused compound ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12218982/]
• 93. Protocol for a systematic review of guidelines for rigour in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8749326/]
• 94. Protocol for a systematic review and meta-analysis of the ... [https://www.nature.com/articles/s41405-025-00320-0]
• 95. How to report and discuss subgroup analyses in clinical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12187882/]
• 96. Cumulative subgroup analysis to reduce waste in clinical ... [https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0744-x]
• 97. Reporting of health equity considerations in cluster and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7118943/]
• 98. Systematic Review Methodology - Public Health 190 (Bradman) [https://libguides.ucmerced.edu/c.php?g=1216220&p=8901474]
• 99. Editorial: Five grand challenges in toxicology [https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2024.1533238/full]
• 100. Beat Resource Chaos in Client Work [https://www.teamwork.com/blog/resourcing-chaos/]
• 101. The most common resource management problems (and ... [https://www.teamwork.com/blog/resource-management-problems/]
• 102. Top 10 common resource management mistakes you must ... [https://www.rocketlane.com/resources/psa/resource-management-mistakes-to-avoid]
• 103. 14 of the Most Common Mistakes to Avoid When Scaling ... [https://www.itmagination.com/blog/14-most-common-mistakes-avoid-scaling-first-engineering-team]
• 104. How to Solve the Time Dilemma? The Influence of Team ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8341075/]
• 105. Quantitative systems toxicology [https://www.sciencedirect.com/science/article/pii/S2468202017300700]
• 106. Challenges faced when modeling clinical toxicology and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9124354/]
• 107. risk assessment - EFSA - European Union [https://www.efsa.europa.eu/en/glossary/risk-assessment]
• 108. Guidance on risk–benefit assessment of foods - EFSA [https://www.efsa.europa.eu/en/efsajournal/pub/8875]
• 109. Environmental risk assessment | EFSA - European Union [https://www.efsa.europa.eu/en/topics/topic/environmental-risk-assessment]
• 110. Cochrane Handbook for Systematic Reviews of ... [https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current]
• 111. Cochrane Methods Report 2025 [https://www.cochrane.org/about-us/news/cochrane-methods-report-2025]
• 112. Comprehensive benchmarking of computational tools for ... [https://jcheminf.biomedcentral.com/articles/10.1186/s13321-024-00931-z]
• 113. TOXRIC: a comprehensive database of toxicological data ... [https://pubmed.ncbi.nlm.nih.gov/36400569/]
• 114. Manuals and Reporting Guidelines - Systematic Reviews [https://guides.mclibrary.duke.edu/sysreview/manuals]
• 115. PRISMA statement [https://www.prisma-statement.org/]
• 116. Reporting guidelines under development for systematic ... [https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/]
• 117. The PRISMA Extension Statement for Reporting ... [https://www.equator-network.org/reporting-guidelines/prisma-extension-network-meta-analyses/]
• 118. The PRISMA statement extension for systematic reviews ... [https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-the-prisma-statement-extension-for-S2387020616306015]
• 119. Updating the PRISMA reporting guideline for network meta ... [https://www.medrxiv.org/content/10.1101/2025.02.06.25321746v1]
• 120. Policies and Guidelines - Environment International [https://www.sciencedirect.com/journal/environment-international/about/policies-and-guidelines/guidance-notes-for-authors-of-systematic-reviews-systematic-evidence-maps-and-related-manuscript-types]
• 121. Evaluation of AI Tools Versus the PRISMA Method ... - JMIR AI [https://ai.jmir.org/2025/1/e68592]
• 122. Types of Reviews - Systematic Reviews - Guides [https://guides.mclibrary.duke.edu/sysreview/types]
• 123. LSE Table and Figure [https://www.atsdr.cdc.gov/pha-guidance/toolbox/LSE_Tables_Figures.html]
• 124. Statistical analysis for toxicity studies - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC5820099/]
• 125. Downloadable Computational Toxicology Data [https://www.epa.gov/comptox-tools/downloadable-computational-toxicology-data]
• 126. Capturing the influx of living systematic reviews [https://www.sciencedirect.com/science/article/pii/S0895435625002379]
• 127. Capturing the influx of living systematic reviews [https://pubmed.ncbi.nlm.nih.gov/40712752/]
• 128. Artificial Intelligence Applications in Emergency Toxicology [https://www.jmir.org/2025/1/e73121]
• 129. Writing a Systematic Review and Meta-analysis: A Step-by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12402582/]
• 130. A primer on systematic reviews in toxicology - PMC [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489636/]
• 131. Strategy for Data Synthesis in Systematic Review [https://www.distillersr.com/resources/systematic-literature-reviews/strategy-for-data-synthesis-in-systematic-review]
• 132. Paracetamol (acetaminophen) poisoning; consensus definitions of poisoning types and outcomes to be used in the clinical toxicology recommendations collaborative systematic review - PubMed [https://pubmed.ncbi.nlm.nih.gov/40162912/]